









PROTEASES OF THE NEUTROPHIL MEMBRANE 
REPRESENT AN ALTERNATIVE FIBRINOLYTIC 
PATHWAY TO THAT MEDIATED BY PLASMIN 
by 
Susan Ann Adams, BSc, MBChB 
A thesis presented to the University of Cape Town for the degree of 
Doctor of Philosophy (Medicine) 
September 1996 
T 
t- I ' ,..,..,,.. <-'Vf:'"1 










The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 











for my parents 
ii 
Acknowledgements 
This thesis represents the culmination of five years work undertaken at the MRC/UCT Liver Research Centre. 
Throughout the time I have been fortunate to have been assisted and supported by many people. I would like to 
thank in particular: 
Prof Enid Shephard for her supervision and guidance, from my first hesitant steps in the laboratory until this thesis 
has finally seen the light of day. She has taught me of science, of integrity and the pursuit of a goal. 
Prof Ralph Kirsch who has remained ever supportive, ever enthusiastic and ever aware of the greater picture, while 
I got lost in the "small print". 
Sharon Kelly who began the journey, for her support and friendship both from near and afar. 
Brent Jennings for ensuring I never lose that touch with reality and for sharing the dreams, his generousity of spirit 
and for proof reading this thesis. 
Mr Mick Wells, for whom nothing was too much trouble and who always solved the problem. 
Lesley Frith and Val Hancock for always being so willing and helpful in their continuous supply of purified 
fibrinogen. 
Prof Trevor Sewell, Mohammed Jaffer and Charlie Bruinjties from the electron microscopy unit for their assistance 
in producing the electron rnicrographs. 
Simon Robson for introducing me to the world of the laboratory. 
Lavinia Petersen for so generously helping with the formating of this thesis. 
For all those at the liver research centre who have become so much more than colleagues and given so unselfishly 
of their time and expertise especially Wendy Spearman, Anne Corrigall, Vivienne Woodburne and Richard Kirsch. 
Bethwell Daki and Mogamat Samuels for cheerfully keeping me supplied with clean glassware and laboratory 
equipment, and Leslie Martins for "greening" my life. 
Ed Sturrock and Colette Cywes for their friendship and belief in me, always. 
My parents for their love, for giving me the vision and allowing me to persue it unconditionally. 
I have been supported during this time by scholarships both from the Medical Research Council of South Africa 
and the Guy Elliot Fellowship for postgraduate medical research, for which I am deeply grateful. 
iii 
If you have built castles in the air, your work need not be lost; that is where they should be. Now 
put the foundations under them. 
Henry David Thoreau 
iv 
Chapter 4 Literature Review - Platelets ............................ .... ................... .......... ..... .......... 46 
Introduction ........................................................................................... .......... 47 
GP1Ib-I1Ia and platelet aggregation .................. ... .... ....... ..... ... ................... ....... 48 
Platelets and fibrinolysis ....................... ... ......... .... ................... ... ................... ... 53 
Clot retraction ...... .... ..... ... ........................... ....................... .................. .... ....... 54 
Neutrophil-platelet adhesion mechanisms ................. ..... ... ........ ... .. ................... 56 
Platelet-neutrophil interactions .... ......... .. ........................ .......... .... ...... .............. 59 
Chapter 5 Experimental section .......... .......... ... .. .. ................... .... ................... ............ .... .. 61 
Proteases of the neutrophil membrane act as an alternative fibrinolytic pathway 
to that mediated by plasmin 
Introduction ......................................... .. ...... ................................................... 62 
Results .... ..... ... .................. ... ..................... ......................... .. .......... .......... ...... . 64 
Neutrophil fibrinolysis ..... ..... .............. ......... ..................... .. .... ........ .......... 64 
Fibrinolysis by neutrophils incorporated into the clot. ...... ..... ..................... 68 
The effect of neutrophils on plasrnin solubilization of 1251-labelled 
fibrin ........ ...... .. ........ ... ....... ... ..... ............ ... ...... ....... .... ................... .... ....... 69 
125 · · Nature of soluble I-labelled fibrm products ... ......................................... 70 
Effect of inhibitors on the solubilization of 1251-labelled fibrin ..... ...... ..... .... 71 
Identification of proteases in a neutrophil membrane preparation 
capable of degrading fibrin .............. .. ........................................ .... ............ 71 
Electron microscopy of fibrinolysis by neutrophils incorporated 
within the fibrin matrix ........................... ... ......... .... ... .. ........ ...................... 73 
Mechanism of neutrophil-mediated fibrin degradation ... ......... .. ................. 76 
Discussion ........................... .................... ............ ..... ... ..... ................. ..... .. .... ... 79 
Chapter 6 Experimental section ................... .... .............. ........ .... ... ...................... ... .... ..... .. 83 
Modification of platelet function by fibrin degradation products generated by 
neutrophil membrane proteolytic activity on fibrin 
Introduction ....................... ....................................................... .......... ..... ....... 84 
Results ............. .............. .... ......... .... ............................................ .. ... ............ ... 86 
vi 
Plasmin-mediated fibrinolysis : modification by the presence of 
platelets and neutrophils .............. ...... ..... ... .... ....................................... .. .. 86 
Modification of platelet function by FD P' s generated during fibrin 
lysis by neutrophil membrane proteolytic activity ................ ... ... .... ... .. ..... .. 86 
Plasmic fibrin lysis in the presence of platelets: modification by 
peptides produced by neutrophil membrane lysis offibrin .............. ......... ... 90 
Discussion ....... .... ... ... ....................... .......... .... .... .... .... ... .... ....... ... .................... 91 
Chapter 7 Experimental section .. .................. ...... .. .. .... .................... .. .............. ... ... ....... ..... 94 
Digestion of 1251-labelled plasmin-derived fibrin degradation products by 
neutrophil lysosomal enzymes 
Introduction .......................... ........................................ ................ ...... ... ... ...... 95 
Results ........................ .... .................................. ........ ............................ .......... 97 
Degradation of plasmic 1251-labelled fibrin products with neutrophil 
lysosomal enzymes ........... ............................. .................................... ....... 97 
Effect of inhibitors on the degradation of plasmin-derived 1251-labelled 
FDP' s by neutrophil lysosomal enzymes .............. ........................... ......... .. 98 
Inhibition of disulfide bonding .. ..... ........ ...... .. .... .............................. ... ....... 101 
Isoelectric point of the lysosomal enzyme-derived high molecular 
weight 1251-labelled FDP ......... .... .. ...... .. ... ........................................... ...... 102 
Western blotting using monoclonal antibody directed against D-dimer ...... 103 
Discussion ........ ........ ...... ... ... .. .................... .............................................. .. .. .. 104 
Chapter 8 Summary and conclusions ..... ..... ............................... ....................................... 107 
Appendix 1: Methods ....... .. ...... .. ...................... ................ .... ........................ .................. .... 110 
Appendix 2: Abbreviations .. .... .... ......... .... ........ .... ... ...... .... . ...... .. .. . ............ ...... .... . 119 
Appendix 3: Experimental data .............. .... .... ............................................ ... .... ............. .... 122 
References .... .... .. ... .... ... ....... ..... ..... .... ... ... .... ...... ..... ...... ........... .. ... .. ..... ......... .. ... 128 
vii 
Abstract 
Proteases of the neutrophil membrane represent an alternative fibrinolytic 
pathway to that mediated by plasmin 
The cellular components of the blood, which become associated with fibrin through specific 
cellular adhesive processes, play a significant role in the breakdown of fibrin . Fibrinolysis by 
elastase and cathepsin G, enzymes present within the azurophilic granules of the neutrophil, has 
previously been shown. Recent studies have demonstrated neutrophil-mediated fibrinogenolysis 
by a membrane-associated protease which suggests that proteases connected with the neutrophil 
membrane might also be capable of clot dissolution. Investigations showed that neutrophil-
mediated clot lysis was effected by a membrane-associated serine protease that can be dissociated 
by SDS-PAGE to bands that migrate to apparent molecular weights of 501 kDa, 398 kDa, 316 
kDa, 245 kDa and 209 kDa. This degradation was distinct fro_m that produced by plasmin, 
neutrophil lysosomal enzymes and purified human neutrophil elastase and enhanced the action of 
plasmin in clot solubilization. Preincubation of neutrophils with monoclonal antibodies directed 
against the CD 11 c/CD 18 integrin was able to significantly inhibit neutrophil membrane-dependent 
fibrinolytic activity. Upregulation of enzyme activity occurred following association of fibrin 
substrate with the cell membrane and was dependent on the activation of cellular kinases, m 
particular protein kinase C. 
Fibrin products generated by neutrophil membrane proteolytic activity were found to poss~ss 
biological activity. The low molecular weight peptides effected substantial inhibition of thrombin-
induced platelet aggregation while the presence of the higher molecular weight material could 
partially overcome platelet-induced resistance to plasmic lysis. No modulation of platelet-
mediated fibrin clot retraction was observed using these same fibrin products. 
Neutrophil lysosomal enzyme activity was shown to further degrade the end products of plasmic 
fibrin degradation into low molecular weight material, followed by reassembly of higher molecular 
weight products in a process dependent on calcium and factor XIII. The reformed products have 
a similar molecular weight to those produced by plasmic lysis of fibrin, as well as a putative 
crosslinked site. However, the isoelectric point of these reformed products indicates they are 
distinctly different from plasmin-derived fibrin products. These reassembled products were 
recognized by a monoclonal antibody raised against D-dimer. Processing by neutrophils of the end 
products of plasmic fibrin degradation may have the potential for modulating the immune 
response as well as compromising the predictive value of tests measuring D-dimer, used as a 
laboratory marker of a number of thromboembolic disorders encountered in clinical practice. 
September 1996 
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CHAPTERl 
Introduction 
Blood coagulation and the fibrinolytic system compnses a vast array of finely controlled 
biochemical pathways. Clot formation and clot lysis are essential initial and final components 
respectively of haemostasis, the cessation of bleeding that follows traumatic interruption of 
vascular integrity. Vascular damage alters the normal anticoagulant surface of the endothelial cells 
to a procoagulant surface. Concomitantly endothelial cells acquire adhesive properties for 
leukocytes and platelets, due to upregulated expression of endothelial cell adhesion molecules. 
These processes are a consequence of endothelial cell surface expression of tissue factor during 
vascular injury. Tissue factor is known to play a major role in promoting coagulation, through 
activation of coagulation factors which leads ultimately to the generation of thrombin, a serine 
protease and a key enzyme in the haemostatic process. Cleavage of the soluble plasma 
glycoprotein fibrinogen by thrombin is the initial step in the formation of insoluble fibrin polymer 
clot. In addition thrombin activates platelets and is involved in the upregulation of platelet and 
endothelial cell P-selectin which supports leukocyte adhesion to these cells. Thus fibrin deposition 
and accumulation of platelets and leukocytes at sites of vascular injury is a dynamic process. 
With regard to fibrinolysis the serine protease plasmin, arising through the action of plasminogen 
activator cleavage of the proenzyme plasminogen, is considered to be the major enzyme 
participating in fibrinolysis . Plasmin catalyses the degradation of fibrin to a number of predictable 
and well described end products (Pizzo et al, 1973). The knowledge that granulocytes are not 
merely trapped within the developing thrombus but are present due to specific cellular adhesive 
processes (Palabrica et al, 1992) suggests that there may be important physiological repercussions 
to their presence within thrombi. It has been recognized since the turn of the century that 
leukocytes, in particular neutrophils, play a role in fibrinolysis (Rulot, 1904; Opie, 1907). The 
entire fibrinolytic potential of the neutrophil has been ascribed to the proteases cathepsin G and 
elastase, found within the intracytoplasmic azurophilic granules of the neutrophil and requiring 
high activation states of the cell to be released (Moroz, 1984; Plow and Edgington, 1978). Little 
consideration has been given to the importance of membrane-associated proteases, which are in 
direct contact with fibrin substrate and thus would be expected to be far more readily mobilised 
than elastase and cathepsin G. 
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The experimental section of this thesis is aimed at investigating the contribution of proteases 
associated with the neutrophil membrane to the fibrinolytic pathway. This process will be 
compared to the classical plasmin-mediated degradation pathway as well as that of the lysosomsal 
enzymes, previously assesssed as being soley responsible for the ability of the neutrophil to digest 
fibrin. These studies were prompted by the recently published data showing that a 600 kDa 
membrane-associated neutrophil protease is capable of digesting fibrinogen in a manner distinct 
from that of plasmin and neutrophil lysosomal enzymes (Kelly et al, 1994). This protease is also 
capable of processing the acute phase reactant C-reactive protein to a number of bioactive 
peptides (Shephard et al, 1989). 
The close association of neutrophils with fibrinogen has long been established and the role of the 
leukocyte specific p2 integrins is of particular relevance (Wright et al, 1988; Altieri et al, 1990; 
Altieri et al, 1993; Diamond and Springer, 1993b ). These adhesion molecules, together with the 
leukocyte response integrin, have been shown to specifically bind fibrinogen. In this manner 
"protected pockets" are formed, which allow released proteinases to exert their effects under 
relative protection from circulating proteinase inhibitors (Weitz et al, 1987). It has also become 
clear that the integrins act not only as adhesion molecules but are also essential in signal 
transduction pathways, both into and out of the cell . Ligand occupation of receptor triggers a 
series of intracellular events resulting in cytoskeletal changes, activation of various kinases, 
protein phosphorylation and resulting functional effects (Pavalko and La Roche, 1993; Pavalko 
and Otey, 1994; Wang et al, 1993; Petty and Todd, 1996). In light of this the mechanisms 
involved in membrane-associated fibrinolysis were investigated, with particular emphasis on the 
role of cellular kinases and the p2 integrins. 
In addition to the role of the fibrinogen molecule within the haemostatic and coagulation system, 
degradation of the parent molecule into fragments releases products with vasoactive properties 
and immunomodulatory functions. For the most part, the biological role of plasmin-derived fibrin 
degradation products have been investigated. This thesis aims to assess the importance of 
neutrophil membrane protease-derived fibrin degradation products in modulating platelet function. 
Following disruption of the vascular endothelial cell lining platelets adhere to the exposed 
subendothelial matrix and undergo a series of calcium dependent biochemical and structural 
changes. The functional activity of the platelet essentially involves four mechanisms: adhesion, 
aggregation, contraction and secretion. Fundamental to these changes is the binding of 
fibrin( ogen) to the platelet by the P3 integrin receptor, GPIIb-Illa. This occurs via specific regions 
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both in the fibrinogen molecule and the subunits of the GPIIb-Illa receptor (Smith et al, 1990; 
Kloczewiak et al, 1982; Takada et al, 1992; Bajt et al, 1992; D' Souza et al, 1990). Peptides 
incorporating these specific recognition sequences have been found to act as both agonists and 
competitive antagonists of integrin function (Plow et al, 1987; Du et al, 1991). It is tenable 
therefore, that products released following neutrophil membrane proteolytic degradation of fibrin 
may have the ability to modulate platelet function . Studies on the resulting platelet aggregation 
and clot retraction in the presence of these products were therefore performed. Platelet rich clots 
have been found to be relatively resistant to plasmic lysis (Falk, 1992), probably on the basis of 
platelet production of plasminogen activator inhibitor-I (Levi et al, 1992), increased clot 
retraction (Kunitada et al, 1992) and greater extent of crosslinking of the fibrin molecule (Reed et 
al, 1991 ). The role of the neutrophil in overcoming this inhibition together with the possible 
modulation by neutrophil membrane-derived fibrin degradation products in the fibrinolytic process 
was investigated. The theoretical basis behind this study was provided by Braaten et al (1994) 
who showed that the potent anti-adhesive peptide D-RGDW was able to "uncouple" fibrin from 
the platelet fibrinogen receptor and significantly increase the rate of plasmin-mediated fibrinolysis 
occuring at the platelet-fibrin interface. The use of neutrophil-derived products as opposed to 
synthetic peptides would provide a more realistic representation of what may occur in the in vivo 
situation. 
Plasmin digestion of fibrin gives rise to a number of predictable end products which have 
biological activity. These range from inhibition of neutrophil oxidative metabolism (Kazura et al, 
1989) and modulation of neutrophil endothelial cell interactions (Fischer et al, 1991) to effects on 
cell proliferation (Robson et al, 1993; Hatzfield et al, 1982) and the release of cell-derived 
growth-factors (Lorenzet et al, 1992). Significantly high concentrations of these products are 
found in the peripheral circulation of patients receiving exogenous thrombolytic drugs as 
treatment for pathological thromboembolic conditions such as myocardial infarction, pulmonary 
embolism and deep vein thrombosis. These therapeutic agents have also been found to 
significantly increase the number of circulating activated neutrophils (Ranjadayalan et al, 1991; 
Adams et al, 1995). Only two very recent publications have addressed the question of neutrophils, 
and more specifically human neutrophil elastase, secondarily digesting these plasmin-derived fibrin 
products (Leavell et al, 1996; Bach-Gansmo et al, 1996). This study attempts to investigate more 
closely the role of neutrophil lysosomal enzymes in degrading these products and to characterize 
the enzymatic and biochemical processes involved. 
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It is hoped that the studies undertaken will provide a greater understanding of neutrophil 
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CHAPTER2 
Fibrinogen and fibrin 
Introduction 
Maintenance of the integrity of the vascular system plays a key role in survival. Central to this role 
is the plasma glycoprotein, fibrinogen, which participates in the final phase of the blood 
coagulation cascade. Elucidation of the function and structure of this remarkable molecule, which 
on exposure to the protease thrombin is able to transform from soluble fibrinogen within the 
plasma to a gel-like fibrin clot, the primary ingredient of blood clot, has occupied the energies and 
attention of scientists for many decades. Investigations have encompassed both the ambit of 
conventional protein chemistry and the rapidly emerging field of molecular biology. The 
proteolytic alteration of fibrinogen from a soluble molecule into fibrin is characterized by the 
formation of fibrin monomer, which can then link up with other monomers and form a long 
thread-like insoluble polymer, fibrin . Polymerized fibrin serves as a template for the localized 
assembly and activation of the fibrinolytic system which modulates fibrin deposition and clot 
dissolution. Binding of fibrinogen to vascular cells such as platelets supports platelet aggregation 
and to endothelial cells facilitates tissue repair. The interaction of fibrinogen with platelets and 
neutrophils will be discussed within the relevant sections in the literature review. 
Approximately 75% of the body's fibrinogen is found within the plasma (Takeda, 1966) but it is 
also found distributed within the interstitial fluid and the lymph. Plasma fibrinogen is synthesized 
exclusively by hepatocytes at a rate of 1.7 to 5 g/day (Straub, 1963; Takeda, 1966) in the steady 
state situation, and has a half-life of 3 to 5 days once in the plasma (Collen et al, 1972). However, 
the synthetic reserve for fibrinogen is large and up to 20-fold increases in production may occur 
(Reeve and Franks, 1974) in response to a variety of stresses including inflammation, trauma and 
pregnancy (Aronsen et al, 1972). Fibrin degradation products (FDP's), in particular fragment D, 
appear to play a major role in controlling synthesis of fibrinogen by feedback mechanisms (Nham 
and Fuller, 1986). In a rat hepatocyte model this fragment interacts with peripheral blood 
monocytes/macrophages which in turn produce hepatocyte-stimulating factor (Ritchie et al, 1982) 
or interleukin-6 (IL-6) (Gauldie et al, 1987) which are able to increase fibrinogen synthesis. IL-6 
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is thought to activate an intracellular mechanism involving protein kinase C (PKC) to stimulate 
the production of the mRNAs for fibrinogen (Evans et al, 1987). 
Platelets represent an additional fibrinogen source (Castaldi and Caen, 1965) and make up 
approximately 3% of the circulating plasma pool. Controversy exists regarding whether this 
fibrinogen is functionally, metabolically or structurally different from plasma fibrinogen (Doolittle 
et al, 1974; James et al, 1977). The site of platelet fibrinogen synthesis also remains a matter for 
debate. There is evidence to suggest that megakaryocytes may synthesize fibrinogen (Levin et al, 
1985) but an increasing number of studies indicate that endocytosis of exogenous fibrinogen 
occurs with incorporation of exogenous fibrinogen into the platelet a-granules (Harrison et al, 
1989). It appears that endocytosis may occur following binding of fibrinogen to the GPIIb-Illa 
integrin receptor (see Chapter 4) (Harrison et al, 1990). This study was further substantiated by 
Handagama et al (1993) in experiments where kistrin was used to block endocytosis of fibrinogen 
into guinea pig megakaryocyte and platelet a-granules. Kistrin belongs to a group of integrin 
inhibitory proteins isolated from viper venoms termed disintegrins which contain the Arg-Gly-Asp 
sequence through which they bind to GPilb-Illa. The question of how fibrinogen is able to bind to 
unstimulated platelets and become endocytosed is controversial. It has been suggested that shear 
stress may induce fibrinogen binding to GPIIb-Illa in the peripheral circulation, fibrinogen may 
become immobilised to biological surfaces and thereafter bind to GPIIb-Illa or alternatively 
platelets may undergo cycles of activation within the circulation allowing them to bind fibrinogen 
(Handagama et al, 1995). 
Fibrinogen is a large dimeric glycoprotein with a molecular weight of 340 kDa, which 
corresponds to a total of about 3000 amino acids. It is made up of three pairs of disulfide bonded 
polypeptide chains termed Aa (610 amino acids), B~ (461 amino acids) and y (441 amino acids) 
with molecular weights of 66 kDa, 52 kDa and 46.5 kDa respectively (McKee et al, 1966; 
Henschen et al, 1983; Doolittle, 1983). The six polypeptides are arranged into three globular 
domains, the central E-domain and two excentric and larger D-domains which are linked by a 
coiled-coil triple helix structure of 111 amino acids (Doolittle et al, 1978). The presence of the 
coiled-coil region of fibrinogen has important consequences for the assembly of the three chains, 
the mechanical properties of the resultant fibrin fibres and plasmic digestion of the fibrin clot 
(Hantgan et al, 1994). The computed molecular weight of the total molecule is therefore 
approximately 330 kDa. However, although the Aa chain contains no carbohydrate, the B~ and y 
chains have four carbohydrate sidechains linked through N-acetylglucosamine to asparagine 52 of 
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each y chain and asparagme 364 of each BP chain (Mills and Triantaphyllopoulos, 1969; 
Blomback et al, 1973; Tepfer-Peterson et al, 1976) which increases the molecular weight to 340 
kDa (Scheraga and Laskowski, 1976). 
The three pairs of polypeptide chains of the fibrinogen molecule are held together by 29 disulfide 
bonds. This dimeric molecule consists of two half-molecules, with each half molecule containing 
the three nonidentical polypeptide chains. The two half molecules are joined by three symmetrical 
disulfide bonds between adjacent Aacys28 and ycys8 and cys9 (Blomback et al, 1976; Hoeprich 
and Doolittle, 1983) as well as a disulfide link between Aacys36 of one half molecule and Bpcys6s 
of the other half molecule (Huang et al, 1993). The central E domain contains the amino termini 
of the 6 polypeptide chains. The two terminal D domains are formed by globular carboxy terminal 
(C-terminal) domains of the BP and y chains. The C-terminal globular domains of the larger Aa 
chains are thought to fold back and contribute to the structure of the central node (Weisel et al, 
1986). The coiled-coil alpha-helical region of 111 amino acids is flanked, in each of the 
polypeptide chains, by 2 pairs of cysteines which are involved in interchain linkages within each 
half molecule and are termed disulfide rings (Doolittle et al, 1978). The disulfide rings which flank 
the coiled-coil region play an important role in the interchain assembly of the half molecules of 
fibrinogen as well as in the final dimer formation (Zhang and Redman, 1994). In addition there are 
several intrachain disulfide bonds. In all, 29 disulfide bonds (Blomback et al, 1968); 8, 11 and 10 
cysteine residues on the Aa, BP and y chains respectively with all of the 58 cysteine residues in 
the molecule participating in these 29 disulfide bonds (Henshen, 1964; Garlund et al, 1977). In all 
vertebrate species studied this complex disulfide-linked fibrinogen structure is essentially the same 
with a probable common assembly pathway (Oddoux and Grieninger, 1994). 
The a , P and y chains of the molecule are encoded by three independent genes present on 
chromosome 4 (Chung et al, 1983a, 1983b, 1990; Rixon et al, 1983; Kant et al, 1985). Extensive 
homology exists between the amino acid sequences of the three chains as well as between various 
species studied indicating that the present fibrinogen genes evolved from a common ancestral 
gene (Doolittle et al, 1979). The individual polypeptide chains are processed, glycosylated and 
assembled. This assembly into the fibrinogen complex occurs within the endoplasmic reticulum of 
the cell (Hurtley and Helenius, 1989) with BP chain synthesis appearing to be the rate limiting 
step in fibrinogen assembly (Roy et al, 1991). Newly synthesized BP chains are used and secreted 
more rapidly than Aa or y chains and a large intracellular pool of free a and y chains exists. The 
BP chains appear to bind to BiP, the immunoglobulin heavy chain binding protein, thought to act 
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as a so-called "molecular chaperone" within the endoplasmic reticulum. It is involved in the 
assembly of immunoglobulin chains as well as aiding in folding, assembly and oligomerization of 
proteins together with prevention of transport of malformed or aberrantly glycosylated proteins 
(Kassenbrock et al, 1988). The BP domain between amino acids 73 and 93 is necessary for the 
assembly of the three fibrinogen chains and marks the start of the alpha-helical "coiled-coil" 
region of fibrinogen (Zhang and Redman, 1992). In addition to disulfide bonds mentioned 
previously, noncovalent interactions of other amino-terminal amino acid residues in the three 
fibrinogen chains are also of importance in dimer formation (Zhang and Redman, 1996). Although 
surplus fibrinogen chains occur intracellularly within hepaocytes, only fully assembled fibrinogen 
is secreted (Plant and Grieninger, 1986). Degradation of surplus polypeptide chains of fibrinogen 
may occur in the endoplasmic reticulum or lysosomes of the cell (Kassenbrock et al, 1988). 
Three high affinity binding sites for calcium have been characterized on human fibrinogen, two of 
which are associated with the D-domain while the site of the third remains controversial. 
Marguerie ( 1977) favoured a site formed by the two a-chain extensions while Niewenhuizen 
( 1981) assigned the third site to the central domain. These calcium binding regions are fully 
occupied in circulating fibrinogen (Nieuwenhuizen et al, 1981 ). Low affinity calcium binding sites 
are also thought to exist, with evidence to suggest that sialic residues in human fibrinogen fulfil 
this role (Dang et al, 1989). These divalent ions play a major role in maintaining the structure and 
stability of fibrinogen. Millimolar calcium concentrations limit the extent of plasmin digestion of 
both fibrinogen and fibrin (Haverkate and Tiinan, 1977) and protect fibrinogen against 
denaturation by heat (Ly and Goda!, 1973) and acidic pH (Margeurie, 1977). The presence of 
calcium is also able to accelerate fibrin formation (Boyer et al, 1972) and the mechanical strength 
of these fibrin clots, formed in the presence of millimolar concentrations of calcium, are 
considerably greater (Shen et al, 1975). In addition, the transglutaminase factor XIIIa, essential 
for covalent stabilization of the fibrin molecule is functionally dependent on the presence of 
calcium (Laudano and Doolittle, 1981 ). 
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Figure 1 Schematic model of fibrinogen and its conversion to fibrin monomer by the action of thrombin. The 
1ibrinogen molecule consists of three pairs of polypeptide chains Aa., BP and y. The central E domain contains the 
N-terminal regions of all six chains joined by disulfide bonds to form a dimeric structure. Conversion of fibrinogen 
to fibrin is initiated by the action of thrombin, leading to the release of fibrinopeptides A and B from the Aa. and 
B~ chain respectively. Also indicated are the binding sites on the molecule for Ila, t-PA, factor XIII and a.i-








The conversion of soluble fibrinogen into the insoluble fibrin polymer involves three steps: the 
thrombin catalyzed removal of fibrinopeptides, a non-covalent assembly process and covalent 
stabilization of fibrin by factor Xllla-catalyzed crosslinking. In addition to the importance of fibrin 
in creating a haemostatic plug in trauma and acting as a temporary matrix in wound healing and 
inflammation, more recently other functions have been ascribed to this insoluble protein. Qi and 
Kreatzer (1995) were able to demonstrate that the presence of fibrin matrix in cultures of 
endothelial cells isolated from calf pulmonary endothelium was able to induce endothelial 
morphological changes. These included cell retraction and disorganization and occurred in a 
protein concentration dependent manner and were reversible on removal of the clot. In this same 
study fibrin was also shown to induce leukocyte chemotactic activity, possibly related to 
interleukin-8 (IL-8) expression in these vascular endothelial cells. Following thrombin-induced 
cleavage of fibrinopeptide B from fibrinogen, a fibrin-specific region is exposed which appears to 
play an important role in stimulating vascular cell responses. These include spreading of platelets 
and endothelial cells as well as the release of von Willebrand factor (vWf) (Ribes et al, 1987; 
Bunce et al, 1992; Hamaguchi et al, 1993). Sporn et al (1995) were able to show that cell 
proliferation, an important determinant of revascularization, requires exposure of this same fibrin-
specific site. The biological role ofFDP's will be discussed later on in this chapter. 
The serine protease thrombin not only plays a central role in haemostasis but is also an activator 
of many cell-mediated events. Functional domains throughout the molecule are involved in the 
processes of cell adhesion, chemotaxis and proliferation (Bar-Shavit and Wilner, 1986; Bar-Shavit 
et al, 1992). It has been suggested that plasminogen activators associated with extracellular 
matrix may play an important role in converting the circulating zymogen prothrombin to 
thrombin. The thrombin generated also binds to extracellular matrix to exert functional effects 
involving cellular invasion, proliferation and growth (Benezra et al, 1993). Clot-bound thrombin 
is able to act as a reservoir for enzymatically active thrombin which is resistant to inactivation by 
circulating thrombin inhibitors (Weitz et al, 1990). This bound thrombin is able to activate factor 
XIII, necessary for covalent stabilization of the fibrin molecule (see next section). 
Thrombin acts on fibrinogen to hydrolyse specific Arg-Gly bonds on the Aa and B~ chains to 
release two peptides, fibrinopeptide A and B (Blomback, 1958). Thrombin specificity appears to 
be due in part to the presence of a set of hydrophobic residues in the Aa chain (Aa16_17) of 
fibrinogen which bind with a complementary apolar region on thrombin. This interaction positions 
11 
the ArgwGly17 peptide bond of the Aa chain within the catalytic site of thrombin (Marsh et al, 
1983; Ni et al, 1989). The active site within the thrombin molecule can be considered as two 
separate domains: a catalytic site that includes the Arg-His-Ser catalytic residues and an extended 
fibrinogen recognition site distinct from the catalytic site (Binnie and Lord, 1993). Thrombin 
binds to the central domain of the fibrinogen molecule via ionic interactions (Vali and Scheraga, 
1988; Kaczmarek and McDonagh, 1988), facilitated by a cluster of positively charged residues in 
the thrombin molecule termed the "anion-binding exosite" (Fenton et al, 1988). Fibrinopeptide A 
release, through cleavage at ArgwGly17 in the Aa fibrinogen chain, initially occurs more rapidly 
than release of fibrinopeptide B. This delay is thought to be necessary for normal protofibril and 
fibre assembly. After a lag period fibrinopeptide B release accelerates, a mechanism thought to be 
due to the presence of polymerized protofibrils (Ruff et al, 1988). Following fibrinopeptide B 
release, through cleavage of the BP chain at ArgwGly15, lateral aggregation occurs allowing for 
the formation of thick, well-ordered fibres (Weisel et al, 1993). 
The thrombin release of fibrinopeptides A and B results in the formation of the intermediate fibrin 
monomer and exposure of new binding sites. Loss of fibrinopeptide A exposes the peptide 
sequence Gly-Pro-Arg (GPR) and allows calcium-dependent binding on the E domain of the 
fibrinogen molecule with a complementary site y357_373 (Cierniewski and Budzynski, 1993) on the 
outer D domain of another fibrinogen molecule (Olexa and Budzynski, 1980). Removal of 
fibrinopeptide B exposes a site on the E domain involving the sequence Gly-His-Arg-Pro (GHRP) 
which binds non-covalently to a complementary region on another fibrinogen molecule. Various 
other complementary regions have been proposed and include the y chain of the distal D domain 
(Weisel, 1986), the C-terminal region of the Aa chain (Hasegawa and Sasaki, 1990) and the distal 
domain of the BP chain (Laudano and Doolittle, 1981 ). Although the GPR region in the Aa 
chain, exposed by thrombin release of fibrinopeptide A, acts as a very effective inhibitor of fibrin 
polymerization (Kawasaki et al, 1993; Laudano and Doolittle, 1980) the GHRP peptide, exposed 
during thrombin cleavage of the B p chain, is unable to prevent polymerization (Laudano and 
Doolittle, 1980 and 1981). Following release of fibrinopeptides, polymer formation is initiated by 
noncovalent intermolecular interactions between D and E domains (Olexa and Budzynski, 1980; 
Budzynski et al, 1983) forming double-stranded staggered and overlapping fibrils (Mosseson, 
1990). Thereafter, lateral fibrin association occurs causing an increase in fibril thickness (Hewat et 
al, 1983). The C-terminal portion of the Aa-chains, which extend from the D-domain (Farrell et 
al, 1993), are important for lateral aggregation by intramolecular interaction of the Aa C-domains 
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(Gorkun et al, 1994). However, the C-terminal portions of the Aa chain are susceptible to 
plasmin cleavage and these free fragments are then able to compete for complementary binding to 
adjacent fibrin molecules, interfering with the normal polymerization process (Veklich et al, 
1993). 
Fibrin stabilization and crosslinking by factor XIII 
The final step in formation of an insoluble fibrin clot involves formation of covalent isopeptide 
bonds (Folk et al, 1977), a reaction which is catalyzed by a calcium dependent enzyme, factor 
XIIIa or plasma transglutaminase. Isopeptide linkages are formed by replacing the y-amide group 
of glutamine residues of one chain with the E-amino group of lysine residues of another chain 
(Folk et al, 1977). Factor XIIIa may be generated from two zymogen forms of the enzyme: 
plasma factor XIII, an a2b2 tetramer that circulates freely in the plasma, and platelet factor XIII, 
an a2 dimer found primarily in platelets and placenta (Hornyak and Shafer, 1992). Platelets have 
been shown to contain nearly 50% of blood factor XIII (McDonagh et al, 1969, Lopaciuk et al, 
1976) and provide additional factor XIII at sites of vessel injury or thrombosis where they 
accumulate in reponse to tissue damage. A tissue transglutaminase also exists as a cytosolic 
enzyme present in a variety of cells. It is released into the plasma environment during haemolysis 
or from endothelial cells during atherosclerotic plaque formation. This tissue transglutaminase is 
reported to be responsible for intramolecular crosslinking between the constituent Aa and y 
chains of monomeric fibrinogen, giving rise to an Aa.y hybrid which is virtually incoagulable by 
thrombin (Murthy et al, 1991). 
Plasma factor XIII is activated by the thrombin-catalyzed proteolysis at Arg37 in the a subunits 
releasing an activation peptide (Ichinose et al, 1986a). Exposure of the cleaved zymogen to 
calcium ion results in dissociation of the b subunits yielding catalytically active factor XIIIa 
(Lorand and Konishi, 1964; Chung et el, 1974). The zymogen form of plasma factor XIII 
circulates as a complex bound to the D domain of plasma fibrinogen (Greenberg and Schuman, 
1982; Mary et al, 1987). In fibrin stabilization, several crosslinking reactions occur including 
formation of fibrin y-chain dimers (Chen and Doolittle, 1971), incorporation of the plasmin 
inhibitor, ai-antiplasmin, into the a-chain of fibrin (Sakata and Aoki, 1980) and the formation of 
fibrin a-chain polymers (McKee et al, 1970), which is the critical determinant in maintaining clot 
integrity (Gaffney and Whitaker, 1979). The C-terminal part of the Aa chain is an autonomous, 
functionally active and flexible region that plays a key role in a polymer formation and 
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functionally active and flexible region that plays a key role in a polymer formation and 
stabilization of fibrin clots by factor XIIIa (Mutsuka et al, 1996). The first two reactions are 
relatively rapid, occurring within 5 minutes after initiation of clot formation whereas the latter 
reaction may take many hours to complete (Finlayson and Aronsen, 1974). These reactions result 
in mechanical stabilization of the thrombus (Shen and Lorand, 1987) as well as increased 
resistance to plasmin mediated degradation (Gormsen et al, 1967). In the presence of high 
concentrations of factor XIII the fibrin produced exhibits greater size and complexity of highly 
crosslinked a-polymer chains and increased resistance to solubilization by plasmin (Francis and 
Marder, 1988). This increased resistance to plasmin degradation is due to multiple effects of 
factor XIII : decreased plasminogen binding (Sakata et al, 1984), increased inhibitor crosslinking 
(Sakata and Aoki, 1980) and the ability of factor XIIIa to crosslink both fibronectin (Mosher, 
1975) and vWF (Hada et al, 1986) to fibrin Aa chains. In addition, rigidity and elasticity of the 
gel are dependent on the extent of factor XIII crosslinking (Shen et al, 1975; Gladner and Nossal, 
1983). In vivo proof of the participation of factor XIII in clot rigidity was shown by the use of a 
factor Xllla inhibitor, L-722,151, before initiation of thrombus formation in a canine model of 
coronary thrombosis. Administration of the inhibitor was associated with a threefold decrease in 
thrombolysis time when using tissue-type plasminogen activator (t-P A) (Shebuski et al, 1990). 
Fibrin polymers have been found to be responsible for the fibrin( ogen)-dependent acceleration of 
factor XIII activation (Lewis et al, 1985) but this occurs only when the y-y dimer formation is less 
than 40% complete (Lewis et al, 1985). This ensures targeting of factor XIIIa activity at the 
growing fibrin protofibrils, without excessive crosslinking within the fully assembled fibrin clot. 
The net re~ult of the fibrin assembly process is the formation of a three dimensional, highly 
interconnected network of fibrin fibres which functions as a haemostatic plug (Hantgan et al, 
1994). Fibrin clots formed by these non-covalent interactions will, under the influence of various 
forces, undergo viscous deformation changes (Mosseson, 1990). However, incorporation of 
covalent bonds into their structure by the transglutaminase factor Xllla dramatically changes the 
viscoelastic properties of the clot (Mosseson, 1990). 
Plasmic digestion of fibrin( ogen) 
Modification of soluble fibrinogen by thrombin to form an insoluble fibrin network is essential for 
wound healing and haemostasis. However, it is of paramount importance that there exists a 
system to allow for dismantling of this fibrin clot as wound repair progresses and to act as a 
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safeguard against the threat of thrombosis and embolism. A proteolytic process complementary to 
the one that generates thrombin is thus present and dissolution progresses primarily through a 
plasmin mediated pathway. Circulating plasminogen binds selectively to fibrin allowing for 
generation of plasmin activity at the clot surface (Nieuwenhuizen, 1988; Fears, 1989). The 
zymogen plasminogen, released from vascular endothelial cells, is converted to active plasmin via 
t-PA, a serine protease showing specificity for the Arg561-Vals62 peptide bond in plasminogen 
(Collen, 1980). In addition to its action in plasminogen activation recombinant t-PA is able to 
release fibrinopeptides A and B from fibrinogen (Weitz et al, 1988). 
t-PA binds to the D-domain of fibrin( ogen) and two distinct CNBr fragments of fibrinogen (FCB) 
in this region, namely FCB-2 and FCB-3, have been found to contain amino acid sequences 
required to stimulate plasminogen activation by t-P A (Niewenhuizen et al, 1983; Schiel en et al, 
1991 ). Binding oft-PA to fibrin involves, for the most part, a lysine-independent interaction with 
the D-domain contributed by sequences present in FCB-5 and FCB-2. A lysine-dependent 
interaction with FCB-2 only is also detectable but is probably only of minor relevance (Grailke et 
al, 1994). U rokinase-type plasminogen activator ( u-P A) is also a highly specific serine protease 
that cleaves plasminogen at the same site as t-PA to generate active plasmin (Linjen and Collen, 
1991 ). It is synthesized by a variety of human cells and secreted initially as prourokinase or single-
chain urokinase which is enzymatically inactive. Following cleavage of urokinase at Lys158-Ile159 
by a variety of proteases including plasmin it is converted to active two-chain urokinase (Nielsen 
et al, 1982; Ichinose et al, 1986b). It has been reported that t-PA, which binds strongly to fibrin, 
is primarily involved in fibrinolysis whereas u-P A, which does not show significant affinity for 
fibrin, is involved in degradation of the tissue matrix of basement membrane proteins (Thorsen et 
al, 1972; Blasi et al, 1987). However, Husain (1993) has shown that in the presence of zinc, 
single-chain u-P A is specifically and effectively bound to fibrin and therefore may have a role to 
play in fibrinolysis . Plasminogen and t-PA bind specifically to the fibrin clot surface 
(Nieuwenhuizen, 1988) and plasmin generated fragments of fibrin, D-dimer, and fibrinogen are 
able to accelerate plasminogen activation (Verheijen et al, 1982). The sites within the molecule 
responsible for the enhanced activation appear to reside at positions Aa148•160 (FCB-2) 
(V orskuilen et al, 1987) and y311.319 (FCB-5) (Yonekawa et al, 1992), portions of the Aa and y 
chain exposed during the conformational changes occurring following cleavage of fibrinopeptide 
A and B (Schielen et al, 1991 ). Therefore fibrin is able to regulate its own destruction. 
Plasminogen has been shown to accumulate severalfold in a superficial layer on clot during lysis 
(Sakharov and Rijken, 1995). Under conditions of diffusional transport of fibrinolytic enzymes 
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from outside a clot, which occurs in situations when insignificant or no pressure is applied across 
the thrombus (non-occluding thrombi, venous thrombus), extensive lysis appears to be restricted 
to a zone of 5-8 µm from the clot surface and a sharp zone of demarcation exists between 
completely lysed and virtually non-lysed areas of a clot (Sakharov et al, 1996). This allows for a 
layer by layer dissolution of thrombi without the release of partially lysed but insoluble material 
into the circulation. 
Fibrinolysis appears to follow a similar course to that of plasmin mediated fibrinogenolysis 
(Gaffney, 1973) with remarkably similar products being generated (Gaffney, 1973; Ferguson et al, 
1975). Thus, the intermolecular associations between the fibrin units, which are limited to the 
nodular bodies of the fibrin monomers, do not protect them from proteolytic attack. In addition 
plasmin, which shows a specificity for lysyl peptide bonds (Plow, 1980), needs only to cleave at 
the narrow three-stranded connectors to initiate dissolution. Thereafter, digesti<?n may then 
continue until the production of a set of core products (Pizzo et al, 1973 ). 
Plasmin begins its digestion of fibrinogen by attack at several sites within the Aa chain from the 
carboxyl terminus. This releases several Aa chain peptides termed fragments A, B and C, with 
molecular weights of approximately 15 k.Da (Pizzo et al, 1973) and the fibrinogen product, 
fragment X (240-265 k.Da) which may exist in a number of forms depending upon the extent of 
Aa chain and subsequent B 13 chain degradation. The y chain of the molecule is the most resistant 
to degradation but as it begins to break down and the a and 13 chains are further cleaved, other 
forms of fragment X along with fragments D (83-100 k.Da), E (41 k.Da) and Y (approximately 
150 k.Da) appear. Fragments X and Y are transient intermediate products whereas A-E represent 
terminal products of plasmin digestion (Doolittle, 1984). Fragment D contains extensively 
degraded Aa chains and partially degraded Bl3 and y chains. In addition fragment D may contain 
different forms of the cleaved y chain (Pizzo et al, 1973). Fragment E contains extensively 
degraded Aa, Bl3 and y chains which are linked through disulfide bonds. 
The major difference between fibrinogen and fibrin digests is observed with factor XIIIa-stabilized 
fibrin. Factor XIII transglutaminase catalyzes a reaction in which an isopeptide linkage is formed 
by replacing the y-amide group of glutamine residues of one chain with the E-amino group of 
lysine residues of another chain (Schwartz et al, 1973). This cross-linking of two antiparallel 
gamma-chain regions results in plasmin digestion generating D-dimer fragments and not individual 
D fragments (Chen and Doolittle, 1971). In addition, interaction of the central E domain with two 
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complex to be isolated (Hundry-Clergeon et al, 1974; Gaffney et al, 1975). Crosslinked fibrin 
polymers circulating within the plasma are linked primarily through their y chains and the plasmic 
degradation product of these crosslinked fibrin polymers is D-dimer (Kornberg et al, 1992). 
During fibrinolysis, plasmic digestion releases soluble products that remain complexed to active 
thrombin (Francis et al, 1983) which may be important in the phenomenon of rethrombosis 
following thrombolytic treatment (Mirshahi et al, 1989). Also of interest is that cross-linked 
complexes from plasmin dissolved clot that have been observed by electron microscopy reveal 
plasminogen bound to the end of fibrin. This allows for bridging of the ends of two fibrin 
molecules with the formation oflarger complexes (Weisel et al, 1994). 
The incorporation of cellular components such as platelets and leukocytes into fibrin clots may 
have a significant effect on the speed of subsequent clot lysis (see chapter 4). Actin filaments 
released from cells as a consequence of cell death may also become entrapped within a developing 
thrombus. Their presence, which renders the thrombus more brittle and unable to withstand 
substantial deformation without structural changes, is able to inhibit plasmin-mediated fibrinolysis 
through a change in the viscoelastic property of the clot (Janmey et al, 1992). 
Nonplasmin-mediated fibrinolysis 
The well characterized plasminogen/plasmin system has long been seen as the major component in 
contributing to fibrinolysis . However, it has become clear that the cellular consituents of the 
blood, and in particular the neutrophil, play a significant role in the fibrinolytic process. This 
cellular activity may be increased by various stimuli including exercise (Langleben and Moroz, 
1985), venous occlusion (Hammouda and Moroz, 1986) and surgical trauma (Moroz and 
MacLean, 1979). It has been suggested that the success of exogenous thrombolytic therapy in 
producing coronary reperfusion following acute myocardial infarction is due to intrinsic cellular 
phase activity present before the initiation of treatment (Langleben et al, 1990). Rulot (1904) and 
Opie ( 1907), at the turn of the century, showed that leukocytes contain proteolytic enzymes that 
are capable of digesting fibrin and that the presence of leukocytes within a fibrin clot is able to 
significantly increase the rate of fibrinolysis . Leukocytes are found in close contact to fibrin at 
sites of ongoing inflammatory activity. They accumulate intravascularly, within complex thrombi 
consisting of fibrin and platelets (Barnhart, 1965) and more recently have been found to be 
incorporated into platelet-rich clots due to specific cellular adhesive processes, related to the 
expression of P-selectin on activated platelets binding to a counter receptor on the neutrophil 
membrane (Palabrica et al, 1992). Extravascular accumulation may also occur under 
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membrane (Palabrica et al, 1992). Extravascular accumulation may also occur under 
circumstances where leukocytes migrate to sites of injury associated with fibrin deposition (Riddle 
and Barnhart, 1964). Neutrophils express the cellular receptor for urokinase-type plasminogen 
activator (uPA-R). This receptor also associates in a reversible fashion with the leukocyte integrin 
Mac-1 (Kindzelskii et al, 1996). Following binding of u-PA to its receptor the enzyme becomes 
localized to the surface of the cell which may facilitate neutrophil infiltration into fibrin clot, 
enhancing fibrinolysis (Henjgers et al, 1995) .. Although it was noted in 1907 (Opie) that white 
blood cells can dissolve fibrin clots the majority of studies have investigated fibrinogenolysis 
rather than fibrinolysis by leukocytes. 
In 1984 Moroz stated that "all fibrinolytic activity that is extractable from PMN (neutrophils) can 
be accounted for by two lysosomal enzymes, the elastase-like proteinase (PMN elastase) and the 
chymotrypsin-like proteinase ( cathepsin G)", a view supported by many other investigators (Plow, 
1980; Plow and Edgington, 1978; Schmidt and Havemann, 1977). These enzymes, present within 
the primary granules of the cell (Ohlsson et al, 1977), are capable of degrading both fibrinogen 
and fibrin in a manner that is distinct from that of plasmin (Plow and Edgington, 1975). Gramse et 
al ( 1978) looked at fibrinogen degradation by purified human neutrophil elastase, the major 
enzyme responsible for neutrophil-mediated fibrinogenolytic activity (Bilezikian and Nossel, 
1977), and found the Aa chain to be highly susceptible to this enzyme with the y chain much less 
susceptible. Degradation was progressive as well as time and concentration dependent, whereas 
plasminolysis gave rise to specific end products. Elastase shows specificity for alanyl peptide . 
bonds and release of fibrinopeptide A and fibrinopeptide B containing fragments occurs early on, 
following its interaction with fibrinogen, whereas plasmin produces a fibrinopeptide A containing 
fragment only at the final stages of digestion (Bilezikian and Nossel, 1977; Plow 1980). The initial 
elastase-derived degradation products arise from cleavage at the C-terminus of the molecule 
(Bach-Gansmo et al, 1994) and have anticoagulant properties but unlike plasmin, cleavage is not 
confined to the carboxyl termini of the Aa and BP chains (Plow, 1980). Cathepsin G also 
contributes to the fibrinogenolytic and fibrinolytic action of the neutrophil (Plow, 1980) and 
shows specificity for leucyl bonds as well as aromatic amino acids (Zimmerman and Ashe, 1977), 
in contrast to plasmin which shows specificity for lysyl peptide bonds (Weinstein and Doolittle, 
1972). In the presence of calcium chloride cathepsin G initially cleaves the Aa chain followed by 
the BP and then the y chain of fibrinogen (Gramse et al, 1980), whereas in the absence of calcium 
ions they chain shows greater susceptibility to cathepsin G than the BP chain. Elastase has been 
shown to inactivate plasminogen activator inhibitor- I (P AI-1) leading to enhanced fibrinolysis 
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and cathepsin G with limited proteolysis giving rise to miniplasminogen, which is more readily 
activated by plasminogen-activators (Machovich et al, 1990). Impaired clot lysis in the presence 
of neutrophil elastase has also been described due to reduced t-PA mediated activation of 
plasminogen (Bach-Gansmo et al, 1995). 
Kolev et al (1996) investigated the relative contributions of plasmin, miniplasmin, neutrophil 
elastase and cathepsin G to the fibrinolytic process. Mini-plasminogen is produced following 
exposure of plasminogen to neutrophil elastase. Activation by plasminogen-activators yields 
miniplasmin (Moroz, 1981 ), a molecule with enhanced fibrinolytic activity compared to plasmin 
and relatively resistant to inhibition by a 2-antiplasmin (Moroz, 1981 ). When present on the 
surface of preformed clot elastase and cathepsin G were less efficient than plasmin and mini-
plasmin at fibrin degradation. Under conditions of crosslinking of the clot by factor Xllla in the 
presence of a 2-antiplasmin there is increased clot resistance to plasmin and mini-plasmin while the 
action of leukocyte proteases is· unaffected. Both elastase and cathepsin G are able to potentiate 
the action of plasmin on crosslinked fibrin containing plasmin inhibitor, possibly by their 
conversion of plasmin to miniplasmin and inactivation of plasmin inhibitor (Kolev et al, 1996). 
Numerous elastase inhibitors are found within plasma and interstitial spaces (Travis and Salvesan, 
1983). However, Weitz et al (1987) were able to show that N-formyl-methionyl-leucyl-
phenylalanine (FMLP)-stimulated neutrophils, migrating through fibrinogen-coated filters in the 
presence of proteinase inhibitors, were still able to exhibit significant elastase-mediated 
fibrinogenolytic activity. In contrast, these same proteinase inhibitors were able to completely 
block the fibrinogenolytic activity of soluble purified elastase. An explanation for this 
phenomenon was provided by Loike et al (1992). FMLP-stimulated neutrophils are able to 
interact with fibrinogen coated surfaces via the adhesive surface-membrane receptors, the f3r 
integrins. One of the consequences of this interaction is that protected compartments are formed 
allowing for release of proteases into an enviroment protected from proteinase inhibitors present 
within the plasma. These compartments are able to exclude plasma proteins of >40 kDa and thus 
enable neutrophil proteases to degrade extracellular matrix components despite the presence of 
inhibitors. A role for oxidant inactivation of proteinase inhibitors, in particular a 1-proteinase 
inhibitor, has been suggested (Carp and Janoff, 1978; Matheson et al, 1981 ). In view of the fact 
that stimulated neutrophils are a source of oxidant activity it was proposed that they may play a 
role in decreasing the local elastase inhibitory capacity of a 1-proteinase inhibitor (Carp and Janoff, 
1979). However, Campbell et al (1982) were unable to show that this was the case under 
19 
1979). However, Campbell et al (1982) were unable to show that this was the case under 
physiological conditions due to the presence of antioxidants and competetive antagonists. This 
remains a controversial point however, as Bangalore and Travis (1994) were able to show that 
upon degranulation of neutrophils stimulated by FMLP or phorbol 12-myristate 13-acetate 
(PMA), released elastase and cathepsin G are able to re-bind in an active form to the neutrophil 
membrane, in a form relatively resistant to proteinase inhibitors. In addition, myeloperoxidase is 
released and likewise is capable of binding to the cell membrane where it was found to oxidatively 
inactivate a.1-proteinase inhibitor. Owen et al (1995a) showed in a similar study that membrane 
bound elastase and cathepsin G remain catalytically active, yet relatively resistant to proteinase 
inhibitors. 
More recently a 600kDa neutrophil membrane neutral protease has been described capable of 
degrading fibrinogen in a manner distinct from that of neutrophil lysosomal enzymes and plasmin 
(Kelly et al, 1994). It cleaves the bond between amino acids valine and glutamic acid at positions 
21 and 22 respectively from the Aa. chain to release an Aa.1-21 peptide, previously seen as a 
reflection of overall elastase activity (Weitz et al, 1986). Digestion of the B~ chain occurs at 
positions within the C-terminus while proteolysis of the N-terminus of the y chain is produced at 
the bond bet~een amino acids isoleucine and glycine at positions 394 and 395 (Kelly et al, 1994). 
The products thus formed do not exhibit anticoagulant activity. 
Relatively little data is available on the contribution of other . blood cells to fibrin( ogen)olysis. 
Platelets do possess proteases capable of digesting fibrin (Nachman and Ferris, 1968) but these 
appear to play only a minor role in the process (Moroz, 1977). Peripheral blood lymphocytes have 
been found to have no detectable fibrinolytic activity and erythrocytes negligible amounts while 
the fibrinolytic activity of eosinophils appears similar to that of neutrophils (Moroz, 1984). 
Monocytes do possess fibrinolytic potential although this is at a relatively low level compared to 
that provided by the neutrophil (Grau and Moroz, 1989). Werb and Gordon (1975) described 
elastase secretion by macrophages. This enzyme was immunologically unrelated to neutrophil 
elastase. Release of monocyte non-plasmin fibrinolytic enzymes appears to be triggered by 
fibrin(ogen) contact with the cell (Grau and Moroz, 1989). This interaction with the cell is 
mediated via the CD 11 b/CD 18 integrin and following binding of fibrin( ogen) the ligand is 
internalized and degraded via a lysosomal-mediated pathway (Simon et al, 1993). It has now been 
shown that the enzyme responsible for monocyte-mediated plasminogen-independent fibrinolysis 
is cathepsin D. This is an aspartyl protease with a pH activity profile similar to that of neutrophil 
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lysosomal enzymes. Cleavage of the a., ~' and y chains by cathepsin D generates multiple low 
molecular weight fragments (Simon et al, 1994). 
Bioactivity of fibrin( ogen) degradation products 
Fibrin has long been recognised as an histological feature of both the acute and chronic 
inflammatory process. Moreover, fibrin( ogen)-derived proteolytic fragments have been found to 
produce many effects relevant to inflammation. High levels of FDP's are present during situations 
associated with ongoing thrombosis and fibrinolysis such as in patients with disseminated 
intravascular coagulation, commonly associated with septicaemia and eclampsia of pregnancy, and 
those receiving exogenous thrombolytic agents for treatment of pulmonary embolism or 
myocardial infarction. In particular the severity of atherosclerosis shows significant correlation 
with circulating fibrinogen and D-dimer levels (Lassila et al, 1993). The effectiveness of 
fibrinolytic therapy following administration for thrombosis is often monitored by the plasma 
levels of D-dimer. However, the D-dimer levels measured following fibrinolytic therapy may well 
be a result of the effect of plasmin on soluble fibrin monomer as well as lysis of solid thrombus 
(Francis and Kornberg, 1992). The fibrin(ogen) derived peptide B~3o-43 is a sensitive marker of 
neutrophil activation and proteolytic activity in clot lysis which occurs early in the course of acute 
myocardial infarction and is accelerated by fibrinolytic treatment (Sylven et al, 1992). The 
biological activity associated with these various products may have important immunomodulatory 
consequences in certain pathological situations. Numerous investigators have studied these 
effects, sometimes with conflicting results. 
Wound healing and atherosclerosis are processes that involve cell proliferation which is dependent 
on various growth factors. Lorenzet et al (l 992) were able to show that products generated by 
plasmin digestion of fibrinogen were able to increase the release of endothelial cell-derived growth 
factors from porcine aortic endothelial cells. This property appeared to be related to the low 
molecular weight FDP' s (ie <10 kDa) and was not displayed by intact fibrinogen, nor fragments D 
and E. Along with the release of growth factors, the low molecular weight products were also 
able to induce endothelial cell damage and with prolonged incubations, cell detachment and death. 
Human fibrinopeptide B, a 14 amino acid peptide released from the amino-terminus of the B~-
chains of fibrinogen by thrombin and also contained within the primary plasmin cleavage product 
of fibrinogen, has been shown to induce neutrophil chemotaxis without release of lysosomal 
enzymes or production of superoxide anion (Senior et al, 1986; Kay et al, 1974). Skogen et al 
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(1988) subsequently found that BJ3 1-42, released from the BJ3 chain offibrinogen by plasrnin, could 
act as a chemoattractant and this activity was not confined only to the BJ3 chain 1-14 segment. 
Other properties ascribed to low molecular weight polypeptides derived from fibrinogen include 
inhibition of lymphocyte blastogenesis (Edgington et al, 1985) as well as anticoagulant activity 
(Lau, 1993). Weitz et al (1991) showed that the soluble products oft-PA-induced lysis of cross-
linked fibrin are able to potentiate t-P A-mediated fibrinogenolysis by providing a surface for _t-PA 
and plasrninogen binding, and in doing so are able to promote plasrnin generation. 
The effects of fragment D on endothelial cell function have been extensively studied. High levels 
of this fragment are seen in patients with adult respiratory distress syndrome (Rinaldo and Rogers, 
1982), thrombotic thrombocytopaenic purpura (Ridolfi and Bell, 1981) and disseminated 
intravascular coagulopathy (Bell, 1980) which are associated with endothelial cell abnormalities. 
Dang et al (1985) showed that fibrinogen fragment D was able to produce a specific 
disorganization of cultured vascular endothelial cells with cell retraction, detachment and 
redistribution of actin filaments . The mechanism for this endothelial cell detachment has been 
ascribed to the ability of fragment D to increase secretion of endothelial plasrninogen activators 
which enhances the generation of plasrnin and contributes to the proteolysis of extracellular 
matrix (Ge et al, 1992). The effect of both fragment D and Eon neutrophil function has also been 
investigated. Kazura et al (1989) found that elevated levels of these products were able to inhibit 
several neutrophil functions critical to the bactericidal role of these cells. These included inhibition 
of superoxide release and chemotaxis in response to FMLP as well as inhibition of superoxide 
production on exposure to PMA and zymosan-activated serum. In addition, Fischer et al (1991) 
were able to demonstrate that at a concentration of 50 µg/rnl , fragments D and E were able to 
inhibit attachment of neutrophils to both glass and human umbilical vein endothelial cells. 
Fragment D has been reported to play a role in stimulating the proliferation of certain human 
haematopoietic cells (Hatzfeld et al, 1982). However, Robson et al (1993) reported that products 
with an intact D domain C-terminal y chain are able to inhibit lymphocyte proliferation in response 
to T-cell rnitogens, allogenic mononuclear leukocytes and anti-CD3 in vitro. Fragment DD (D-
dimer) binds specifically to monocytes by the integrin CDllb/CD18 (Altieri et al, 1990) and 
following intracellular degradation the synthesis and release of biologically active IL-1J3, IL-6 and 
plasrninogen activator inhibitors from monocytes is enhanced (Robson et al, 1994). 
Fragment E has been shown to be associated with both angiogenic and rnitogenic activity in 
experiments using chick chorioallantoic membranes (Stirk et al, 1993). The key event in the 
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Fragment E has been shown to be associated with both angiogenic and mitogenic activity in 
experiments using chick chorioallantoic membranes (Stirk et al, 1993 ). The key event in the 
formation of stenosing atherosclerotic lesions is thought to be focal smo.oth-muscle proliferation 
(Schwartz et al, 1990), thus fragment E may be playing an important role in this pathological 
process. The crucial event in conferring biological activity to this fragment appears to be the initial 
cleavage of fibrinopeptides from E by thrombin (Thompson et al, 1992) and is therefore confined 
to fibrin- and not fibrinogen-derived fragment E. 
Both fragment D and E have been found to exhibit anticoagulant properties. Fragment D, which is 
6-fold more potent as an anticoagulant than fragment E (Marder et al, 1969), inhibits fibrin 
polymerization by binding to sites complementary to it on the E domain of fibrin monomer (Olexa 
et al, 1981) whereas fragment E acts as an anticoagulant by competitive inhibition of the action of 
thrombin on fibrinogen (Larrieu et al, 1972). 
The biological effects of fibrin( ogen) degradation fragments are therefore numerous and varied 
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N eutrophils, first described by Ehrlich in 18 79, represent the first line of defense against invading 
pathogens both within the circulation and at extravascular sites and make up 90% of the 
circulating granulocyes. The granulocyte series, consisting of eosinophils, basophils and 
neutrophils, are produced in the bone marrow at a rate of approximately 80 million/min with a 
lifespan of two to three days (Roitt, 1989). Following differentiation within the bone marrow into 
committed stem cells and myeloblasts, synthesis of the azurophil granule proteins occurs at the 
promyelocyte stage of development. As maturation proceeds specific granules are synthesized at 
both the myelocyte and metamyelocyte stage with the neutrophil acquiring its functional 
capabilities (Borregaard, 1988). After maturation the neutrophil will, under normal circumstances, 
spend up to five days within the bone marrow before release into the circulation (Borregaard, 
1988). 
To carry out its primary function of killing foreign pathogens the neutrophil must emigrate from 
the vasculature to a site of inflammation. This necessitates the attachment of the cell to the vessel 
wall, migration into the tissue through extracellular matrix, followed by phagocytosis or 
exocytosis of granule contents. These processes are designed to defend the host from invading 
microbes but the cell has little ability to distinguish host from foreign antigens. Thus the cell's 
destructive potential may, under certain circumstances, be unleashed on host as well as foreign 
tissue (Weiss, 1989). The neutrophil is therefore important not only in host defence, but also in 
the pathogenesis of certain noninfectious diseases such as adult repiratory distress syndrome, 
rheumatoid arthritis and reperfusion injury following myocardial infarction (Malech and Gallin, 
1987). 
Chemotaxis depends on a unique group of surface receptors that include both low and high 
affinity receptors for N-formyl peptides of bacterial origin (Snyderman, 1985), receptors for C5a 
and those for lipid products such as P AF and leukotriene B4 (Baggiolini et al, 1991 ). IL-8, a 
potent proinflammatory cytokine, also plays a key role in recruitment and activation of 
neutrophils. Binding is via two distinct types of receptor. The type 1 receptor interacts exclusively 
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with IL-8 with high affinity whereas type 2 is able to bind a variety of chemokines (Wernette-
Hammond et al, 1995). Occupancy of these receptors leads to shape changes and directional 
movement (Snyderman, 1985) with the leading edge of the neutrophil orientated in the direction 
of the highest concentration of chemoattractant (Cohen, 1994). 
Effective killing is dependent on engulfment of the foreign particle via pseudopodia and 
entrapment within a phagosome. This process may be nonopsonic or opsonic dependent. 
Nonopsonic killing occurs following neutrophil surface receptor recognition of microbial sugar 
residues (Ofek et al, 1992). Important receptors in the opsonic process include those for 
immunoglobulin and complement (Leigh et al, 1979). Microbial killing and tissue destruction is 
the result of both proteolytic activity (see neutrophil proteases) and the formation of reactive 
oxygen intermediates, in particular superoxide anions and hydrogen peroxide. Central to this is 
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. This system 
converts molecular oxygen into superoxide anion by transporting an electron from NADPH. 
These unstable superoxide anions lead to subsequent formation of hydrogen peroxide. 
Hypochlorous acid, which is primarily responsible for killing bacteria within phagosomes, is 
formed by the action of myeloperoxidase on hydrogen peroxide. This so-called respiratory burst 
occurs at the cell membrane with release of toxic oxygen metabolites into both the extracellular 
matrix and the phagosome (Van der Valk and Herman, 1987). Efficiency of the microbicidal 
process is also dependent on an acid enviroment within the phagosome. This is achieved by a 
number of mechanisms including release of lysosomal acid hydrolases into the phagosome, 
generation of protons by internalized microorganisms, dissociation of carbonic acid formed 
through the hexose monophosphate shunt and active transport of hydrogen ions (Cohen, 1994). 
This review will concentrate on the proteolytic potential of the neutrophil associated with both the 
granules and the cell membrane. Thereafter, adhesion will be discussed with particular emphasis 
on the integrin superfamily of adhesion receptors and the interaction of the neutrophil with 
fibrin( ogen). 
Neutrophil granules 
The neutrophil has been recognised as a highly sophisticated cell capable of communicating with 
its environment with mobilization of four types of intracellular granules and vesicles depending on 
the stimulus received. It has the capacity for rapidly changing the protein profile of its surface 
membrane and consequently its capacity for interaction with other cells and microorganisms 
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(Kuijpers et al, 1991 ). This follows the incorporation of intracellular membranes into the plasma 
membrane after cell stimulation (Kuijpers et al, 1991; Miller et al, 1987). These granule 
membranes contain proteins with major functional implications for an effective neutrophil 
response at sites of inflammation (Borregaard et al, 1993a). Several distinct subsets of granules 
exist. The two well recognized categories are the peroxidase positive (primary, azurophil) 
granules and the peroxidase negative (secondary, specific) granules (Bainton, 1975). 
Azurophil granules represent the main source of bactericidal and proteolytic potential of the 
neutrophil. They contain myeloperoxidase, central to the hydrogen peroxide-halide system and 
necessary for oxygen dependent bactericidal activity (Klebanoff, 1970), while relatively few 
proteins have been identified in the membrane of azurophil granules. The azurophil granules are 
mobilized and exocytosed only to a limited extent during activation by inflammatory mediators 
and it is possible that their main function is executed only after cell disintegration (Borregaard et 
al, 1993b). 
The extent of peroxidase negative granule mobilization is measured by lactoferrin and vitamin 
B 12-protein release (Spitznagel et al, 1974). Subsets exist within the peroxidase negative granules. 
15% contain lactoferrin and a novel 25 kDa protein NGAL and 60% contain both lactoferrin, 
NGAL and gelatinase (Kjeldsen et al, 1993a). A NGAL-gelatinase complex exists in these 
(Kjeldsen et al, 1993b ). There is also a subset, constituting 25% of peroxidase negative granules, 
which contains gelatinase but no lactoferrin or NGAL (Kjeldsen et al, 1993 c ). G-proteins, capable 
of receptor interaction have also been found associated with membranes of specific granules 
(Rotrosen et al, 1988). Although the matrix proteins contained within specific and gelatinase 
granules differ, the granule membrane appears similar (Borregaard et al, 1993a). These granules 
are more readily mobilised than those containing the gelatinase-NGAL complex, which in turn are 
liberated to a greater extent than NGAL or lactoferrin alone (Kjeldsen et al, 1993c). Release 
occurs in response to inflammatory mediators such as granulocyte macrophage colony stimulating 
fac~or (GM-CSF), IL-8, leukotriene B1 (LTB1), PAF and Fl\.1LP (Borregaard et al, 1993b). 
Differential mobilization of subpopulations of specific granules was shown by Suchard and Boxer 
(1993). Spreading alone was found not to be sufficient for H20 2 production, the major 
requirement being exocytosis of a distinct population of lactoferrin-containing specific granules. 
The delivery of cytochrome b from lactoferrin-containing specific granules to the plasma 
membrane during activation contributes to oxidant production in neutrophils adherent to 
extracellular matrix proteins. 
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Secretory vesicles represent a specialised form of endocytic vesicle, they contain plasma proteins 
not synthesized by the cell. Once formed however, they behave functionally like granules with 
respect to mobilization and are very sensitive to secondary mediators (Sengelov et al, 1993), the 
principal intracellular signal leading to exocytosis being an increase in cytosolic calcium ion 
concentration (Lew, 1989). The secretory vesicles act as a source of membrane proteins that can 
be readily incorporated into the plasma membrane in response to cell stimulation. They contain 
cytochrome b550, Mac-1 (CR3), CRl and the FMLP receptor (Borregaard et al, 1993b; Sengelov 
et al, 1994). Secretory vesicles are virtually completely mobilized during extravasation and are 
not regenerated after release. The plasma proteins released are non-toxic to the host even when 
exocytosed into the circulation or close to the vessel wall during diapedesis (Sengelov et al, 
1995). 
Selective mobilization of granules and secretory vesicles in response to inflammatory mediators is 
essential for an efficient response involving adhesion, migration and bactericidal activity of 
neutrophils. Degranulation is a guanosine triphosphate (GTP)-dependent process. Small GTP-
binding proteins are thought to be involved in differential exocytosis of different granules. Two of 
these, rap 1 and rap2, have been found to associate with the membrane of specific granules on the 
plasma membrane (Maridonneau-Parini and de Gunzburg, 1992). The granules that form first are 
the most dense and the least mobilizable (Sengelov et al, 1993). It has been suggested that 
mobilization is brought about by granules and secretory vesicles hooking on to the microtubule 
system of the cell. Following exposure to a stimulus the lighter and smaller organelles move faster 
when exposed to mechanical forces by the microtubule apparatus (Borregaard et al, 1993b). 
Proteases of the neutrophil 
Neutrophil proteases serve two primary functions: digestion of the basement membrane and 
extracellular matrix components of the host during migration of the neutrophil from the 
intravascular compartment to sites of inflammation and destruction of foreign pathogens. The 
proteases of the neutrophil responsible for these processes fall primarily into either the 
metalloprotease or serine protease class. 
Neutrophil matrix metalloproteinases 
This class of enzymes contains an essential zinc binding domain and an amino terminal domain 
which functions to preserve the latent state of the enzyme. The enzymes are secreted as zymogens 
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which undergo extracellular activation and are dependent on both calcium and zinc for their 
activity. The C-terminal of the enzyme is the major determinant in substrate specificity (Hirose et 
al, 1993). They are able to digest extracellular matrix and basement membrane components 
including collagen, glycoproteins and proteoglycans (Hirose et al, 1993). The neutrophil is a 
source of two matrix metalloproteases, gelatinase and collagenase. 
Neutropltil gelatinase (MMP-9) 
Neutrophils secrete a 92 kDa gelatinase (MMP-9) which is highly homologous to MMP-2, a 72 
kDa gelatinase found in fibroblasts, lipocytes and bronchial epithelial cells. This enzyme is found 
within specific granules (Mainardi et al, 1991) and the expression of gelatinase mRNA appears to 
be controlled in a coordinate fashion together with lactoferrin (Graubert et al, 1993). It is released 
as an inactive proenzyme which becomes activated by oxygen metabolites or by serine proteinases 
(Woessner, 1991). Both gelatinolytic and type IV collagenase activity is exhibited (Morel et al, 
1993) contributing to the cells' ability to extravasate from the intravascular compartment and 
migrate through the extracellular matrix. 
Neutropltil collagenase (MMP-8) 
Neutrophil collagenase is stored as a 75 kDa glycosylated protein within specific granules of the 
neutrophil and secretion of the inactive enzyme is triggered by a range of inflammatory mediators 
(Knauper et al, 1990). Conversion to the active enzyme can be achieved by other proteinases such 
as cathepsin G, mercurials and oxidative processes (Knauper et al, 1990) and occurs as the result 
of removal of 80 to 81 N-terrninal amino acid residues (Knauper et al, 1990). Unlike fibroblast 
procollagenase it appears resistant to plasmin activation (Murphy et al, 1989). Following 
activation the enzyme cleaves interstitial collagens at a single peptide bond. Substrate specificity 
for interstitial collagen is determined by a 16 amino acid sequence within the C-terminal domain 
of neutrophil collagenase and maximal activity is related to the integrity of a disulfide-defined loop 
in this region (Hirose et al, 1993). Mutation of Asp253 , within the zinc binding locus, results in 
complete loss of activity of the enzyme (Hirose et al, 1993 ). 
The serine proteases 
This class of enzyme makes up the largest group of neutrophil proteases and includes many 
digestive enzymes, those involved in the complement system as well as those of the coagulation 
and fibrinolytic pathways. The serine proteases of the blood coagulation and complement 
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cascades consist of only a single domain, the catalytic unit, with a molecular weight of 
approximately 25 kDa and Jack other regulatory or binding domains. These proteases contain an 
active site serine195 residue which is esterified by the inhibitor diisopropyl fluorophosphate (DFP) 
resulting in loss of catalytic activity. A histidine residue is also critical for effective functioning of 
the enzyme (Barrett, 1980). It acts as a hydrolase and utilises the serine's hydroxyl group side 
chain to attack and cleave internal peptide bonds. These proteases are associated with the 
neutrophil azurophilic granules and show similarities to pancreatic trypsin and chymotrypsin. 
There is evidence to suggest that they arose from a single ancestral protein via duplications and 
mutations (Caughey, 1994). 
Huma1111eutrophil efastase (HNE) 
Elastase is present within the azurophilic granules of the cell. The enzyme has an apparent 
molecular weight of 30 kDa and an isoelectric point of 5.5 to 5.9. Its specific substrates are elastin 
and type IV collagen and it cleaves the peptide bonds on the carboxyl side of valine and, to a 
lesser extent, alanine. Elastase is capable of digesting the matrix components of lungs, arteries, 
skin and ligaments (Janoff, 1972; Palmgren et al, 1991) and has been implicated in the 
pathogenesis of emphysema, adult respiratory distress syndrome and rheumatoid arthritis 
(Thomas et al, 1991). 
The most important physiological inhibitor of HNE is a 1-proteinase inhibitor, a member of the 
serpin superfamily (Thomas et al, 1991). The serpins are found in extracellular fluids and recently 
a serpin-like protein, that complexes with the serine proteases elastase and cathepsin G by binding 
to the active site, has been identified within the cytosol of the cell. It is speculated that this 
protects the intracellular environment from proteolytic injury during degranulation (Thomas et al, 
1991). Congenital deficiency of the a 1-proteinase inhibitor, with absent or decreased levels within 
the blood and lungs, manifests itself in pulmonary emphysema (Laurell and Eriksson, 1963). Other 
serine protease inhibitors such as ai-macroglobulin and antileukoprotease are also effective 
against elastase. Secreted HNE has the ability to rebind to the neutrophil membrane in an active 
form that is relatively resistant to proteinase inhibitors (Bangalore and Travis, 1994; Owen et al, 
1995a). 
In addition to its role in digestion of extracellular matrix components elastase may have profound 
effects on the inflammatory response. Neutrophils generate the chemotactic cytokine IL-8 after 
stimulation by a variety of inflammato1y mediators (Baggiolini and Clark-Lewis, 1992). Serine 
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proteases of the neutrophil azurophil granules, HNE, cathepsin G and proteinase-3 (PR3) are able 
to process IL-8 and generate forms which exhibit greater biological activity than the native 
molecule (Padrines et al, 1994). Similarly, fibronectin can be degraded into low molecular weight 
products that have bio~ogical activity (McDonald and Kelley, 1980). 
Increased neutrophil elastase release has been shown in unstable angma pectoris and acute 
myocardial infarction (Dinerman et al, 1990) suggesting significant neutrophil activation. 
Leukocyte elastase is thought to contribute to reperfusion injury ie: the conversion of reversibly 
injured myocytes and endothelial cells to irreversibly injured cells. Use of elastase inhibitors 
during t-PA-induced coronary artery thrombolysis has been shown to significantly decrease the 
amount of myocardial injury effected on reperfusion in a dog model (Nicotini et al, 1991). 
Neutrophil infiltration into ischaemic myocardium has been found to be significantly less following 
reperfusion in the presence of the HNE inhibitor ICI 200,880 (Mehta et al, 1994). Erythrocyte 
damage may occur in the presence of HNE due to degradation of membrane proteins (Bykowska 
et al, 1993). Modulation of platelet function due to proteolysis by elastase of membrane 
glycoproteins such as glycoprotein lb and thrombin binding sites resulting in inhibition of platelet 
aggregation has also been shown (Brower et al, 1985). 
There are reports in the literature of both enhanced and decreased clot lysis in the presence of 
HNE. Plow ( 1982) showed that elastase release from neutrophils occurred in concert with, or 
shortly after clot formation with maximal release 20 to 40 min after clot formation. This was 
independent of thrombin, calcium or magnesium levels. Elastase possesses the ability to cleave 
and inactivate PAI-1 and thereby increase fibrinolysis (Wu et al, 1995). However, Bach-Gansmo 
et al (1995) have shown that HNE-mediated fibrin degradation is associated with decreased t-PA 
activation of plasrninogen, leading to impaired clot lysis. Fibrin-bound HNE is relatively resistant 
to inhibition (Kolev et al, 1994). 
Elastase has the ability to increase the expression of CD 18 on neutrophils along with CD 11 b. This 
was found to affect migration but not adhesion (Woodman et al, 1993). Neutrophil effector 
function with up-regulation of the oxidative response to inflammatory stimuli also occurs (Kusner 
and King, 1989). 
Catltepsin G 
Cathepsin G is a chymotrypsin-like serine protease with an apparent molecular weight of 29 kDa 
which is released from the azurophilic granules of the neutrophil. It has the ability to degrade 
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connective tissue components collagen I, collagen II and cartilage proteoglycans and also exhibits 
antibiotic activity (Gabay, 1994). Its release is able to upregulate the oxidative response of 
neutrophils (Kusner and King, 1989). As with HNE the most important physiological inhibitor is 
a 1-proteinase inhibitor (Thomas et al, 1991). Similarly, it has has the ability to degrade 
erythrocyte membrane proteins (Bykowska et al, 1993) and process IL-8 into more biologically 
active fragments (Padrines et al, 1995). 
It is able to play a pro-thrombogenic role with depression of the fibrinolytic system by releasing 
PAI-1 from platelets and human umbilical vein endothelial cells (Pintucci et al, 1992). Cathepsin 
G is also able to act as a strong platelet agonist (Selak et al, 1988) with induction of platelet 
aggregation, increase of cytoplasmic calcium ion concentrations and a rise in thromboxane A2 
production. Cathepsin G released in areas of close membrane-to-membrane contact is resistant to 
antiproteinases (Evangelista et al, 1991 ; Bangalore and Travis, 1994; Owen et al, 1995b). This 
close contact is a P-selectin mediated process (Evangelista et al, 1993). 
Proteinase 3 (PR3) 
This enzyme, present within the azurophilic granules, was first described by Baggiolini et al 
(1 978) but generated very little interest compared to elastase and cathepsin G until it became 
evident that it had the capacity to degrade elastin and induce emphysema in a hamster model (Kao 
et al, 1988). The disease produced was of equal or greater severity than that mediated by HNE. 
PR3 is also able to degrade fibronectin and type IV collagen (Kao et al, 1988). 
PR3 is a neutral serine protease of approximate molecular weight 29 kDa and is present in 
concentrations intermediate between that of elastase and cathepsin G, with an amino-terminal (N-
terminal) amino acid sequence highly homologous to theirs (Campanelli et al, 1990a). PR3 has 
been shown to be a member of a cluster of elastase-related genes in the terminal region of the 
short arm of chromosome 19 (Sturrock et al, 1992). It shows a similar specific activity and 
substrate binding pocket to elastase and may share a major role in inflammation where neutrophil 
elastase has been implicated (Campanelli et al, 1990b). Its broad proteolytic activity suggests its 
importance in neutrophil migration through the basement membrane (Henson and Johnston, 1987) 
and in digesting phagocytosed microbes (Janoff, 1985). The inhibition profile is distinct from that 
of elastase and cathepsin G. There is no decreased activity in the presence of antileukoprotease 
and only weak inhibition by eglin C, with the most efficient inhibitory activity being displayed by 
a1-proteinase inhibitor and ai-macroglobulin (Rao et al, 1991). 
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PR3 has been shown to be the target antigen of anti-cytoplasmic antibodies circulating in the 
disease Wegener's granulomatosis (Csernok et al, 1990), characterized by systemic necrotising 
vasculitis and granuloma formation. The antibodies are able to activate neutrophils and induce 
respiratory burst and degranulation (Jennette and Falk, 1989). The antigen is located both within 
the azurophilic granules of the neutrophil and the cytoplasmic granules of monocytes with small 
amounts also present on the plasma membranes of both cell types. PR3 has been detected on the 
plasma membrane of neutrophils from patients with active AN CA-associated vasculitis as well as 
patients with sepsis who do not display ANCA. Both TNFa. and IL-8 are able to induce 
translocation of PR3 from intragranular loci to the cell surface (Csernok et al, 1994). A 
mechanism thought to be important in the development of vasculitis is related to the induction of 
E-selectin expression on the surface of endothelial cells with subsequent neutrophil adhesion 
(Mayet et al, 1993). 
PR3 is thought to play a role in neutrophil-mediated platelet activation. Renesto et al (1994) 
showed that PR3 and elastase, at concentrations ineffective by themselves, were able to potentiate 
platelet activation induced by cathepsin G. Cytolysis and detachment of endothelial cells occurs in 
the presence of PR3 along with elastase (Ballieux et al, 1994). 
Azurocidi1t (cationic a1ttimicrobial protein, huma11 heparin bindi11g protein 3 7) am[ azuropl,il 
granule protein 7 (AGP7) 
Azurocidin and AGP7 represent approximately 15% of the acid extractable protein content of 
azurophil granules (Gabay et al, 1989) and show considerable sequence homology to elastase 
(Wilde et al, 1990). Azurocidin shows 65% sequence homology with the active site of elastase 
but the catalytic serine has been replaced with glycine and it is therefore unable to bind the 
inhibitor DFP (Wilde et al, 1990). AGP7 is 70% homologous with elastase at the active site but is 
capable of binding DFP (Wilde et al, 1990). The genes encoding for PR3, azurocidin and elastase 
are all found as a cluster on the short arm of chromosome 19 (Zimmer et al, 1992). 
Azurocidin migrates as three dominant bands on sodium dodecyl sulphate polyacrylamide 
electrophoresis (SDS-PAGE) around apparent molecular weight 30 kDa. It appears to be an 
important mediator for recruiting monocytes to sites of inflammation (Pereira et al, 1990) and is 
also cytotoxic to certain microorganisms especially gram negative bacteria (Gabay, 1994). 
Azurocidin has also been found to be stored in small amounts in human platelets (Flodgaard et al, 
1991). AGP7 is made up of four distinct glycoforms of molecular weights between 28 and 34 kDa 
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(Wilde et al, 1990). Both enzymes are insoluble at neutral pH and it has been suggested that they 
may be associated with the cell membrane (Jenne, 1994). 
Proteases of the neutrophil membrane 
Cell surface-associated enzymatic activity has been implicated as being important in certain 
cellular functions including cell-mediated cytotoxicity (Hatcher et al, 1978), the generation of 
biologically active peptides by polymorphonuclear leukocytes (Coblyn et al, 1979) and the 
inactivation of migration-inhibitory factors (Remold et al, 1978). Elastase-type proteases on the 
surface of human blood monocytes have also been suggested as having a possible role in amyloid 
formation (Lavie et al, 1980). Connelly et al (1985) described a neutrophil endopeptidase of the 
metalloprotease class associated with a membrane fraction from disrupted neutrophils that was 
able to cleave the chemotactic tripeptide FMLP, raising the possibility that it may have an 
important function in inflammation and chemotaxis. It is constitutively expressed on the cell 
membrane and abnormally high levels have been measured in patients with adult respiratory 
distress syndrome and septic pneumonia. Subsequent studies showed that inhibition of this neutral 
endopeptidase completely blocked FMLP-mediated chemotaxis (Painter et al, 1988). 
Pontremoli et al (1986) described a neutral serine protease with an apparent molecular weight of 
30 k.Da and a pH optimum of 7.4 to 7.8. It is distinct from elastase and cathepsin G and is 
released into the extracellular medium upon stimulation of neutrophils with PMA at 10 ng/rnl, a 
concentration which produces only minor discharge of secondary granules. At this concentration 
approximately 60% of total activity is released by 30 mins increasing to 80% and greater than 
90% in 60 and 90 minutes respectively. The release of the enzyme from the neutrophil membrane 
appears to be almost entirely dependent on the addition of adenosine triphosphate (ATP) and is 
associated with phosphorylation of membrane proteins (Melloni et al, 1986). Inhibitor studies 
indicate that membrane-bound PKC activity is essential in the release of the neutral proteinase and 
the production of oxygen radicals. Pontremoli et al (1990) have subsequently shown that this 
protease is found at the sites of interaction of the membrane with the cytoskeleton and appears to 
be involved in downregulation of PKC activity following FMLP or PMA stimulation. 
King et al (1987) described a chymotryptic enzyme, with a molecular weight of 150 to 180 k.Da, 
situated on the neutrophil membrane and important in regulation of the membrane associated 
functions of cyclic adenosine monophosphate ( cAMP) and oxygen generation. This calcium 
dependent enzyme, displaying serine protease activity, was subsequently shown to have an 
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apparent molecular weight of 65-70 kDa and an isoelectric point of 6.3 (King et al, 1991 ). 
Antibody 1-15, a murine anti-human neutrophil IgG1 monoclonal antibody specific for the 
enzyme, inhibits activity related to cell activation, in particular superoxide generation and cAMP 
production after PMA or FMLP stimulation (King et al, 1986). It is able to inhibit 
polymorphonuclear cell degranulation and adhesive responses to FMLP but notably has no effect 
on cell chemotactic reponses to this peptide. 
Bangalore and Travis (1994) described degranulation of human neutrophils following stimulation 
with micromolar concentrations of FMLP or PMA with concomitant release of human leucocyte 
elastase, cathepsin G and myeloperoxidase into the surrounding medium. It was found that some 
of these proteases were able to rebind in an active form to neutrophil plasma membranes or 
membrane fragments . These bound proteinases displayed increased resistance to inhibition by 
proteinase inhibitors. This phenomenon was again described by Owen et al (1995a). Priming of 
neutrophils by tumour necrosis factor-a (TNFa) and P AF is able to express increased amounts of 
surface bound cathepsin G (Owen et al, 1995b). 
A neutral protease found in association with the neutrophil membrane and capable of degrading 
C-reactive protein (CRP) was first described in 1989 (Shephard et al). Inhibitor studies 
characterized this enzyme as a serine protease, maximally activated by PMA stimulation of the 
neutrophil. This PMA stimulation was achieved with greatest effect at a concentration of 10 ng/ml 
and resulted in increased association of CR.l> with neutrophils and maximal generation of 
trichloroacetic acid (TCA)-soluble CRP-peptides in the extracellular medium: Degradation 
products were detected within 2 minutes following CRP incubation with neutrophils. These 
soluble CRP-derived peptides were found to be biologically active and had the ability to suppress 
superoxide production from activated neutrophils. Further characterization of this protease was 
performed (Shephard et al, 1992) and established it as a probable submembrane protease localized 
at sites of interaction of the cytoskeleton with the membrane. It appeared to exist as an enzyme 
complex of 600 kDa which could be dissociated using SDS-P AGE into four discrete bands of 
209, 316, 398 and 501 kDa molecular weight. Cellular kinases activated by PMA and inhibited by 
1-( 5-isoquinolinesulphonyl)-2-methylpiperazine (H7) and trifluoperazine (TFP) appear to be 
involved in upregulating the CRP-degrading activity of the neutrophil during cellular degradation. 
Further investigations (Kelly et al, 1994) showed the importance of this protease in acting as an 
alternative pathway to fibrinogenolysis to that mediated by plasmin and neutrophil lysosomal 
enzymes. It degrades fibrinogen in a time and concentration dependent manner with cleavage of 
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all three constituent chains of fibrinogen to produce unclottable products that do not exhibit 
anticoagulant activity. Release of an Aa.1_21 peptide occurs following cleavage of the bond 
between alanine and glutamic acid at positions 21 and 22 respectively from the N-terminus of the 
Aa. chain. Levels of this peptide have previously been used as a marker of human neutrophil 
elastase activity (Weitz et al, 1987). 
Neutrophil adhesion 
Adhesive interactions between cells and the extracellular matrix are crucial to differentiation of 
cells, maintenance of tissue architecture, wound healing, tumour metastasis and the inflammatory 
response. These adhesion events, which are mediated by cell-surface receptors that bind to ligands 
on adjacent cells or in the extracellular matrix, also regulate intracellular signal transduction 
pathways that control adhesion-induced changes in cell physiology. The adhesion events are 
mediated by transmembrane receptors that belong to a limited number of supergene families that 
include the integrins (Ruoslahti, 1991 ; Hynes, 1992), the immunoglobulin superfamily (Buck, 
1992), cadherins (Takeichi, 1991) and selectins (Lasky, 1992; McEver, 1992). 
Neutrophils are functionally dependent on various members of these supergene families for 
migration from the vasculature to sites of inflammation. The process of recruitment from the 
vascular lumen to tissue requires a cascade of sequential adhesion events (Butcher, 1991). The 
first step is often initiated by cytokines which are able to stimulate adhesion through leukocyte or 
endothelial cell activation. Leukocyte rolling on post-capillary venular endothelium is mediated 
via selectins with L-selectin on leukocytes interacting with E-, P-selectin or other carbohydrate 
ligands on other endothelial cells (Picker et al, 1991) in a process known as tethering. Shedding 
ofL-selectin follows with an associated increase in avidity of other adhesion molecules, including 
the f32 integrins and members of the immunoglobulin superfamily. Shedding of L-selectin occurs 
within seconds by a metalloprotease-dependent proteolytic event which may contribute 
significantly to the velocity of leukocyte rolling and may be physiologically important in limiting 
leukocyte aggregation and accumulation at sites of inflammation (Walcheck et al, 1996). The 
subsequent firm adhesion mediated by integrins and the immunoglobulin superfamily then allows 
for movement of neutrophils through the endothelium. Endocytosis of integrins and recycling to 
the leading edge of migrating neutrophils has been shown (Lawson and Maxfield, 1995), 
providing a gradient of adhesive strength from the front to the rear of the cell. 
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A full review of all the supergene families of adhesion receptors is beyond the scope of this thesis. 
Only the integrin family will be discussed in detail in this chapter with particular emphasis on the 
interaction of fibrinogen with neutrophils, an integrin mediated process. 
The role of integrins 
Integrins are transmembrane glycoproteins which exist as non-covalently associated heterodimers 
made up of an a (120-180 kDa) and p (90-110 kDa) subunit (Hynes, 1987). To date, 16 a 
subunits and eight p subunits have been identified that can heterodimerize to produce more than 
20 different receptors (Clark and Brugge, 1995). Additional complexity is added by alternative 
splicing of the a and p subunits (Hynes, 1992). The integrin family is divided into classes based 
on the P subunit. The most widely distributed belonging to the P 1 class or very late antigens 
(VLA), (Hemler, 1990). Several of these were initially characterised on platelets before being 
recognised as belonging to an integrin superfamily. The second class are leukocyte specific and 
are made up of one of three a subunits that associate with a common P2 subunit (Larson and 
Springer, 1990). The leukocyte specific P2 integrins consist of aLP2 (LFA-1), aMP2 (Mac-1) and 
axP2 (p150,95) (Hynes, 1992). More recently a leukocyte specific leukocyte response integrin, 
with immunological homology to GPIIb-Illa has been described. The cytoadhesins constitute the 
third class (Phillips et al, 1988) and include the receptor GPIIb-IIIa found on platelets (Plow et al, 
1986), cells of megakaryocytic lineage (Keiffer et al, 1991) and some tumour cells (Chen et al, 
1992). This integrin is reviewed in detail in Chapter 4. 
Both integrin subunits are transmembrane glycoproteins with a single hydrophobic transmembrane 
segment. The cytoplasmic domains are for the most part short (<50 amino acids) except for that 
of the P4 integrin (> 1000 amino acids). The extracellular domains associate to form ap 
heterodimers and the ligand binding pocket (Smyth et al, 1993) with high affinity ligand 
recognition requiring both a and p subunit participation (Loftus et al, 1994). Extensive disulfide 
bonding occurs in both subunits and the presence of compact folded domains renders them fairly 
resistant to proteolysis (Calvete et al, 1991). Receptor function is dependent on divalent cations 
and they may be required for ap subunit association of some integrins (Kirchhofer et al, 1990). 
The cytoplasmic domains interact indirectly with cytoskeletal components via linker proteins such 
as talin and a-actinin (Pavalko and Otey, 1994). p cytoplasmic domains are necessary and 
sufficient to target integrins to focal adhesions in a ligand-independent manner while a 
cytoplasmic domains regulate the specificty of the ligand dependent interaction (LaFlamme et al, 
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1994). Of interest is that different a. subunits have very different cytoplasmic sequences and 
therefore a range of receptors for a given ligand can vary in their apparent associations with the 
cytoskeleton. This may lead to a range of cellular responses to a common extracellular ligand 
depending on the receptor engaged (Hynes, 1992). A conserved region (Argm-Lys142) in the P2 
cytoplasmic domain appears to be critical for cytoskeletal association, assembly and transport to 
the plasma membrane of the a.LP2 (LF A-1) heterodimer. The conserved membrane proximal 
GFFKR motif confers stability to the a.p complex (Pardi et al, 1995). In the extracellular region 
of the a. subunit of the p2 integrins are two prominent features : the cation binding region and a 
200 amino-acid insertion or I-domain (Corbi· et al, 1987; Kaufman et al, 1991 ; Pytela, 1988). The 
binding sites for four distinct ligands for Mac-I namely IC3b, intercellular adhesion molecule-I 
(ICAM-1 ), fibrinogen and the counter-receptor for neutrophil homotypic adhesion, identified as 
L-selectin (Simon et al, 1993 ), have all been mapped to the I domain on the a. chain of Mac- I 
(Diamond et al, 1993) suggesting it is a major recognition site for both soluble and cellular 
ligands. More recently ICAM-2, a member of the immunoglobulin superfamily expressed on 
endothelial cells and a cell-surface ligand for LFA-1 , has been found to bind to CD11b/CD18 
through the I domain (Xie et al, 1995). ICAM-2 was also found to be the sole ICAM molecule 
found on the surface of platelets and may have a role to play in leukocyte/platelet interactions in 
inflammation and thrombosis (Diacovo et al, 1994). Three extracellular divalent cation-binding 
sites are present in the a. subunit, a feature conserved among all integrins (Hynes, 1992). 
Michishita et al (1993) showed an additional fourth metal-binding site in CR3 in the I domain 
which is essential for ligand binding. Calreticulin, a highly conserved and ubiquitously expressed 
calcium-binding protein interacts with the cytoplasmic domain of the a. subunit of all integrins 
(Rojiani et al, 1991) in an area immediately adjacent to the transmembrane domain as well as on 
the cell surface. Interaction with the protein affects the functional status of the integrin 
(Coppolino et al, 1994). Binding of calreticulin is via the GFFKR amino acid sequence on the 
integrin and its deletion results in expression of constitutively active integrins (O 'Toole et al, 
1994). 
The ligands recognized by integrins are many and varied and fall into one of three classes: 
extracellular matrix proteins ( collagen, fibronectin, fibrinogen, laminin, thrombospondin, 
vitronectin), plasma proteins (fibrinogen, factor X) and cell surface molecules (C3bi, vascular cell 
adhesion molecule-I (VCAM-1), ICAM-1 ,2,3) (Hynes, 1992). The amino acid sequence RGD 
represents a common recognition motif for many integrins (Ruoslahti and Pierschbacher, 1987). 
Another important recognition sequence is that of KQAGDV in fibrinogen bound by GPIIb-Illa 
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and the leukocyte response integrin (Kloczewiak et al, 1984; Gresham et al, 1992). Various other 
sequences have been identified as being important in ligand binding to integrins. Synthetic 
peptides corresponding to these recognition sequences often do not bind with the same affinity as 
the native protein, suggesting that protein conformation and additional contact sites provide 
additional components necessary for optimal binding (Smyth et al, 1993). Interaction of integrin 
with ligand may also result in the exposure of novel binding sites, "ligand-induced binding sites", 
resulting in increased binding affinity (Hogg et al, 1993). The same integrin expressed on different 
cell types displays different ligand binding specificities which appears to be related to cell-type 
specific structural modification of integrins or association with cell-type specific lipid or protein 
factors (Smyth et al, 1993 ). 
In addition to their role as adhesion molecules there is increasing evidence to suggest that 
integrins are essential for signal transduction both into and out of the cell. For the most part 
adhesion mediated by integrins requires activation of the receptor by specific signals. The 
activation of the receptor is able to induce a conformational change leading to ligand binding 
(Andrew et al, 1993). Ligand occupation of the receptor subsequently triggers a series of 
intracellular events. The cytoskeleton of the cell, consisting of microtubules and actin filaments 
(microfilaments), plays a crucial role in many aspects of cellular function. These include 
intracellular transport, cell motility, mitosis and meiosis, phagocytosis, adhesion and maintenance 
of cellular morphology. Current research strongly suggests that signalling via specific receptors is 
involved in regulating the state of actin polymerization, the organization and distribution of actin 
filaments and cell motility (Pavalko and LaRoche, 1993). Actin filaments must be anchored to the 
cytoplasmic face of the membrane in order to produce the force in cells necessary for performing 
many cytoskeletal dependent functions (Luna and Hitt, 1992). 
Receptor signal transduction refers to events that take place after binding of ligand to receptor 
and generally results in activation of receptor associated G-proteins. G-proteins consist of three 
polypeptide subunits a., P and y. The p and y subunits are identical for all G-proteins whereas the 
GTP-binding a. subunits are distinct and determine the nature of G-proteins. Following ligand 
binding to receptor the a. subunit of the associated G-protein complex binds GTP and dissociates 
from the complex · to perform its activity. The dissociated a.-subunit complex activates 
phospholipase C and the resulting hydrolysis of phosphatidyl-inositol gives rise to water soluble 
inositol triphosphate and the lipid soluble diacylglycerol. Inositol triphosphate liberates calcium 
from internal stores and increases the concentration of cytosolic calcium. Diacylglycerol 
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participates in binding of PKC, a phospholipid calcium dependent kinase located in the cytosol of 
nonactivated cells. Diacylglycerol generated in the plasma membrane binds PKC and this 
translocates it from the cytosol to the plasma membrane where it becomes active (Litwack, 1992). 
Although much is known about extracellular interactions between integrins and their ligands much 
less is understood about intracellular biochemical pathways and cellular functions regulated by 
integrins. Engagement and clustering of integrin receptors results in cell spreading and the 
formation of focal adhesions with integrins linking to intracellular cytoskeletal complexes and 
bundles of actin filaments (Pavalko and Otey, 1994) thereafter concentrating at sites of close 
approximation between cell and substrate (Burridge, 1988). These focal adhesions are at sites of 
end-on insertion of actin microfilaments into the plasma membrane and where certain cytoskeletal 
and signalling molecules concentrate (Schwartz, 1992). Both the a. and P subunit cytoplasmic 
domains appear to be involved in the process of cell spreading and formation of focal adhesions 
(Ylanne et al, 1993). 
Activation of p2 integrins may be achieved with phorbol esters and inflammatory mediators such 
as TNF, C5a, PAF or FMLP. Upregulation of integrin expression may also occur in response to 
various growth and differentiation factors such as TNF-P, interferon-y (IFN-y) and retinoic acid 
(Smyth et al, 1993). This increased avidity of binding is transient and after a period of time "de-
adherence" follows (Hogg et al, 1993). Phospholipase Ai-derived lipid mediators regulate a 
number of neutrophil responses which include degranulation, adhesion and Mac-1 expression 
(Jacobson and Schrier, 1993). Thus phospholipase A2 appears to play an obligatory role in signal 
transduction pathways affecting acute inflammatory reponses. 
It has been recognized that neutrophils adherent to extracellular matrix proteins react differently 
to physiological stimuli compared to neutrophils in suspension (Liles et al, 1995). TNF, a 17 kDa 
cytokine, is important for a variety of biological activities that regulate the immune response. It 
mediates a number of neutrophil effector functions by inducing neutrophil activation with 
degranulation and a respiratory burst. However this will only occur if the neutrophils are adherent 
to an extracellular matrix via specific integrins with CD 11 b/CD 18 being of particular relevance 
(Nathan et al, 1989). Adherent neutrophils exposed to TNF show increased tyrosine 
phosphorylation of several proteins (Fuertes et al, 1993) with the p2 integrins being implicated in 
the triggering of this process (Berton et al, 1994). A 42 kDa protein, identified as a member of 
the mitogen activated protein kinase family, shows the most striking increase in tyrosine 
phosphorylation following exposure of neutrophils to TNF (Rafiee et al, 1995). Neutrophil 
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stimulation by other agonists such as P AF, GM-CSF and FMLP is also able to induce functional 
reponses via tyrosine phosphorylation, and G proteins play a crucial role in the coupling of 
chemotactic factor receptors to this tyrosine phosphorylation (Rollet et al, 1994). 
The urokinase-type plasminogen activator receptor is a 55 kDa GPI-linked membrane protein 
which is extensively glycosylated and able to promote leukocyte migration and the invasion of 
metastatic cells. It also represents a means of focussing and controlling a key component of the 
fibrinolytic system at the cell surface. Of particular interest is that it is physically associated with 
Mac-1 on intact neutrophil membranes (Xue et al, 1994). The interaction of the two receptors is 
reversible and correlates with cell polarization. During the process of polarization, as the cell 
begins to migrate the urokinase plasminogen activator-receptor (uPA-R) and Mac-1 dissociate by 
an as yet uncharacterized mechanism but reassociate when the cell returns to a spherical shape 
(Kindzelskii et al, 1996). Engagement of uP A-R leads to tyrosine phosphorylation and 
diacylglycerol formation (Bohuslav et al, 1995). In view of its role in migration and invasion, its 
function appears to be complementary to that of the integrin superfamily and its close association 
with Mac-1 indicates their functional cooperation. 
Pavalko and LaRoche (1993) showed that activation of neutrophils by FMLP or cytokines 
induces an association between CD 18 and a-actinin with a-actinin binding to an 18 amino acid 
region in the N-terminal half of the CD 18 cytoplasmic domain. This interaction is weak or non-
existent in resting cells and no similar association could be detected between CD 18 and either 
talin or vinculin. In addition to the interaction of a-actinin with the amino terminal region of 
CD 18, filamin also binds here and is thought to play an important role in cortical membrane 
stability and the regulation of integrin function at the leading edge of migrating cells (Sharma et 
al, 1995). The role of integrins as mechanoreceptors was shown by Wang et al (1993). Magnetic 
microsperes were coated with the RGD peptide and used in combination with an external 
magnetic field to exert controlled mechanical stress on the integrin receptor without changing cell 
shape. A significant mechanical constraint on the twisting of the integrin-bound beads was found 
due to cytoskeletal linkage to integrins. This mechanotransduction would be instantaneous and 
more rapid than any diffusion-based signalling system. 
The link between actin cytoskeleton and the neutrophil membrane is an important mechanism for 
enhancing adhesion and transendothelial migration. The interaction peaks at five to ten minutes 
after stimulation and is reduced to near baseline at 30 minutes. There is particularly strong 
sequence homology in the amino terminal half of the cytoplasmic domain of the P-subunit of many 
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integrins. It is therefore possible that the mechanism is common to many different integrin 
subfamilies. Engagement of J3 2 integrins in non-adherent neutrophils resulted in rapid and 
sustained increases in the F-actin content of neutrophils with concomitant significant formation of 
phosphatidylinositol triphosphate formation. This correlated with the cell's ability to undergo 
significant actin polymerization (Lofgren et al, 1993). Transition of CR3 from a low to a high 
avidity state is related to the phosphorylation of the cytoplasmic tail of CD 18 on multiple residues 
(Rabb et al, 1993). 
Protein phosphorylation is one of the earliest events detected in response to integrin stimulation. 
This was first shown in platelets (Clark et al, 1994) with integrins shown to regulate agonist-
induced tyrosine phosphorylation. Serine-threonine kinase families· such as PKC and mitogen 
activated protein (MAP) kinases are also activated upon integrin stimulation (Schlaepfer et al, 
1994 ). MAP kinases appear to regulate, in part, neutrophil adhesion (Pillinger et al, 1996). There 
is now considerable evidence to suggest that certain GPI-linked proteins, which are only 
expressed at external membrane surfaces, interact physically with J32 integrins. Thus, ligand 
binding to GPI-linked receptors by inflammatory mediators is able to influence the P2 integrins 
which are in direct mechanical and biochemical contact with the cytoplasm of the cell (Petty and 
Todd, 1996). The intervening pathways and steps occurring following ligand binding to integrin 
receptor and resulting protein phosphorylation with involvement of G protein-coupled receptors 
are as yet uncharacterized. 
Interaction of neutrophils with fibrin( ogen) 
The close association of fibrin(ogen) with neutrophils has long been established. In 1987 Weitz et 
al showed that migration of neutrophils in response to a chemotactic stimulus across a fibrinogen-
coated surface was accompanied by the release of HNE. The elastase released is protected from 
proteinase inhibitors in the surrounding medium by the presence of a protected pocket formed 
between the cell and the substrate. Wright et al (1988) showed that a neutrophil integrin receptor, 
the integrin CD1 lb/CD18, binds fibrinogen. The region recognized in the fibrinogen molecule lies 
at the C-terminal region of they chain (a portion not removed during conversion of fibrinogen to 
fibrin) . Monocytes are also able to utilize CD 11 b/CD 18 as a fibrinogen receptor (Trezzini et al, 
1988). Subsequent to binding and internalization of the ligand, lysosomal degradation occurs. 
This binding requires adenosine diphosphate (ADP) stimulation and is calcium ion dependent 
(Simon et al, 1993). 
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Altieri et al (1990) showed that the plasmin-derived fragment D produced a dose-dependent 
inhibition of the interaction of fibrinogen with neutrophils and monocytes. This fragment lacks the 
RGD sequences located in the Aa chain as well as the C-terminal dodecapeptide recognition 
sequence of they chain. Thus they concluded that fibrinogen interacts with CD 11 b/CD 18 through 
a novel recognition site not shared with other known integrins that function as fibrinogen 
receptors. The recognition motif was subsequently found to be glycine190-valine202 of the 
fibrinogen y chain (Altieri et al, 1993 ). Induction of the fibrinogen binding capacity of 
CD 11 b/CD 18 is characterized by rapid changes of cytosolic calcium concentration (Altieri et al, 
1988). Diamond and Springer (1993) showed that binding of fibrinogen to phorbol ester-
stimulated neutrophils occurs via a small subpopulation ( approximately 10%) of CD 11 b/CD 18 . 
This population is recognized by an activation-specific antibody CBRMl/5 which binds to the a 
subunit of the integrin. This same subpopulation also mediates the binding of neutrophils to 
ICAM-1 . The binding site for fibrinogen as well as iC3b and ICAM-1 is the I domain on the a 
chain ofCDl lb/CD18 (Diamond et al, 1993). 
CD 11 c/CD 18 has also been established as being able to function as a fibrinogen receptor on TNF-
stimulated neutrophils and recognizes the Gly-Pro-Arg (GPR) sequence on the N-terminal domain 
of the Aa.17_19 chain of fibrinogen (Loike et al, 1991). The interaction between CD11/CD18 
integrins with surface-bound ligands supports adhesion of phagocytes and their spreading, 
diapedesis and phagocytosis. Adherent neutrophils stimulated with TNF released large quantities 
· of hydrogen peroxide but required adhesion to surfaces coated with extracellular matrix proteins 
for this to occur (Nathan et al, 1989). This may be an adaptation so that respiratory burst will 
occur in neutrophils that have aggregated, adhered or emigrated but not from those in the 
circulation exposed to cytokines that may have "spilled into" the blood from inflammatory sites. 
In the platelet-neutrophil interaction the ~2 integrin CD 11 c/CD 18 is of importance. Fibrinogen 
appears to bridge GPIIb-IIIa on platelets with CD1 lc/CD18 on neutrophils and recognizes the 
Aa chain of platelet-expressed fibrinogen (Ruf and Patscheke, 1995). 
Inhibition of neutrophil activation has been reported subsequent to fibrinogen binding (Higazi et 
al, 1994) with physiological levels inhibiting chemotactic activity triggered by zymosan activated 
serum, C5a and IL-8 . Precoating of culture well surfaces with fibrinogen has also been reported 
to completely suppress the polystyrene-triggered release of hydrogen peroxide from neutrophils 
(Nathan, 1987). 
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It is evident that most studies to date have concentrated on interactions of neutrophils with 
fibrinogen via integrins and subsequent biological effects. However, very little data is available on 
interactions of neutrophils with insoluble crosslinked fibrin and adhesion receptors that may be 
involved in this process. 
Leukocyte response integrin (LRI) 
In 1989 Gresham et al described a heterodimeric receptor, termed the leukocyte response integrin 
(LRI), with ligand binding specificity for the Arg-Gly-Asp sequence and showing immunological 
cross-reactivity with GPIIb-Illa on platelets. Isolation of LRI (Carreno et al, 1993) showed the 
receptor to have two subunits of 13 5 and 90 kD. A monoclonal antibody, B6H21, was developed 
that bound to this receptor and was able to inhibit both RGD-mediated ligand binding and 
extracellular matrix-stimulated phagocytosis by neutrophils (Gresham et al, 1989). Ligand binding 
could be rapidly inhibited by oxidants generated by neutrophils during release of myeloperoxidase 
and activation of the respiratory burst. It was hypothesized that the receptor may play an 
important role early in the inflammmatory response as a signal transducing molecule. 
Subsequently Brown et al (1990) showed that the antigen recognized by B6H12 was in fact a 50 
kDa molecule expressed on the plasma membrane of all haematopoeitic cells. In the case of 
platelets and placenta this protein is associated with the ~3-like LRI. Antibodies directed against 
either of these molecules are able to inhibit Arg-Gly-Asp stimulation of phagocytosis. Thus the 50 
kD protein, termed integrin associated protein (IAP), is able to modulate LRI function and may 
play a role in signal transduction for activation of phagocytes by RGD-containing adhesive 
proteins. The extracellular domain is thought to be important in the interaction of IAP with its 
associated integrins (Lindberg et al, 1993) and multiple membrane-spanning domains exist in the 
C-tenninus which may be important in signal transduction. Gresham et al (1992) examined the 
ligand binding specificity of LRI by investigating its interaction with fibrinogen. The RGD 
sequence occurs twice in the fibrinogen a chain and the KQAGDV sequence occurs in the 
carboxyl-terminal region of the y chain (Phillips et al, 1991 ; Smith et al, 1989; Kloczewiak et al, 
1984), these regions being involved in fibrinogen binding to the platelet integrin GPIIb-Illa. It 
was established that both the RGD as well as the y chain peptide are ligands for LRI. In addition, 
when the native y chain sequence KQAGDV was mutated to KGAGDV this was also able to act 
as a ligand. When neutrophils were stimulated with FMLP or immune complexes, ligand binding 
specificity for the sequence was markedly increased and reduced for RGD. Thus this unique 
amino acid sequence may represent a specific ligand for LRI and the specificity of LRI ligand 
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binding may be regulated by the activation state of the cell. Zhou and Brown (1993) have shown 
that ligation of LRI by surface-bound ligands and antibodies is able to directly activate the 
respiratory burst in neutrophils and monocytes, with LRI and IAP acting as a signal transduction 











GPIIb-IIIa and platelet aggregation 
Platelets and fibrinolysis 
Clot retraction 






Platelets originate in the bone marrow by fragmentation of the cytoplasm of mature, granular 
megakaryocytes and circulate in the blood as small cellular anucleate discs of between 2 and 5 µm 
diameter with a life span of approximately 10 days. Platelets have a normal circulating level of 
250 ± 50xl09/l of blood. Once in the circulation they are able to react with a variety of agonists to 
fulfil their primary role of haemostasis and the maintenance of vascular integrity. Disruption of 
this finely tuned process may lead to pathological conditions of thrombosis or uncontrolled 
bleeding. 
Platelets, m the quiescent state, have a smooth, convex outer membrane which on closer 
inspection contains numerous deep invaginations representing sites of communication between the 
exterior of the cell and the channels of the surface connected open canalicular system. A 
cytoskeleton consisting of filaments and microtubules exists which is important both structurally 
and functionally. The microtubules are able to maintain the discoid shape of the cell in the resting 
state. Upon activation the filaments are rearranged and polymerized allowing for extension of 
pseudopods and contractile processes which move the cytoplasmic granules towards the cell 
centre. Within the cytoplasm are a-granules, dense granules, glycogen particles and lipid droplets 
as well as mitochondria and remnants of the Golgi apparatus. The functional activity of the 
platelet in haemostasis involves four fundamental mechanisms, namely adhesion, aggregation, 
contraction and secretion. Following vascular endothelial cell damage, platelets adhere to exposed 
subendothelial structures and undergo various calcium dependent biochemical and shape changes. 
The contents of dense bodies and a-granules which are extruded into the canalicular system and 
finally into the extracellular medium include fibrinogen, calcium, seretonin and ADP and are able 
to recruit other platelets to the injured area. 
External agonists interact with specific glycoprotein or glycolipid receptors on the platelet 
surface. These receptors may be of the G-protein, seven transmembrane domain type, or receptors 
used in adhesive interactions. These latter receptors generate messengers which are able to 
stimulate intracellular mobilization of calcium and degranulation of platelets, processes occurring 
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as a result of activation of kinase-phosphatase cascades (Berridge, 1987). Following engagement 
of a specific agonist to its receptor a biochemical signal is transduced across the membrane which 
allows for platelet activation. Among the substances that stimulate these intracellular pathways 
are thromboxane A2, thrombin, norepinephrine, collagen and ADP (Letkovits et al, 1995). Platelet 
release of ADP, thromboxane A2 and serotonin in concert with the presence of other agonists in 
the microenvironment is able to trigger the recruitment and activation of surrounding platelets 
(Fuster and Jang, 1994). Regardless of the agonist involved, the end result is platelet shape 
change, aggregation, release of granule contents and induction of platelet coagulant activity 
(Coller, 1991). Glycoprotein Ilb-Illa plays a pivotal role in this process with fibrinogen and vWF 
the principal ligands acting to bridge platelets by binding between GPIIb-Illa molecules on 
adjacent platelets. 
The platelet glycoproteins can be classified as members of one of five gene families (Charo et al, 
1994). The most abundant are those of the integrin family and include GPIIb-Illa, which mediates 
platelet aggregation via fibrinogen binding. A second gene family expressed on platelets is the 
leucine-rich glycoprotein family of which GPib-V-IX complex is a member. The GPib-V-IX 
complex plays a critical role in the initial interaction of platelets with exposed subendothelium as 
well as aggregation under conditions of high shear stress in a process involving vWF. The 
selectins are represented by GMP-140 (P-selectin), a glycoprotein present within a-granules 
which becomes exposed on the platelet membrane after surface activation and is able to mediate 
interactions between platelets, endothelial cells and leukocytes. Members of the immunoglobulin 
and quadraspandin family are also present. This review will provide a detailed discussion of 
GPIIb-Illa and P-selectin as they are directly relevant to the experimental work undertaken. 
GPIIb-Illa and platelet aggregation 
The GPIIb-Illa integrin was the first integrin to be associated with a human disease (Nurden and 
Caen, 1974; Phillips and Agin, 1977), the first to be biochemically purified (Jennings and Phillips, 
1982), and the first to be expressed in completely recombinant form (O'Toole et al, 1989; Bodary 
et al, 1989). It is the most abundant of the platelet integrins with approximately 50 000 copies per 
cell and is present only on platelets and cells with megakaryoblastic potential (Phillips et al, 
1991). It consists of an a (136 kDa) and a f3 (92 kDa) subunit. The light chain of the a subunit 
has a short cytoplasmic tail, a transmembrane region and short extracellular domain while the 
heavy chain is entirely extracellular (Poncz et al, 1987). The f3 subunit consists of a 762 amino 
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acid single polypeptide with a short cytoplasmic tail, a transmembrane region and a large 
extracellular domain (Fitzgerald et al, 1987; Phillips et al, 1988). The noncovalently bound 
receptor complex is present as a calcium-dependent heterodimer (Kunicki et al, 1981; Fujimura 
and Phillips, 1983). The cytoplasmic domains of these transmembrane glycoproteins associate 
with the underlying cytoplasmic actin filaments (Fox, 1985). Following ligand binding to GPIIb-
Illa cytoskeletal-integrin complexes are formed . This stabilizes the integrin-ligand interaction 
required for selective movement of ligand-occupied integrin into the surface connected open 
canalicular system (Fox, 1996). 
Integrins are capable of signalling in both directions across the plasma membrane. When platelets 
are activated by various agonists the conformation of GPIIb-Illa changes so that it can bind one 
of four soluble adhesive proteins: fibrinogen, vWF, fibronectin and vitronectin (Plow and 
Ginsberg, 1989, Sims et al, 1991). In resting platelets this integrin is able to bind fibrinogen to a 
limited extent which is important in the constitutive transport and incorporation of the molecule 
into a-granules or when fibrinogen is bound to a surface or to another activated platelet (Keiffer 
et al, 1992; Luscher and Weber, 1993 ). The exact involvement of this receptor in the mechanism 
of platelet activation remains unclear but seems to involve the cytoplasmic domain of both 
subunits (O'Toole et al, 1994) and phosphorylation of either GP Illa (Elmore et al, 1990) or other 
molecules interacting with the integrin (Clemetson, 1995). Recently Law et al (1996) showed that 
the f33 subunit undergoes tyrosine phosphorylation in response to thrombin-induced platelet 
aggregation. It appears that this tyrosine phosphorylation is important in initiating "outside-in" 
signalling cascades and induces the association of signalling components directly with the integrin. 
The phosphorylation state of the f33 subunit represents a major factor in the exposure of ligand-
binding sites on GPIIb-Illa (van Willigen et al, 1996) 
Activation of GPIIb-Illa and binding of fibrinogen represent the initiation of processes leading to 
platelet aggregation and kinase activation with subsequent clustering of the platelet receptors 
(Isenberg et al, 1987). These clustered GPIIb-Illa molecules occupied by fibrinogen are important 
in establishing links between platelets and thus allowing for aggregation to occur. In addition 
these clustered and occupied receptors are able to bind and activate resting platelets (Luscher and 
Weber, 1993 ). Adhesion of platelets to an altered surface such as damaged vascular endothelium 
is the first step in their response to vascular i1~ury. There is a transition from a resting to an 
activated state in response to agonists generated subsequent to injury. Formation of a thrombus 
capable of arresting haemorrhage involves the interaction of platelets with one another after initial 
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adhesion to a thrombogenic substrate. The process of platelet aggregation only will be discussed 
in more detail as discussion of adhesion is beyond the scope of this review. 
The mechanism of platelet aggregation following adhesion of platelets to exposed collagen 
depends upon the level of shear stress within the system. Under conditions of high-shear stress the 
receptor GPib-lX-V complex and vWF that binds to it are central to mediating platelet 
aggregation (Ikeda et al, 1991). The importance of this interaction under high shear stress is 
thought to be due to the ability of vWF to take on an extended filament shape and offer an array 
of interactive sites capable of multivalent binding to receptors on the platelet membrane (Federici 
et al, 1989). This allows for the increased strength of interaction necessary at high shear stress. 
Binding is thought to increase the transmembrane flux of calcium ions, with intracellular calcium 
concentrations rising by two to threefold. Thus activation of the platelet may occur without the 
presence of agonists necessary for activation at low shear stress (Ruggeri, 1994). After initial 
binding to GPib and a rise in intracellular calcium a change in the ligand specificity of GPIIb-Illa 
is thought to occur that enables it to bind vWF and thereafter support platelet adhesion (Ikeda et 
al, 1993). 
At lower shear stresses fibrinogen plays a vital role in platelet aggregation, acting as a molecular 
bridge from platelet to platelet via binding to the platelet fibrinogen receptor GPIIb-Illa. For the 
most part fibrinogen will bind only to these receptors on platelets activated by various agonists. 
These may be strong agonists such as thrombin or thromboxane A2 which are associated with 
phospholipase C and PKC activation (Shattil and Brass, 1987) or weak agonists such as ADP 
which result in calcium mobilization and phosphorylation of myosin light chain (Gachet and 
Cazenave, 1991). Exposure of platelet fibrinogen receptors may also occur subsequent to 
interaction with various proteolytic enzymes such as chymotrypsin and human neutrophil elastase 
(Niewiarowski et al, 1981 ; Kornecki et al, 1988). The role of neutrophil-derived proteinases in 
inducing platelet activation was further investigated by Renesto and Chignard ( 1993) who looked 
at the role of elastase and cathepsin G which are released simulataneously from the azurophilic 
granules of activated neutrophils. They found that although elastase was unable to activate 
platelets by itself, it was able to significantly enhance cathepsin G-induced platelet activation in 
terms of aggregation, dense and a-granule secretion and thromboxane B2 production. 
The interaction of fibrinogen with GPIIb-Illa, the crucial event leading to platelet aggregation, 
requires recognition of specific peptide sequences contained within the fibrinogen molecule. The 
Arg-Gly-Asp (RGD) sequence is recognised by several integrins (Ruoslahti and Pierschbacher, 
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1986; D'Souza et al, 1991) and the fibrinogen molecule contains two RGD sequences: the 95-97 
and 572-574 residues on the Aa. chain, with the more N-terminal sequence primarily involved in 
binding to GPI1b-I1Ia (Smith et al, 1989). Peptides containing the RGD sequence can act as 
potent inhibitors of the interaction between fibrinogen and GPIIb-IIIa (Plow et al, 1987). In 
contrast, other reports of binding of RGD peptides to GPIIb-IIIa, which do not require agonist 
activation of the platelet, show an associated conformational change within the receptor leading 
to the acquisition of a high affinity fibrinogen-binding state (Du et al, 1991 ). Thus, these peptides 
may act as partial agonists as well as competitive antagonists of integrin function. The 
dodecapeptide sequence 400-411 found at the extreme C-terrninus of the fibrinogen y chain (Lys-
Gln-Ala-Gly-Asp-Val) and found only in fibrinogen also has the ability to bind to GPIIb-IIIa 
(Kloczewiak et al, 1982) and is probably the predominant site of fibrinogen binding (Farrell et al, 
1992; Weisel et al, 1992) although this is disputed by Hantgan et al (1992). Both the 
dodecapeptide and the RGD peptide are able to induce changes in the dynamics and fluidity of the 
platelet membrane. Rigidification of the membrane lipid bilayer and increasing immobilization of 
platelet membrane proteins occurs following binding of the RGD peptide. In contrast, subsequent 
to interaction with the dodecapeptide, fluidization of the platelet lipid bilayer occurs with 
increasing mobility of thiol-containing domains of membrane proteins (Watala, 1996). Synthetic 
peptides containing the fibrinogen 400-411 dodecapeptide adhesion sequence are also effective 
inhibitors of platelet aggregation and binding of adhesive ligands. This appears to be true for both 
static conditions as well as in flowing whole blood (Hantgan et al, 1992; Bennet et al, 1988). 
Savage et al (1995) further investigated differences in fibrinogen binding depending on flow state 
and suggested that multiple sites are responsible for the adhesive potential of fibrinogen, 
depending on the state of receptor activation and flow conditions. The interaction of fibrinogen 
with its platelet receptor results in conformational changes within the fibrinogen molecule itself 
The bound molecule expresses receptor induced binding sites which are not available in the free 
ligand. One such sequence is at y112_119 and the other is the RGD sequence at Aa.95_98 (Ugarova et 
al, 1993 ). Thus this RDG sequence does not participate in the initial binding of the molecule to 
GPIIb-IIIa. Ugarova et al (1993) proposed a model in which binding of fibrinogen to its receptor 
would alter the C-terminal aspects of the Aa.-chains and thereafter expose sequences occurring in 
the coiled-coil segment between the D and E domains. These receptor-induced binding sites may 
then mediate unique functions of the receptor-bound molecule. In contrast to the calcium 
dependent binding described above, an irreversible calcium independent and non-covalent binding 
of immobilised fibrinogen to the purified GPIIb-IIIa receptor has been described involving novel 
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binding sites on both the fibrinogen molecule and the receptor (Parise et al, 1993). In a study 
investigating binding of fibrinogen degradation products to platelets, Peerschke and Galanakis 
(1 996) showed that non-RGD, non-dodecapeptide containing platelet recognition sequences in 
the D and E domains of fibrinogen were able to support platelet adhesion in both a cation 
dependent and independent fashion. 
Muller et al (1993) described biphasic binding of soluble fibrinogen as initially a weak and 
reversible interaction followed by strong and irreversible binding. More recently Wencel-Drake et 
al (1996) have shown that under conditions of irreversible binding of fibrinogen to GPIIb-Illa, 
fibrinogen is rapidly internalized by the activated platelets to a surface inaccessible, intracellular 
pool. Following internalization there is a loss in ability of platelets to aggregate. This 
downregulation of surface fibrinogen in circulating platelets may represent an important 
antithrombotic mechanism. The possibility exists that internalized fibrinogen may be recycled back 
to the platelet surface in response to secondary stimulation (Wencel-Drake, 1996). 
The complementary binding sites on the GPIIb-Illa receptor have been characterized. Two RGD 
binding sites have been identified on the P3 chain (Illa): residues 119-130 (Takada et al, 1992) 
and residues 211-222 (Bajt et al, 1992). The sites of RGD-binding on GPIIIa are well conserved 
amongst other P-subunits of the integrin family (Ruoslahti, 1988). The dodecapeptide from the 
extreme C-terminus of the y-chain of fibrinogen appears to selectively crosslink to GPIIb between 
residues 294 and 314 (D' Souza et al, 1990), an area that encompasses one of the putative metal-
binding domains of GPIIb. Thus ligand binding may modulate calcium binding to this receptor. 
NMR studies have now shown that important sequences for GPilb-Illa interaction with 
fibrinogen are RHDLL and PL YM from GPilb 300.314,HYMR from GPilb 656•667 and SRNR from 
GPIIIa 211-223 (Yao and Mayo, 1996). GPIIb 656-667 is able to bind soluble fibrinogen calcium-
independently and is selective for the y chain (Calvete, 1993). Alemany et al (1996) showed that 
the sequence 274-368 in the P3-subunit of GPIIb-Illa acts as a calcium independent fibrinogen 
ligand-binding domain for the y-chain of fibrinogen. This is distinct from the RGD-binding site, is 
involved in both the adhesion and aggregation of platelets and functions independently of platelet 
activation. 
The effect of plasmin on GPIIb-Illa may be a subject of particular importance in those patients 
receiving high doses of exogenous plasrninogen activators for various thrombotic disorders. The 
effect of plasrnin on platelet function is somewhat controversial with both pro- and 
antiaggregatory effects being reported (Niewiarowski et al, 1973; Shaefer and Adelman, 1985, 
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Torr et al, 1990). Pasche et al (1994) have also reported that plasmin is able to modify GPIIIa by 
a unique proteolytic event in plasma that is dependent on fibrinogen binding and thereafter is 
accompanied by significant reductions in fibrinogen binding and aggregation responses. This is in 
contrast to work done by Gouin et al (1991) who reported that incubation of human platelets in 
citrated plasma with streptokinase led to an aggregation defect related to a decrease in fibrinogen 
concentration and the impeding effects of fibrinogen degradation products binding to the platelet. 
However, there was no alteration or proteolysis of the platelet receptor GPIIb-IIIa. 
Platelets and fibrinolysis 
It has been found that platelet-rich clots are relatively resistant to plasmic lysis (Falk, 1992). A 
number of mechanisms have been proposed to account for this including platelet secretion of P Al-
l (Levi et al, 1992; Braaten et al, 1993 ), platelet-mediated clot retraction (Kunitada et al, 1992), 
release of ai-plasmin inhibitor from platelet a-granules (Mullertz and Clemmensen, 1976; Sakata 
and Aoki, 1980), release of factor XIII from platelets leading to increased cross-linking of fibrin 
clot as well as cross-linking of a 2-antiplasmin to fibrin clot (Reed et al, 1991; Francis and Marder, 
1987). However, the relative contribution of each of these processes to resistance to plasrnin-
mediated fibrinolysis remains controversial. 
Platelets are a potent source of plasminogen activator inhibitors. They contain P AI-1 as well as a 
low concentration of a 2-antiplasmin (6 ng/108 platelets) (Plow and Collen, 1981; Booth et al, 
1988). Investigations have tended to favour the concept that PAI-1 is the major platelet-secreted 
protein that is responsible for thrombolytic resistance (Braaten et al, 1993). However, others have 
found that this platelet P AI-1 is largely inactive (Booth et al, 1988) and argue that ai-antiplasrnin, 
which crosslinks to the fibrin clot by factor XIII, is a much more potent plasrnic inhibitor although 
present in lower concentrations (Reed et al, 1991). Fay et al (1994) performed experiments with 
PAI- I-deficient platelets and plasminogen activators with differential sensitivity to inhibition by 
P AI-1 and obtained results which suggested that P AI-1 is indeed an important determinant of 
platelet dependent clot lysis inhibition. However, this alone could not account for the inhibition 
observed and it was suggested that clot retraction may be an additional important mechanism of 
inhibition of clot lysis as described by Kunitada et al ( 1992). 
As mentioned previously, the interaction between GPIIb-lIIa and fibrinogen involves the RGD 
sequence as well as the KQAGDV sequence found at the C-terminus of they chain of fibrinogen . 
Braaten et al (1994) investigated the effect of the peptide D-RGDW, a paticularly potent 
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antiadhesive peptide, on platelet-delayed lysis. This peptide as well as an anti-GPIIbIIIa 
monoclonal antibody were able to effectively inhibit clot retraction but did not affect the overall 
delay in fibrinolysis due to platelets. The use of a P AI-1 resistant mutant oft-PA, with or without 
D-RGDW-inhibited clot retraction, could effectively increase the rate of fibrinolysis . This 
confirmed their earlier work implicating P AI-1 as playing an important role in thrombolytic 
resistance (Braaten et al, 1993). Of additional interest was the finding that platelet-bound fibrin 
exhibited a different course of fibrinolysis from that of the bulk clot. The platelet-bound fibrin 
took longer to lyse than the thrombus as a whole but when D-RGDW was added, acting as an 
agent which uncoupled fibrin from the platelet receptors, the time required to achieve 50% 
surface lysis decreased to a value comparable to that of the whole clot. Thus two complementary 
effects due to fibrin binding and clot retraction were postulated (Braaten et al, 1994) that could 
be contributing to the mechanism for lytic resistance of platelet-associated fibrin. Binding to 
GPilb-Illa and retraction creates local areas of high fibrin concentration which may in addition 
retard the diffusion of fibrinolytic enzymes through the matrix. The process of retraction may also 
exclude plasminogen and plasminogen activator containing fluid from the thrombus. 
Alternatively it has been proposed that the platelet may serve as a site for assembly of proteins of 
the plasrninogen activator system and once bound to the surface, t-P A is able to exhibit enhanced 
catalytic activity (Loscalzo et al, 1995). At high concentrations plasrnin is also able to activate 
platelets directly, further facilitating effective binding of plasrninogen and plasminogen activators 
and subsequent plasrnin generation (Loscalzo et al, 1995). 
Clot retraction 
Clot retraction represents another important aspect of platelet function. Once the fibrin network is 
formed , the incorporated platelets are able to exert force on the network strands. Fibrin strands 
conform to the platelet surface (Morgenstern et al, 1984) as platelet pseudopods extend outward 
along fibrin bundles (Cohen et al, 1982). Platelets are able to constrict through contraction of 
rnicrofilaments and fibrin strands are pulled into alignment (Chao et al, 1976). As forces develop 
the clot begins to retract, shrink in size and express contained serum. This process may be 
important in allowing for recanalization of an obstructed blood vessel. Its importance also lies in 
assisting with approximation of the edges of the wound and concentrating the clot in the injured 
area. The platelet-fibrin network subsequently serves as the scaffolding for tissue repair. The 
structure of the fibrin network is critical to the retraction process and in particular the fibrin fibre 
diameter. The fibre diameter correlates inversely with thrombin concentration (Carr and Hermans, 
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1978) and the thinner the fibrin fibre the greater the inhibition to clot retraction (Taylor and 
Muller-Eberland, 1970). Cross-linking of the clot by factor XIII is also critical to development of 
tension (Cohen et al, 1982). 
The recognition sites on fibrinogen for the platelet integrin GPIIb-IIIa involve the dodecapeptide 
on the C-terminus of the fibrinogen y chain and the tripeptide RGD which occurs in two places on 
the fibrinogen a chain (Kloczewiack et al, 1982; Plow et al, 1987). Cohen et al (1989) looked at 
the effect of peptides and monoclonal antibodies that bind to the platelet receptor GPIIb-Illa on 
the development of clot tension. Peptides incorporating these recognition sites were able to 
increase clot tension considerably and morphological studies revealed that these peptides also 
increased confluence of orientated fibrin and platelet aggregates. Monoclonal antibodies directed 
against different epitopes on the GPIIb-lIIa complex had varying effects on clot tension, some 
inhibiting while others increased it. This effect of peptides on clot tension most probably occurs 
through increasing the interaction between platelets and polymerizing fibrin . From these studies 
with fibrinogen peptides and monoclonal antibodies to regions of the GPIIb-IIIa receptor Cohen 
et al (1989) concluded that clot tension requires a platelet receptor domain for polymerizing fibrin 
which is different from the fibrinogen receptor domain required for aggregation. Rooney et al 
( 1996) constructed a recombinant human fibrinogen that lacks the y chain four C-terminal 
residues which was unable to support platelet aggregation. However, clot retraction 
indistinguishable from that supported by normal recombinant or plasma fibrinogen could still 
occur. Thi.s suggests that the site on fibrinogen required for platelet aggregation is different from 
the site on fibrin required for clot retraction. 
Following binding, GPIIb-IIIa localizes at focal adhesion sites and becomes anchored to the 
cytoskeleton, a key process in the initiation of cell spreading, clot retraction and signal 
transduction (Juliano and Haskill, 1993; Ylanne et al, 1993). There appears to be an important 
role for non-receptor tyrosine kinases in promoting integrin-cytoskeletal interactions. Subsequent 
to ligand-binding, cytoskeletal recruitment and/or activation of these non-receptor tyrosine 
kinases, such as pp60c-src and pp l 25FAK' occurs (Oda et al, 1992). Thereafter these enzymes 
phosphorylate specific structural proteins required for the attachment of integrins to the actin-rich 
cytoskeleton. Schoenwaelder et al (1994) showed that regulation of cytoskeletal attachment of 
GPIIb-IIIa by platelet tyrosine kinases was an essential process for the transmission of cellular 
contractile forces to fibrin polymers. Of interest is that nucleated cells such as fibroblasts and 
tumour cells are also able to interact with the fibrin substrate and induce retraction of fibrin clots. 
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These cells do not possess the GPIIb-IIIa receptor but rather the p3 integrin, avP3, which mediates 
the interaction between the fibrin substrate and the nucleated cells (Katagiri et al, 1995). 
Neutrophil-platelet adhesion mechanisms: the role of P-selectin 
The selectin family of adhesion molecules consists of three members with a standard nomenclature 
designating each family member according to the cell type on which it was first identified: E-
selectin (endothelium), P-selectin (platelets) and L-selectin (lymphocytes) (Bevilacqua et al, 
1991). A high degree of homology exists between these members and the genes for all three are 
clustered over a short region of chromosome 1 (Pigott and Power, 1993) suggesting that they 
arose by duplication of an ancestral gene. Each of these molecules contains an N-terminal lectin-
like domain, an epidermal growth factor (EGF) repeat and a varying number of repeats of a 
domain found in complement regulatory proteins (Bevilacqua and Nelson, 1993). A 
transmembrane region is followed by a short cytoplasmic tail. 
P-selectin was first discovered by investigators interested m events associated with platelet 
activation. A transmembrane glycoprotein of approximately 140 kD was discovered that was 
associated with the a-granules in resting platelets and upon activation was rapidly redistributed to 
the surface of the cell . This same molecule was also found in the Weibel-Palade bodies of 
endothelial cells and similarly could be very rapidly expressed on the cell surface following 
stimulation by thrombin or other agonists (Hsu-Lin et al, 1984; Bonfanti et al, 1989; McEver et 
al, 1989). It is synthesized constitutively and stored intracellularly in both platelets and endothelial 
cells, being targeted to secretory granules by a sorting signal present within its cytoplasmic 
domain (Disdier et al, 1992). Platelet activation is associated with phosphorylation of this region 
(Crovello et al, 1993). Following stimulation of platelets by agonists such as thrombin, histamine, 
terminal complement compounds and hydrogen peroxide there is rapid expression of P-selectin on 
the platelet surface. In endothelial cells this is followed by reinternalization, with surface 
expression declining within minutes (Zimmerman et al, 1992). Within the cytoplasmic domain a 
sequence exists which routes it for degradation in the lysosomes following internalization, a 
constitutive mechanism of down-regulation that does not require extracellular signalling (Green et 
al, 1994). The primary function of P-selectin on platelets appears to be to mediate their binding to 
multiple leukocyte types, while endothelial P-selectin not only plays a role in lymphocyte homing 
but also supports leukocyte adhesion during inflammatory processes ( Hamburger and McEver, 
1990; Toothill et al, 1990; Picker and Butcher, 1992). Following tissue injury leukocytes roll 
along the vessel wall, this process being mediated by P-selectin (Lawrence and Springer, 1991; 
55. 
Dore et al, 1993 ), before other adhesion molecules such as integrins and receptor members of the 
immunoglobulin superfamily immobilize leukocytes in the area of tissue injury. Under conditions 
of flow, subendothelial matrix alone is unable to support neutrophil adhesion and neutrophils will 
adhere predominantly to platelets adherent to subendothelial matrix via P-selectin (Kuijper et al, 
1996). 
P-selectin may also be released from surface membranes following its expression on activated 
platelets and circulate in the plasma in a soluble and potentially functional form (Dunlop et al, 
1992). Cloning data showed a form of P-selectin that lacks the transmembrane domain (Johnston 
et al, 1989) and in support of this human platelets have been found to contain approximately 
equal amounts of mRNA encoding for P-selectin with and without the transmembrane domain 
(Johnston et al, 1990). This soluble form of P-selectin may serve an anti-inflammatory function as 
exposure of TNF-a-activated neutrophils to the fluid-phase variant is able to inhibit neutrophil 
CD 18-dependent adhesion to resting endothelium (Gamble et al, 1990) and superoxide 
production (Wong et al, 1991). Following activation of platelets by strong agonists, release of 
vesicles or microparticles from the platelet occurs. These microparticles, which contain GPIIb-IIIa 
and P-selectin, are able to adhere to fibrin and appear to play a procoagulant role (Siljander et al, 
1996). 
Two high affinity binding sites for calcium exist on P selectin (Geng et al, 1991) and binding of 
calcium induces conformational changes to the protein in a manner that is essential for leukocyte 
recognition. The specific ligands for selectins are carbohydrate-containing compounds notably the 
sialyl Lex antigen (Bevilacqua and Nelson, 1993). Although sialyl Lex is required for P-selectin 
interaction on cell surfaces, it is not sufficient for high affinity binding and a protein component 
within the ligand is also required for high affinity binding (Moore et al, 1991 ). The lectin domain 
plays a critical role in P-selectin ligand recognition, with the EGF domain conferring certain 
binding specificities to the adjacent lectin domain (Furie and Furie, 1995). The P-selectin ligand 
has been found to be distributed on myeloid cells, in particular neutrophils and monocytes, a small 
subpopulation of T-lymphocytes and certain malignant cells (Larsen et al, 1989; Moore and 
Thompson, 1990; Stone and Wagner, 1993). This P-selectin glycoprotein ligand-I (PSGL-1) is a 
mucin-like 110 kD integral membrane protein with an extracellular, a transmembrane and a 
cytoplasmic domain with 50% carbohydrate component. The interaction of P-selectin with the 
ligand is calcium-ion dependent (Sako et al, 1993). Activation of neutrophils induces changes and 
surface expression of the P-selectin ligand with translocation and clustering of the ligand at the 
57 
uropod. Subsequent to this clustering, bound neutrophils detach from the activated platelets. This 
redistribution of the P-selectin ligand therefore has repercussions regarding adhesive interactions 
between neutrophils and activated platelets (Dore et al, 1996). The leukocyte integrin 
CD 11 b/CD 18 displays a similar redistribution following neutrophil activation (Hughes et al, 
1992). Thus, a possible association between CD 11 b/CD 18 and P-selectin may exist. This theory is 
further supported by data showing that P-selectin has a role in activating CD 18-dependent 
phagocytosis of unopsonized zymosan (Cooper et al, 1994). An additional P-selectin ligand, a 
240 kD sialoglycoprotein from leukocyte membranes, has been described by Ma et al (1994). 
The interaction of neutrophils and platelets can thus be seen to be the result of specific cellular 
adhesive processes in areas of thrombus formation and fibrin deposition and not simply due to 
mechanical trapping. Palabrica et al (1992) showed that the presence ofleukocytes within thrombi 
was mediated by P-selectin expressed on activated platelets and the presence of these leukocytes 
promoted fibrin deposition. The mechanism for enhanced fibrin deposition is not entirely clear but 
Celi et al (1994) showed that the presence of P-selectin was able to upregulate the expression of 
tissue factor, the initiator of coagulation, on monocytes. Monoclonal antibodies directed against 
P-selectin are able to dramatically reduce the fibrin content of a developing thrombus and in turn 
lysis is far more rapid upon initiation of thrombolytic therapy (Toombs et al, 1995). Experiments 
to investigate the interaction of activated platelets with neutrophils were done under physiologic 
shear conditions in an effort to simulate a vessel wall injury (Yeo et al, 1994). The binding of 
neutrophils to activated platelets was found to be P-selectin dependent in a saturable, time and 
cation dependent manner. A secondary step involving neutrophil activation after platelet binding 
was necessary for irreversible adhesion to occur, with associated upregulation of CD 11 b/CD 18 
and downregulation of L-selectin. Nagata et al (1993) were able to show enhanced superoxide 
anion production by neutrophils following binding to activated platelets, a process that could be 
inhibited by the addition of anti P-selectin antibodies. Further proof that binding to P-selectin is 
able to alter neutrophil function was provided by Cooper et al (1994) who showed that following 
binding of neutrophils to purified, recombinant P-selectin, there was enhanced phagocytosis of 
unopsonized zymosan particles. The use of antibodies to either CD 18 or CD 11 b could inhibit this 
phagocytosis, suggesting a signalling role for P-selectin in influencing ~i-integrin function . 
Subsequent to P-selectin mediated platelet adhesion to neutrophils there is inhibition of 
neutrophil-platelet adhesion and dissociation of existing neutrophil-platelet conjugates within 30 
to 60 minutes (Rinder et al, 1994). Lorant et al (1993) looked at neutrophils adhering to 
endothelium via P-selectin and showed that they were upregulated and primed for enhanced 
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degranulation when subsequently stimulated with chemotactic factors. However, P-selectin did 
not induce these responses directly and the priming event appeared to be mediated by the 
signalling molecule, PAF. 
Platelet-neutrophil interactions 
The adhesion of platelets to the subendothelial matrix of a damaged vessel wall and subsequent 
activation has been seen as the fundamental event in the pathogenesis of thrombosis. However, it 
has long been realised that leukocytes are found together with platelets within both mature and 
developing thrombi. This is relevant not only at the site of developing thrombus but also at other 
sites of inflammatory reactions. Traditionally, various facets of the immune response have been 
studied in isolation but in reality the different components undergo complex interactions. The 
interaction of platelets with neutrophils is of particular relevance to this thesis. 
Platelets release metabolites of arachidonic acid, P AF, platelet-derived growth factor (PDGF) and 
platelet factor 4 (PF4), all of which have the potential to affect various neutrophil functions 
including adhesion, chemotactic activity, secretion and superoxide anion generation (Weksler, 
1989; Aziz et al, 1995). Activated platelets have been shown to adhere to neutrophils and their 
released products contribute to leukocyte accumulation within the fibrin clot (Larson et al, 1989). 
This stimulus of neutrophils by platelets requires intercellular contact, with fibrinogen exposure on 
the platelet surface (Ruf et al, 1992). Activated leukocytes in turn have the ability to modify 
platelet function. The interaction of platelets with neutrophils is mediated by specific cellular 
adhesive processes involving P-selectin, expressed on activated platelets, and its counter-receptor 
on the neutrophil. 
Eicosanoids is a collective name for unsaturated lipids derived from arachidonic acid and includes 
prostaglandins, thromboxanes, leukotrienes, lipoxins and various hydroxy- and hydroperoxy-fatty 
acids that are produced by platelets. They are able to contribute to the recruitment of neutrophils 
to sites of vascular injury (Fretland et al, 1989 and 1990). 1n addition, stimulation of leukotriene 
B4 synthesis by neutrophils occurs (Maclouf et al, 1982) with this molecule acting as a powerful 
chemoattractant (Ford-Hutchison et al, 1980) further amplifiying neutrophil recruitment. 
Transcellular biosynthesis of arachidonic acid metabolites may occur as a form of cell-cell 
communication enabling platelets and neutrophils to amplify the effects of their own activation 
(Maclouf et al, 1989). PDGF, PF4, serotonin and thromboxane A2 are able to enhance neutrophil 
adhesion to the vessel wall (Morley and Feuerstein, 1989). While ATP and ADP, stored in platelet 
59 
dense bodies and released upon platelet activation, may produce neutrophil activation with 
respiratory burst (Ward et al, 1988) and phagocytosis (Sakamoto and Firkin, 1984). Adenine 
nucleotides, PDGF and other platelet-derived products are able to induce neutrophil 
degranulation (Del Maschio et al, 1989). 
Besides their role in activating neutrophils, platelets may also inhibit neutrophil function. Under 
conditions of close neutrophil-platelet contact, platelets are able to significantly decrease elastase 
secretion from neutrophils in response to stimulation as well as decrease neutrophil phagocytic 
activity (Losche et al, 1996). Platelets are able to secrete transforming growth factor-P and the 
soluble from of P-selectin, both of which are able to inhibit adhesion of neutrophils to cultured 
endothelial cells (Gamble and Vadas, 1988; Gamble et al, 1990). Soluble P-selectin, together with 
PDGF, has the capacity to reduce superoxide anion generation by activated neutrophils. 
Bengtsson et al (l 996) showed that resting platelets could limit the release of oxygen radicals 
from chemoattractant stimulated neutrophils. They were associated with an increase in the 
generation of neutrophil-derived adenosine, an inhibitor of respiratory burst, and peripheral 
accumulation of actin filaments forming a barrier for the extracellular release of reactive oxygen 
radicals. In addition, platelet production of nitric oxide (Radomski et al, 1990) and platelet-
induction of its synthesis by endothelial cells (Vanhoutte and Miller, 1987) may inhibit neutrophil 
chemotaxis, aggregation and adhesion to endothelium (Kubes et al, 1991). 
Neutrophil-dependent activation of platelets is related to production of superoxide aruon, 
hydrogen peroxide, hypochlorous acid, elastase, cathepsin G and PAF (Bazzoni et al, 1991). 
Nitric oxide (Faint et al, 1991) and ADP-ases (Coade and Pearson, 1989) are particularly relevant 
when considering neutrophil-dependent inhibition of platelets. 
60 
CHAPTERS 
Proteases of the neutrophil membrane act as an alternative fibrinolytic 














Fibrinolysis by neutrophils incorporated into the clot 
The effect of neutrophils on plasmin solubilization of 
125I-labelled fibrin 
Nature of soluble 125I-labelled fibrin products 
Effect of inhibitors on the solubilization of 125I-
labelled fibrin 
Identification of proteases in a neutrophil membrane 
preparation capable of degrading fibrin 
Electron microscopy of fibrinolysis by neutrophils 
incorporated within the fibrin matrix 




Proteases of the neutrophil membrane act as an alternative 
fibrinolytic pathway to that mediated by plasmin 
Introduction 
The process of both blood coagulation and fibrinolysis needs to be finely controlled in order that 
the pathological states of uncontrolled bleeding or thromboembolism, with resultant ischaemia, do 
not ensue. This thesis is primarily concerned with fibrinolysis, a mechanism referring to the 
dissolution of fibrin clot and classically ascribed to the plasma zymogen plasrninogen, which 
becomes activated to the proteolytic enzyme plasmin (Sawyer et al, 1960; Kaplan and Austen, 
1972). Fibrinolytic activity, in vivo, is the result of a balance between plasminogen activator and 
inhibitor levels. However, in addition to the plasmin-mediated system of clot lysis, it has become 
apparent that the cellular constituents of the blood and in particular the neutrophil have an 
important role to play in contributing to fibrinolysis (Plow and Edgington, 1975). Elastase and 
cathepsin G, proteases present within the azurophilic granules of the cell and requiring relatively 
high activation states to be released, have both been described as possessing fibrinolytic properties 
(Plow, 1980). Mobilization of these granules is both a time and cell activation dependent process 
and fibrin would be more accessible as a substrate to proteases situated on the neutrophil 
membrane. Recently, a high molecular weight phorbol ester-upregulatable neutral protease, 
located at sites of attachment of the membrane with the cytoskeleton, has been demonstrated to 
possess fibrinogenolytic activity which is distinct from that of plasrnin, neutrophil lysosomal 
enzymes and pure neutrophil elastase (Shephard et al, 1992; Kelly et al, 1994). Simultaneous 
early cleavage of all three constituent chains of fibrinogen to produce unclottable fibrinogen 
products, which do not exhibit anticoagulant activity, appears to be a characteristic of the 
fibrinogenolytic activity of this membrane-associated protease (Kelly et al, 1994). 
Of further interest is that it has been found that leukocytes accumulate within fibrin clots due to 
specific cellular adhesive processes and not merely due to mechanical trapping (Palabrica et al, 
1992). In the case of platelet rich clots accm~ulation is due in part to the specific interaction 
between P-selectin on activated platelets and its counterreceptor expressed on leukocytes. In the 
close interaction of fibrin( ogen) and neutrophils the transmembrane glycoproteins of the integrin 
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supergene family feature prominently. The C-terminal region of they chain of fibrinogen has been 
shown to bind to CD1 lb/CD18 (Wright et al, 1988). Altieri et al (1993) showed a calcium 
dependent binding of fibrinogen, involving the recognition motif glycine190-valine202 of they chain, 
to CD 11 b/CD 18 . PMA-stimulated neutrophil binding to the I domain of CD 11 b/CD 18 occurs via 
a small subpopulation of approximately 10% of cells (Diamond and Springer, 1993; Diamond et 
al, 1993) while the interaction of TNF-stimulated neutrophils with immobilised fibrinogen is via 
the GPR sequence on the N-terminal domain of the Aa. chain with CD I le/CD 18 (Loike et al, 
1991). This same integrin receptor appears to be important in the formation of a fibrinogen bridge 
between neutrophils and the platelet GPIIb-Illa receptor (Ruf and Patscheke, 1995). In addition, 
the fibrinogen RDG and AKQAGDV sequences, in the a. and y chains respectively, as well as a 
novel KGAGDV sequence act as ligands for the LRI (Gresham et al, 1989; Gresham et al, 1992). 
To date no studies have investigated the interaction of the leukocyte specific p2 integrins with 
fibrin and concomitant degradation of the ligand. 
The aim of this study was to investigate the possible role that proteases of the neutrophil 
membrane may play in contributing to fibrinolysis and compare this to fibrinolysis by plasmin and 
the lysosomal enzyme component of the cell. Fibrinolysis by neutrophils and plasmin was 
quantified as the amount of soluble 125I-labelled fibrin ( cpm) released from the 125I-labelled fibrin 
clot, expressed as a percentage of total 125I-labelled fibrin ( cpm) associated with the intact clot. 
The size of the products produced by the various enzyme sources was assessed by SDS-P AGE. 
Similarly, the fibrin degradation occurring without the addition of exogenous proteases was 
quantified and the stability of the clot over time was assessed by SDS-P AGE. Scanning and 
transmission electron microscopy was employed to monitor fibrin matrix alterations and 
morphological changes of the neutrophil. A variety of antibodies directed against the p2 integrins 
were used to study their effect on neutrophil-mediated fibrin degradation under conditions of 
PMA-stimulation at concentrations not associated with azurophil granule release. In addition the 
possible signal transduction pathways involved in this process were also investigated using 
specific kinase inhibitors. The methodology used to obtain the results discussed in this chapter and 




In the absence of proteases (no lysosomal enzyme, intact cells or conditioned medium 
preparation) approximately 1 % of the total radioactivity in the clot was released into the medium 
at 90 mins, indicating minimal spontaneous clot dissolution during the period of experimentation. 
SDS-PAGE (5-20%, reduced) followed by autoradiography shows the fibrin clot to contain both 











Figure 1. SDS-PAGE analysis (5-20% reduced) of fibrin clot formed by 125I-labelled fibrinogen at a final 
concentration of 2 mg/ml HBSS with addition of bovine thrombin at 0.4 units/ml final concentration. Fibrinogen 
standard showing ex (66 kDa), P (52 kDa) and y (46.5 kDa) chains (track l) ; fibrin clot 1 hr after formation 
showing both cx-crosslinked polymer forination and y-y crosslinking (track 2), fibrin clot 24 hr after formation 
(track 3). Molecular weight markers as indicated. 
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The ability of non-stimulated neutrophils and neutrophils stimulated with a low dose of PMA, that 
does not release lysosomal enzymes from these cells (Shephard et al, 1989), to solubilize fibrin 
was evaluated. Solubilization of 
125
I-labelled fibrin for any given concentration of cells was faster 
when the cells were stimulated with PMA (Fig 2A). The contribution of proteases released from 
neutrophils during incubation with 
125
I-labelled fibrin to this solubilization was investigated by 
incubating 
125
I-labelled fibrin with conditioned medium prepared from non-stimulated and PMA-
stimulated neutrophils. Although PMA-stimulated neutrophil conditioned medium released more 
125 
radioactivity than non-stimulated neutrophil conditioned medium, I-fibrin solubilization in the 
presence of cells was 3 times and 2 times greater than that by the conditioned medium from non-
stimulated and PMA-stimulated cells respectively (Fig 2A). When the solubilization of mI-
labelled fibrin by intact neutrophils was compared to that by lysosomal enzymes, prepared from an 
equivalent number of cells, the latter enzyme source always released more radioactivity. The rate 
of 
125
I-labelled fibrin solubilization by lysosomal enzymes from 10x10
6 
neutrophils was 2 fold that 
6 
of lOxlO PMA-stimulated cells (Fig 2A). For each of these neutrophil enzyme sources the 
release of radioactivity (37°C, 60 min) from clotted 
125
I-labelled fibrinogen plateaued with high . 
concentrations of each of these enzyme sources (Fig 2A) and was linear with increasing weights 
of 
125
I-labelled fibrin (Fig 2B). The release of radioactivity from 
125
I-labelled fibrin by each 
neutrophil source was detectable within 2 min and linear up to 90 min (Fig 2C). Solubilization of 
1~ . 
a I-labelled fibrin clot (250 ~tg) by pure human neutrophil elastase (250 ng) was linear up to 45 
min and reached completion in three hours. In contrast to the kinetics of clot solubilization by 
125 
neutrophils, the kinetics of I-labelled fibrin solubilization by plasmin was not linear. At time 
125 
points prior to 60 min the rate of I-labelled fibrin solubilization by plasmin was slower than that 
by the neutrophil enzyme sources but showed an exponential rise with time (Fig 2C). The extent 
125 
of I-labelled fibrin solubilization at 90 min by plasmin, generated from plasminogen at 5 µg/ml, 
equalled that by neutrophil lysosomal enzymes at 90 min (Fig 2C). The variation in clot 
solubilization for 10 different experiments and 10 different batches of 125I-labelled fibrinogen 
varied by less than 10%. 
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Figure 2. Solubilization of a preformed 125!-labelled fibrin clot. Each data point is the mean of triplicated 
determinations which did not vary by more than 2% and the illustrated results are one of ten replicate experiments. 
(A) With respect to enzyme levels at 60 min. Reactions (500 µI) contained the indicated number of neutrophils or 
neutrophil equivalents and 250 µg preformed 125I-Iabelled fibrin. Lysosomal enzyme(*), intact PMA-stimulated 
neutrophils (A), intact non-stimulated neutrophils ce), conditioned medium from PMA-stimulated neutrophils 
(11), conditioned medium from non-stimulated neutrophils (+) . (B) With respect to clot size at 60 min. Reactions 
(500 µI) contained 2.5xl06 neutrophils or neutrophil equivalents and the indicated weight of preformed 
125!-
labelled fibrin . Lysosomal enzymes ( * ), intact PMA-stimulated neutrophils (A), conditioned medium from PMA-
stimulated neutrophils (11) . (C) With respect to time. Reactions (500 µl) contained 125 µg preformed 
125!-labelled 
fibrin and either 2.5xl06 neutrophils or neutrophil equivalents or plasmin generated by activation of 5 µg or 15 µg 
plasminogen/ml with OA IU urokinase/ml. Lysosomal enzymes ( * ), intact PMA-stimulated neutrophils (A), 
conditioned medium from Ptv1A-stimulated neutrophils (11), plasmin (from 5 µg plasminogen) C- -+- -), plasmin 
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Fibrinolysis by neutrophils incorporated into the clot 
The extent of 
125
1-labelled fibrin solubilization by neutrophils, neutrophil conditioned medium and 
lysosomal enzymes incorporated into the clot at 60 min was compared with that when these 
enzyme sources were added to 
125
I-labelled fibrin (Fig 3). Incorporation of each enzyme source 
(neutrophil conditioned medium from non-stimulated or PMA-stimulated neutrophils, non-
stimulated or PMA-stimulated neutrophils, or lysosomal enzymes) into the clot resulted in the 
solubilization being 3.8, 4.4, 3.0, 3.4 and 3.4 times greater at 60 min than when these respective 
enzyme sources were added to the clot (Fig 3). The release of radioactivity from 
125
I-labelled 
fibrin by lysosomal enzymes incorporated into the clot was 2.0 or 1.7 times greater respectively 
than that by an equivalent number of non-stimulated or PMA-stimulated neutrophils that had been 
incorporated into the clot (Fig 3). Complete solubilization of the clot was achieved within 60 min 
6 
when Pl\lIA-stimulated cells were incorporated into the clot at a concentration of 1Ox10 cells/mg 
125 
I-labelled fibrin ( data not shown). The variation in clot solubilization for 10 different 
experiments and 8 batches of 
125
I-Iabelled fibrinogen, when these neutrophil enzyme sources were 
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Figure 3. Comparison of clot solubilization by neutrophils added to a preformed l mg : :5I-labelled fibrin clot ( ) 
and neutrophils incorporated into a l mg 1: 51-labelled matrix ( \\ ). Reactions contained either 2.5:xl06 neutrophils. 
conditioned medium from 2.5xl06 neutrophils or lysosomal enzymes from 2.5xl06 neuuophils in a final rnlume of 
500 µI. A: conditioned medium from non-stimulated neutrophils, B: conditioned medium from PMA-stimulated 
neu trophils. C: intact non-stimulated neulrophils. D: intact PMA-stimulated neutrophils. E: neutrophil lysosomal 
enzymes. Each data point is the mean of triplicate determinations which did not Yary by more than 2% and the 
illustrated results are one of ten replicate experiments . 
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125 
The effect of neutrophils on plasmin solubilization of I-labelled fibrin 
PMA-stimulated neutrophils and PMA-stimulated neutrophil conditioned medium enhanced the 
solubilization of 
125
1-labelled fibrin by plasminogen activated by exogenous urokinase (Fig 4). This 
effect was observed when neutrophils were added to the clot with plasmin at zero time and with 
the addition of neutrophils after plasminogenolysis had progressed for 30 min (Fig 4). When 
plasminogenolysis of a preformed 
125
1-labelled fibrin clot was inhibited with aprotinin (final 
concentration 20 units/ml) and E-amino-n-caproic acid (EACA, 25 mM) at 30 min, solubilization 
of the remaining clot by the addition of PMA-stimulated neutrophils was 2. 7 times greater at 90 
minutes than that by neutrophils alone (Fig 4). Three separate experiments gave results within 
10% of those demonstrated in Fig 4. 
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Figure 4. Influence of PMA-stimulated neutrophils (2.5xl06) or PMA-stimulated neutrophil conditioned medium 
(from 2.5xl06 neutrophils) on plasmin solubilization of a 125 µg preformed 1251-labelled fibrin clot in a final 
volume of 500 µl. Plasmin was generated by the addition of urokinase (50 IU/rnl final concentration) to 15 ~Lg 
plasminogen/ml. PMA-stimulated neutrophils (.._), conditioned medium from PMA-stimulated neutrophils (~), 
plasmin (+), PMA-stimulated neutrophils (0) and PMA-stimulated neutrophil conditioned medium <•) together 
with plasmin at 'O' min, PMA-stirnulated neutrophils with plasmin added at 30 min <•), PMA-stimulated 
neutrophils (D) added to the clot solubilized with plasmin for 30 min then inhibited with EACA (25 mM) and 
aprotinin (20 U/ml). Each point is the mean of triplicates that did not differ by more than 2% and the illustrated 
results are one of three replicate experiments whose results were within 10% of those demonstrated. 
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125 , 
Nature of soluble I-labelled fibrm products 
The products produced on full solubilization of a preformed 
125
1-labelled fibrin clot by PMA-
stimulated neutrophils, PMA-stimulated neutrophil conditioned medium, neutrophil lysosomal 
enzymes, purified human neutrophil elastase and plasmin are shown in Fig 5. The apparent 
molecular mass of the products formed by PMA-stimulated neutrophils and the conditioned 
medium from these cells were similar, but different from the products produced by lysosomal 
enzymes and pure human neutrophil elastase (Fig 5). Plasmin generated soluble 
125
1-labelled fibrin 
products of different molecular mass to those produced by neutrophil enzymes (Fig 5). 





1 2 3 4 5 
Figure 5. SDS-PAGE analysis (10% non-reduced) of the 1251-labelled protein in solution on full solubilization of a 
250 µg 
125
1-labelled fibrin clot in a final volume of 500 µl by PMA-stimulated neutrophils (2.5xI06, track one), 
neutrophil conditioned medium from PMA-stimulated neutrophils (from 2.5x106 neutrophils, track two), lysosomal 
enzymes (from 2.5xl06 neutrophils, track three) incorporated into the clot, pure human neutrophil elastase (0.25 
µg, track four) or plasrnin (generated by the addition of 50 IU urokinase to 15 µg plasrninogen/ml, track five) 
added to a preformed clot. 
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125 
Effect of inhibitors on the solubilization of I-labelled fibrin 
No significant inhibition of solubilization of a preformed clot by PMA-stimulated neutrophils was 
achieved with inhibitors of the plasmin system - EACA (25 mM) and aprotinin (20 units/ml), 
EDTA (5 mM), a thiol protease inhibitor - E64 (20 mM), the cathepsin G inhibitors Suc-(Ala)i-
Pro-PheCH2Cl (1 mM) and Z-Gly-Leu-PheCH2Cl (0, 1 mM) or the human neutrophil elastase 
inhibitors Suc-(Ala)2-ValCH2Cl (1 mM) and Suc-(Ala)3CH2Cl (1 mM) (Table 1). 4-(2-
aminoethyl)-benzene sulfonyl fluoride (AEBSF, Pefabloc® SC - Boehringer Mannheim, Germany, 
1 mM), a water soluble serine protease inhibitor which is non-toxic to cells, inhibited fibrin 
degradation by 95%, while Me0-Suc-(Ala)2-Pro-ValCH2Cl (0.1 mM), an inhibitor of proteases 
such as elastase with specificities related to alanine or valine bonds, inhibited degradation by 35% 
(Table 1). Using a neutrophil lysosomal enzyme preparation to degrade preformed fibrin clots 
showed a very different inhibition profile, with Me0-Suc-(Ala)i-Pro-ValCH2Cl (0.1 mM) 
producing 80% inhibition, Z-Gly-Leu-Phe-CH2Cl (0.1 mM) 44% inhibition and AEBSF (1 mM) 
90% inhibition (Table 1). MeO-Suc-(Ala)2-Pro-ValCH2Cl (0 .1 mM) inhibited the solubilization of 
a preformed clot (250 µg) by pure human neutrophil elastase (250 ng) by 97% (Table 1). When 
neutrophils were incorporated into a 1 mg clot 440 µg 
125
1-labelled fibrin was solubilized in 60 
min. This solubilization was inhibited by 30% by MeO-Suc-(Ala)2-Pro-ValCH2Cl (0 .1 mM) but 
not inhibited by the cathepsin G inhibitor, Z-Gly-Leu-PheCH2Cl (0.1 mM). These inhibitors did 
not inhibit clot formation by thrombin. 
Identification of proteases in a neutrophil membrane preparation capable of degrading 
fibrin 
The fibrinolytic activity associated with the neutrophil membrane was only recovered from 
regions of the SDS-PAGE that contained proteins which migrated to apparent molecular weights 
of 501 kD, 398 kD, 316 kD, 245 kD and 209 kD. These slices released 230 µg, 205 µg, 225 µg, 
160 ~Lg and 160 ~Lg of 1251-labelled fibrin from a 250 ~Lg fibrin clot respectively at 24 hours. 
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Table 1. Influence of inhibitors on 1251-labelled fibrin degradation by neutrophils. 
Inhibitor 1251-labclled fibrin solubilized (µg) 
PMA-stimulated 11eutrophils 
None 38 
EACA (25 mM) 38 
Aprotinin (20 units/ml) 37 
EDTA(5 mM) 38 
E64 (20 mM) 38 
Suc-(Ala)i-Pro-PheCH2Cl (1 mM) 38 
Z-Gly-Leu-PheCH2Cl (0.1 mM) 36 
Sue (Ala)i-Val-CH2Cl (1 mM) 37 
Suc-(Ala)3CH2Cl (l mM) 37 
AEBSF (l mM) 2 
MeO-Suc-(Ala)i-Pro-ValCH2Cl (0.1 mM) 24 
Neutrophil lysosomal e11zymes 
None 50 
Z-Gly-Leu-PheCH2Cl (0.1 mM) 28 
AEBSF (1 mM) 5 
MeO-Suc-(Alah-Pro-ValCH2Cl (0.1 mM) 10 
Pure lu111ra11 11eutrophil elastase 
None 70 
AEBSF (1 mM) 2 
Me0-Suc-(Ala)i-Pro-Va!CH2Cl (0.1 mM) 2 
A preformed 1251-labelled fibrin clot (250 µg) was incubated (60 min) with PMA-stimulated neutrophils (2.5xl06), 
neutrophil lysosomal enzymes (from 2.5xl06 neutrophils) and pure human neutrophil elastase (250 ng) in a final 
volume of 500 µI. The inhibitors were incubated with the enzyme source for 15 min prior to the addition of the 
clot. Solubilized 1251-labelled fibrin is expressed as µg 1251-labelled fibrin/500 µl and is the mean of triplicate 
determinations which did not vary by more than 2%. The illustrated results are one of four replicate experiments. 
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Electron microscopy of fibrinolysis by neutrophils incorporated within the fibrin matrix 
Sca1111i11g Electron Microscopy. The scanning electron micrograph of the fibrin network in the 
absence of incorporated neutrophils revealed fibres organized into a tight matrix (Fig 6a) and 
incorporation of the neutrophils into the fibrin matrix occurred with an even distribution (Fig 6b ). 
When non-stimulated neutrophils were incorporated into the clot a time dependent opening of the 
network in the vicinity of the cells was observed (Fig 6c). After a 10 min incubation period the 
neutrophils were still emeshed within the fibrin matrix (Fig 6d) but by 60 min many of the 
neutrophils were found to be divest of fibrin and gaps within the matrix were visible (Fig 6e ). No 
formation of focal adhesions of the neutrophils were observed and the cells appeared to remain 
round with no spreading on the fibrin matrix, although pseudopodia formation was evident (Fig 
6t) . Electron microscopy analysis of fibrinolysis by PMA-stimulated neutrophils incorporated into 
the fibrin matrix indicated the process to be similar to that by non-stimulated neutrophils. From 
the micrographs it appeared that the time required for gaps to form in the fibrin matrix and the 
neutrophils to become divest of fibrin was far faster when PMA-stimulated neutrophils were 
incorporated into the matrix (Fig 6g) than when non-stimulated neutrophils were incorporated 
into the matrix (Fig 6e). 
Transmission Electron Microscopy. Non-stimulated neutrophils incorporated into the fibrin 
matrix for 60 min, at which time extensive fibrinolysis has occurred, contained a high 
concentration of dense granules (Fig 7a). No evidence of release of these granules into the 
extracellular medium was seen. Examination of the cells at high power revealed extensive ruflling 
of the membrane and pseudopodia formation (Fig 7b). Analysis of PMA-stimulated neutrophils 
that had been incorporated into the clot for a 60 minute period revealed similar membrane 
activation without granule release (Fig 7c). 
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Figure 6. (A) Appearance on scanning electron microscopy of fibrin network with no neutrophils incorporated 
within the matrix. (Magnification 2700x). (B) Incorporation of neutrophils into fibrin matrix showing an even 
distribution of cells using scanning electron microscopy (Magnification l 125x). (C) Incorporation of neutrophils 
into fibrin matrix at 10 min showing opening up of the fibrin network in the vicinity of the cells using scanning 
electron microscopy (Magnification 1800x). (D) Appearance on scanning electron microscopy of neutrophils 
within the fibrin network at 10 min incorporation time (Magnification 4500x). (E) After 60 min it is evident that 
the cell is divest of fibrin and gaps within the matrix are present (Magnification 4500). (F) Scanning electron 
microscopy shows that the cells are rounded with no spreading of the neutrophil on the fibrin substrate, although 
pseudopodia formation is present (Magnification 3375x). (G) Scanning electron micrograph of a PMA-stimulated 
neutrophil emeshed within fibrin at 10 min incorporation time (Magnification 3150x). 
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Figure 7. (A) Transmission electron microscopy shows a neutrophil at 60 min incorporation time with a high 
concentration of dense granules within the cytoplasm and no evidence of extracellular release. {B) Transmission 
electron microscopy of the neutrophil membrane in the vicinity of the fibrin substrate shows ruffling and 
pseudopodia formation. (C) Transmission electron micrograph of a PMA-stimulated neutrophil after 60 min 
incorporation into a fibrin clot, when extensive degradation has occurred. There is a high concentration of dense 
granules within the cytoplasm and similar membrane activation to that seen in neutrophils exposed to fibrin but 
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Mechanism of neutrophil-mediated fibrin degradation 
(1) Fibrin releases proteolytic activity from 11eutrophils 
Solubilization of clots by PMA-stimulated neutrophils was faster than that by conditioned medium 
from PMA-stimulated cells . This might be due to the ability of fibrin to release proteolytic activity 
from the neutrophil. To investigate this, PMA-stimulated neutrophils (2.5xl06 and 5xl06 cells) 
were incorporated into a 1 mg fibrin clot and degradation allowed to proceed for 90 min. 
Experiments were performed with both 1251-labelled fibrin and unlabelled fibrin. After 90 min the 
extent of fibrin degradation in the reaction containing ml-labelled fibrin was assessed as described 
above. The ability of fibrin to release proteolytic activity from the neutrophil during a period of 90 
min was assessed by incorporating the cell-free and fibrin-free supernatant obtained from the 
reaction containing unlabelled fibrin into the preparation of a 1 mg ml-labelled fibrin clot. The 
subsequent fibrinolysis occurring over 60 min was calculated and compared to that by conditioned 
medium prepared for 90 min from PMA-stimulated neutrophils not previously exposed to fibrin 
substrate. PMA stimulation was done at a concentration of 10 ng/rnl, a concentration not 
associated with azurophil granule release (Shephard et al, 1989). The results are illustrated in 
Table 2. 
Table 2. Fibrin solubilization by intact neutrophils and conditioned medium incorporated into fibrin matrix (1 
mg). 
2.5xl06 neutrophils/1 mg fibrin clot 5xl06 neutrophils/1 mg fibrin clot 
125[-labelledfibri11 solubilized by PMA-stimulated 11e11trophils at 90 min (µg) 
650 l 910 
············· ··········································································································································································································· 
125I-labelledfibri11 solubilized at 60 mi11 by co11ditio11ed medium from PMA-stinmlated 
11e11trophils exposed to fibri11 for 90 mi11 (µg) 
396 l 432 
··························································································································· ····························································································· 
125 I-labelled fibril, solubilized at 60 min by co11ditio11ed medium from PMA-stimulated 
11eutrophils (µg) 
260 I 308 
It is clear that conditioned medium from PMA-stimulated neutrophils exposed to fibrin is more 
efficient at subsequent fibrinolysis than conditioned medium from neutrophils stimulated with 
PMAalone. 
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(2) Integrin receptors and cellular fdnases are involved m neutropftil-mediated fibrin 
degradation 
(a) Integri11 receptors 
The effect of antibodies directed against various leukocyte receptors on neutrophil-mediated fibrin 
degradation by cells stimulated with PMA, at a concentration that does not result in azurophil 
granule release, is shown in Table 3. The concentration of monoclonal antibodies required to 
saturate these receptors on PMA-stimulated neutrophils was pre-determined by flow cytometry. 
The control antibody directed against the platelet receptor GPIIb-IIIa (CD41) and that directed 
against the neutrophil IgG Fe receptor (CD16), important in phagocytosis, produced no inhibition 
of fibrin degradation at 60 min. Pre-incubation of PMA-stimulated neutrophils with monoclonal 
antibodies directed against the a. and P subunits of the leukocyte specific p2 integrins before 
incorporation into a fibrin clot were able to inhibit degradation by varying amounts. Anti-CD 11 a, 
-CD11b, -CD1 le and -CD18 produced 15%, 13%, 58% and 58% inhibition of degradation at 60 
min respectively (Table 3). 
· Table 3. Influence of monoclonal antibodies directed against various neutrophil receptors on I125-labelled fibrin 
degradation (60 mins) by PMA-stimulated neutrophils (2.5xl06 neutrophils/1 mg fibrin clot). Monoclonal 
antibodies incubated (37°C, 15 min) with PMA-stimulated (10 ng/ml) neutrophils before addition of I125 -labelled 
fibrinogen and thrombin (0.4 units/ml) to effect clot formation. Degradation was monitored by release of 
radioactivity into supernatant at 60 min. In the absence of antibody 450 µg 125I-labelled fibrin was released into the 
medium at 60 min. The results represent the mean of triplicate experiments that did not vary by more than 5%. 
Monoclonal antibody % Inhibition of degradation 
none 0 







(b) Cellular kinases 
Protein phosphorylation represents one of the most important molecular mechanisms by which 
extracellular signals produce their biological reponses in cells (Cohen, 1992). In view of this, 
specific kinase inhibitors were used to assess their role in the degradation process: ML-9, an 
inhibitor of the myosin light chain kinase; KN-62, an inhibitor of the calcium/calmodulin 
dependent kinase and bisindolylmaleirnide, a specific protein kinase C inhibitor (Ito et al, 1989; 
Tokumitsu et al, 1990; Toullec et al, 1991). From the results presented (Table 4) it is clear that 
protein kinase C plays a fundamental role in the signal transduction pathway leading to fibrin 
degradation. 
Table 4. Influence of various kinase inhibitors on fibrin degradation by non-stimulated and PMA-stimulated 
neutrophils at 60 min (2.5xl06 neutrophils/1 mg fibrin clot). Kinase inhibitors incubated (37°C, 15 min) with non-
stimulated and PMA-stimulated (10 ng/ml) neutrophils before the addition of thrombin (0.4 units/ml) and 1125-
labelled fibrinogen. Degradation was monitored by the release of radioactivity into the supernatant. In the absence 
of inhibitors non-stimulated neutrophils released 120 µg of 1251-labelled fibrin and stimulated cells released 450 µg 
of 1251-labelled fibrin into the medium at 60 min. The results represent the mean of triplicate experiments that did 
not vary by more than 4%. The results of three experiments did not vary by more than 10%. 
Inhibitor % Inhibition (-PMA) % Inhibition (+PMA) 
None 0 0 
ML-9 (20 µM) 0 14 
Bisindolylmaleimide (5 µM) 10 34 
KN-62 (10 µM) 3 17 
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Discussion 
The incorporation of leukocytes into areas of clot formation in vivo is an active process mediated by 
P-selectin expressed on actived platelets (Palabrica et al, 1992) which binds to its ligand, PSGL-1, 
on monocytes and neutrophils (Larson et al, 1989). In addition, the presence of uPA-R on the 
neutrophil membrane localises uP A to the cell surface and may facilitate their infiltration into the clot 
(Herijgers et al, 1995). The presence of leukocytes with their substantial array of proteolytic 
enzymes possibly contributes to the recognized plasminogen independent fibrinolytic pathways 
(Plow and Edgington, 1975; Moroz and Gilmore, 1976; Moroz, 1984). Studies using leukocyte 
lysates as a source of enzymes have ascribed leukocyte fibrinolysis to neutrophil cathepsin G and 
elastase (Plow, 1980) and monocyte cathepsin D (Simon et al, 1994). A distinct difference in the 
overall molecular size of the degradation products from cross-linked fibrin produced by plasmin and 
leukocyte lysates has been reported (Francis and Marder, 1986). Leukocyte-derived elastase may 
contribute indirectly to accelerated fibrinolysis through the generation of a plasminogen-derived 
mini-plasminogen which can be activated by urokinase to yield rnini-plasmin (Moroz, 1981 ). Mini-
plasmin has been shown to have enhanced fibrinolytic activity compared to plasmin and to be 
relatively resistant to inhibition by the primary plasmin inhibitor a.2-antiplasmin (Moroz, 1981 ). In the 
absence of plasminogen, neutrophil elastase may be a major contributor to non-plasmin mediated 
fibrinolysis. Kolev et al ( 1996) looked at the relative contributions of plasmin, miniplasrnin, 
neutrophil elastase and cathepsin G to the process of fibrin degradation. No quantitative difference in 
fibrin degradation was found between plasrnin and mini~plasmin present on the surface of preformed 
clots, but elastase and cathepsin G were less efficient. In the case of fibrin crosslinking by factor 
XIIIa in the presence of a.i-antiplasmin, clot resistance to plasrnin and mini-plasmin is increased 
while the action of leukocyte proteases is not affected. Under the same conditions both leukocyte 
proteases were also able to potentiate the action of plasmin, possibly by its conversion to mini-
plasmin. Degradation of immobilized fibrinogen by intact neutrophils has been shown to occur 
through the release of elastase as a result of the formation of a protected compartment, which 
excludes plasma protease inhibitors, at the fibrinogen-cell interface (Weitz et al, 1987). This occurs 
due to binding of fibrinogen to neutrophils via the ~2 integrins (Loike et al, 1992). Following 
degranulation and release of elastase and cathepsin G into the extracellular enviroment these 
enzymes have been shown to rebind to the cell membrane in an active form that is relatively resistant 
to proteinase inhibitors (Bangalore and Travis, 1994; Owen et al, 1995a). 
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To date no study has addressed the role enzymes of membrane origin play in fibrinolysis when intact 
leukocytes lyse fibrin clots or become incorporated into a clot. In this study we show that during 
incubation of non-stimulated neutrophils and neutrophils stimulated with a dose of PMA that does 
not cause azurophilic granule exocytosis (Shephard et al, 1989), AEBSF sensitive fibrinolysis 
occurred. Neutrophil-mediated fibrinolysis produced products that were distinctly different from that 
of plasmin and were insensitive to plasmin inhibitors, EDT A, thiol protease inhibitors and specific 
cathepsin G inhibitors. Although partial inhibition (3 5%) of clot solubilization was observed with the 
specific elastase inhibitor MeO-Suc-(Ala)2-Pro-ValCH2Cl, it was insensitive to two other specific 
elastase inhibitors. Analysis of the apparent molecular masses of the solubilized products suggests 
125 
neutrophil-mediated and neutrophil conditioned medium solubilization of I-labelled fibrin occurs 
via similar enzymes and not by neutrophil lysosomal enzymes or elastase. 
The results with protease inhibitors together with our finding that fibrinolysis in the presence of 
neutrophils was always greater than that by neutrophil conditioned medium and detectable within 2 
min, suggest that clot solubilization in the presence of neutrophils is predominantly a neutrophil-
mediated process occurring by a membrane-associated protease. Our finding that a neutrophil 
membrane preparation contains fibrin solubilizing activity further supports this conclusion. In 
addition fibrin appears to cause a release of proteolytic activity from the neutrophil which could 
assist degradation in the extracellular medium. This neutrophil membrane protease appears to be the 
same as a previously reported membrane-associated protease, partially resistant to MeO-Suc-(Ala)r 
Pro-ValCH2Cl inhibition and with proteolytic activity of an apparent molecular weight greater than 
200 kD, that degrades both C-reactive protein and fibrinogen during incubation with neutrophils 
(Shephard et al, 1992; Kelly et al, 1994). This reported protease was found to have an apparent 
molecular weight of 600 kDa on gel filtration and to dissociate into distinct subunits that migrated to 
apparent molecular weights greater than 200 kDa on SDS-P AGE. The location of this enzyme was 
proposed to be at sites of interaction of the membrane with the cytoskeleton, since the enzyme was 
found associated with a neutrophil cytoskeleton preparation (Kelly et al, 1994). 
Electron microscopy analysis of clot lysis showed the fibrinolytic process to be localized to the 
vicinity of the cells without the involvement of azurophilic granule release. The number of available 
binding sites for neutrophils on an intact clot appears to be limited. However incorporation of 
neutrophils into the clot, which is analogous to an in vivo process during thrombus formation, 
increased the rate of fibrinolysis by cell-surface proteases and complete solubilization of the clot was 
achieved within 60 min with high neutrophil concentrations. The observed degradation of fibrin by 
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the membrane-associated proteases of the neutrophil, as measured by release of radioactivity from 
the clot, was marginally sensitive to upregulation by stimulating the cells with PMA. However, 
electron microscopy of clot solubilization suggests that the organization of the fibrin matrix is lost 
more readily when neutrophils are stimulated with PMA. This does not appear to be due to the 
release of lysosomal enzymes as no evidence was obtained either by the use of lysosomal enzyme 
inhibitors, analysis of the nature of the final fibrin products on complete solubilization of the clot or 
by transmission electron microscopy analysis of the solubilizing clot. 
Neutrophils appear to enhance the action of plasmin on clot lysis, a system that would be 
expected to occur in vivo. The resistance of platelet rich clots to lysis by plasminogen activators 
has been ascribed to a variety of mechanisms including the production of P AI-1 by platelets 
(Booth et al, 1992), release of a z-plasmin inhibitor by platelet a-granules (Sakata and Aoki, 
1980), release of factor XIII from platelets leading to increased cross-linking of the fibrin network 
as well as cross-linking of az-antiplasmin to the fibrin clot (Reed et al, 1991 ; Francis and Marder, 
1987). Although controversial it appears that the release of PAI-1 represents the most important 
mechanism. We show in this study that initial plasmin attack of the fibrin clot allows neutrophil 
sensitive sites to be exposed and subsequently a more efficient solubilization of the clot by 
neutrophils occurs. 
The p2 class of integrins and the "P3-like" LRI have been shown to be important as receptors on 
the neutrophil for interaction with fibrinogen (Gresham et al, 1992; Wright et al, 1988; Altieri et 
al, 1993; Loike et al, 1991). The monoclonal antibody studies unde1taken in this thesis did not 
determine binding sites on the fibrin matrix for neutrophils. However, the binding of monoclonal 
antibodies directed against either CD 11 c or CD 18 was able to significantly inhibit subsequent 
neutrophil-mediated fibrinolysis, with the monoclonal antibodies directed against the CDlla and 
CD 11 b having a much smaller inhibitory effect on subsequent fibrinolysis . The implication is that 
the membrane protease mediating fibrinolysis must be situated close to or at the site of the 
CD 11 c/CD 18 receptor as occupation of this receptor by antibody inhibits the degradation 
process, possibly interfering with enzyme/substrate interaction. The linkage of integrin receptors 
to the cytoskeleton of the cell has been widely reported (Pavalko and Otey, 1994; Wang et al, 
1993). The protease important in the fibrinolytic process as stated above is more than likely 
localised at the site of attachment of the cytoskeleton with the cell membrane (Shephard et al, 
1992). It is tenable therefore that CD11c/CD18 is the receptor for crosslinked fibrin clot and 
occupation by substrate initiates transduction pathways resulting in cytoskeletal reorganization 
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within the cell, upregulation of enzyme activity and release of enzyme activity into the 
extracellular medium. 
The upregulation of activity of the neutrophil membrane-associated protease that occurs following 
the interaction of fibrin with neutrophils, appears to be due to the activation of cellular kinases 
and in particular PKC, as use of bisindolylmaleimide results in significant inhibition of fibrinolysis . 
Stimulation with PMA enhances the activity of the enzyme possibly through further activation of 
PKC. This serine/threonine kinase was first characterized on the basis of its activation in vitro by 
calcium, phospholipid and diacylglycerol (Nishizuka, 1992) and has subsequently been found to 
consist of a number of isotypes that have separate and unique functions within the cell (Dekker 
and Parker, 1994). PKC is thought not to phosphorylate integrin receptors directly but acts on 
cytoskeletal proteins thereby affecting the interaction of integrins with these intracellular proteins 
(Danilov and Juliano, 1989). It has been shown that PKC is necessary for spreading and adhesion 
of human monocytes on fibrinogen (Kreuzer et al, 1996). Use of specific inhibitors indicates that 
the activity of the myosin light chain kinase, important in microfilament assembly, and the 
calcium/calmodulin-dependent kinases are far less important in the modulation of fibrinolytic 
activity of the membrane proteases of the neutrophil. 
From the results presented it may be concluded that neutrophil membrane proteolytic systems, 
which require relatively low activation states and act together with plasmin, could play an 
important role in early clot dissolution. The fibrinolytic processes described are due in part to the 
activation of PKC following binding of substrate at a site in close proximity to CD 11 c/CD 18. In 
contrast the fibrinolytic activity of neutrophil lysosomal enzymes possibly only plays a role in the 
late inflammatory response following their mobilization, which is a time and cell activation 
dependent process. In the event of clot stabilization as a result of inhibition of plasminogen 
activators by P AI-1 , complete fibrinolysis appears to be achieved through the further action of 
neutrophils. Thus neutrophil membrane proteolytic activity could play a major role in controlling 
fibrin deposition and thrombus dissolution. 
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Modification of platelet function by fibrin degradation 
products generated by neutrophil membrane proteolytic 
activity on fibrin 
Introduction 
In vivo, a thrombus is made up of fibrin and a variety of cellular constituents including 
neutrophils, monocytes and platelets. These different components are associated with each other 
via a myriad of complex interactions which in turn influences clot structure, tension, which is 
related to the clot retraction process, and lysis. 
Resistance to plasrnic lysis is a feature of platelet-rich thrombi (Falk, 1992). The reasons for this 
are manyfold. Platelet release of factor XIII causes crosslinking of fibrin monomers which are 
more difficult to lyse than non-crosslinked monomers (Reed et al, 1991; Francis and Marder, 
1987). Clot tension and retraction is also dependent on the interaction of the platelet receptor 
GPIIb-IIIa with polymerizing fibrinogen. A consequence of this binding is the contraction of the 
rnicrofilaments of the platelet cytoskeleton and alignment and orientation of fibrin strands which 
causes the clot to retract, the extent of which determines the tension of the fibres of the clot 
(Kunitada et al, 1992). During this process the surface of the platelet becomes coated with 
compact fibrin and thus local areas of high density fibrin are created within the clot (Braaten et al, 
1994). Retardation of clot lysis at the platelet surface appears to be the consequence of the 
exclusion of plasminogen and plasminogen activators that are not tightly bound to polymerizing 
fibrin (Braaten et al, 1994). Platelet-bound fibrin has been found to display 20-50% greater 
resistance to lysis than non platelet-bound fibrin. Synthetic peptides modelled on the GPIIb-IIIa-
fibrinogen recognition sequences have been shown to inhibit platelet aggregation through 
inhibition of adhesive interactions between fibrinogen and the platelet and subsequently 
acceleration of clot lysis at the platelet/fibrin interface occurs (Braaten et al, 1994). Recently small 
peptides containing RGD sequences and rich in disulfide bridges called disintegrins, because of 
their ability to inhibit numerous adhesive interactions, have been isolated from viper snake venoms 
(Shebuski et al, 1989). These peptides bind with high affinity to the GPIIb-IIIa receptor inhibiting 
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platelet aggregation (Huang et al, 1991). The conformation of the RGD amino acid sequence 
within the disintegrins accounts for the fact that they are I 000 times more potent than linear 
RGD-containing peptides in inhibiting platelet aggregation. Several studies have indicated that 
these snake venom-derived peptides may be useful antithrombotic agents (Cheng et al, 1994). 
However, this may be too simplistic a view as evidence is emerging that fibrinogen contains 
multiple domains that contribute to the expression of full platelet binding activity, in addition to 
the RGD and dodecapeptide sequences previously described (Peerschke and Galanakis, 1996). 
Components released from constituent cells also influence clot susceptibility to lysis. Platelet 
release of PAI-I and ai-antiplasmin, which becomes crosslinked to fibrin through the action of 
factor XIII, are inhibitors within the clot making it resistant to plasrnic lysis (Braaten et al, 1993; 
Sakata and Aoki, 1980). 
We have shown in the previous chapter that neutrophils possess fibrin solubilizing activity, with 
neutrophil membrane proteases effecting clot lysis in the absence of stimuli and when these cells 
are stimulated with a low dose of PMA that does not cause lysosomal enzyme release. This 
process generates products that are distinctly different in molecular weight from those produced 
during plasmic or lysosomal enzyme lysis of fibrin. The results also suggested that this neutrophil 
activity might modify the resistance of platelet-rich clots to lysis by plasrnin. 
This study monitors the effect of neutrophils on plasmic clot lysis when platelets are incorporated 
into the clot. When the role played by fibrin( ogen) degradation products in modulating plasrnic 
clot lysis is considered, it is possible that the products generated by neutrophil membrane-
mediated clot lysis, may influence plasmic clot lysis in the presence of platelets. 
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Results 
Plasmin-mediated fibrinolysis: modification by the presence of platelets and neutrophils 
Thrombin (0.4 units/ml final concentration) was added to a mixture of ml-labelled fibrinogen 
(125 µg), free of any contaminating plasminogen, 2xl08 washed platelets and urokinase (50 lU/ml 
final concentration) in a final volume of 500 ~tl with or without 2.5x106 neutrophils. Subsequent 
to macroscopically visible clot formation, pure human plasminogen (20 µg/ml final concentration) 
was added to initiate clot lysis. Lysis at 60 min, as measured by release of ml-labelled fibrin into 
the supernatant, was compared to plasmic lysis in the absence of platelets and neutrophils. The 
results are presented in Table 1. Less than 1 % of the fibrin was solubilized in the absence of 
proteases. Plasmic lysis releases 98 µg soluble fibrin products in 60 min. The presence of platelets 
inhibited plasmic clot lysis by 50%. This inhibition was partially overcome by the addition of 
neutrophils such that plasmic lysis was now inhibited by 26% (Table 1 ). 
Table 1. Plasmic degradation of 1251-labelled fibrin clot at 60 min with modification by incorporated platelets and 
incorporated platelets together with PMA-stimulated neutrophils (2.5xl06 neutrophils/2x108 platelets/125 µg 1251-
labelled fibrin clot in a final volume of 500 µl). Each point is the mean of triplicates that did not differ by more 
than 2% and the illustrated results are one of three replicate experiments. 
Constituents of ml-labelled fibrin clot ml-labelled fibrin % inhibition of 
released (µg) plasmin-mediated 
fibrin degradation 
urokinase/plasminogen 98 0 
urokinase/plasminogen + platelets 49 50 
urokinase/plasminogen + platelets + neutrophils 72 26 
Modification of platelet function by fibrin degradation products generated during fibrin 
lysis by neutrophil membrane proteolytic activity 
Since the inhibition of plasmic lysis in the presence of platelets was partially overcome by the 
proteolytic activity of neutrophils, experiments were performed to investigate the effect of the 
neutrophil-derived FDP's on platelet function . 
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Platelet aggregation 
Washed platelets (2xI08 platelets/ml) were preincubated (10 min, 37°C) with FDP's or the low 
molecular weight fibrin peptides or the corresponding controls (see methods), generated during 
fibrin lysis by neutrophils. Platelet aggregation, measured using a platelet aggregometer 
(Chronolog Corporation, Havertown PA, USA), was initiated by the addition of thrombin (0.05 
units/ml final concentration). The effect of the entire mix of FD P's on platelet aggregation could 
not be interpreted as the traces representative of platelet aggregation in the presence of the FDP' s 
indicated evidence of spontaneous aggregation without the requirement for addition of exogenous 
thrombin. Modulation of platelet aggregation by the low molecular weight fibrin peptides is 
indicated in Fig 1. The peptides show a concentration dependent inhibition of platelet aggregation. 
A concentration of 75 µg peptides produced 40% inhibition of aggregation while the presence of 
150 µg of peptides increased this inhibition to 60%. 
Clot retraction 
Washed platelets (2xl08 platelets) were preincubated (15 mm, 37°C) with FDP's, or the low 
molecular weight fibrin peptides or the corresponding controls (see methods), generated during 
fibrin lysis by neutrophils, or echistatin used as a positive control (1 µM final concentration). 
Echistatin is a snake venom-derived small RGD-containing protein (Mr 5.4 kDa) which inhibits 
platelet aggregation through its ability to bind to the GPIIb-IIIa receptor (Garsky et al, 1989). · 
Plasminogen free fibrinogen (250 µg) was added and the volume adjusted to 500 µl with HBSS. 
Clot formation was initiated by the addition of thrombin (0.4 units/ml final concentration). The 
resulting clot retraction following clot formation was observed macroscopically and a 
photographic record kept over a period of 60 min as shown in Fig 2. Complete inhibition of clot 
retraction was observed in the presence of echistatin. No inhibition of clot retraction in the 
presence of the FD P's, or the low molecular weight fibrin peptides or the corresponding controls, 
generated during fibrin lysis by neutrophils was observed. 
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Fi~u re 1. Platelet aggregation in response Lo Lhrombin stimulation of platelets. Platelets were used alone or 
follO\ving preincubation with peptides obtained from neutrophil conditioned medium solubilization of fibin clot 
(h 108 platelets/0. 75 or 1. 5 mg peptides in a final volume of 500 µl) . An equivalent peptide control preincubated 
with platelets showed no inhibition in platelet aggregation compared to platelets alone (results not shown). The 
resulls illustrated are representatiYe of one of four replicate experiments where the percentage inhibition of platelet 
aggregation produced by peptides did not differ by more than 8'Yo for each concentration used. 



















Figure 2. Fibrin clot retraction at 20 min, 30 min, 45 min, 60 min in the presence of platelets alone (Track l); 
platelets and peptides derived from neutrophil conditioned medium degradation of fibrin clot (Track 2); platelets 
and echistatin (Track 3); platelets and peptide control (Track 4). The experiment was repeated three times with the 
same results obtained on each occassion. 
2 3 4 
89 
Plasmic fibrin lysis in the presence of platelets: modification by peptides produced by 
neutrophil membrane lysis of fibrin 
Plasminogen free 1251-labelled fibrinogen (250 µg) was added to washed platelets (2xl08 platelets) 
that had been preincubated (15 min, 37°C) with 1.5 mg FDP's, or 1.5 mg of the low molecular 
weight fibrin peptides or the corresponding controls (see methods), generated during fibrin lysis 
by neutrophils. Clot formation was initiated by the addition of thrombin (0.4 units/ml final 
concentration). Following an incubation period of 25 min, which allowed clot formation and 
retraction to occur, clot lysis was commenced by the addition of urokinase (50 IU/ml final 
concentration) and plasminogen (20 µg/rnl final concentration). Plasmic lysis of fibrin in the 
absence of platelets and the FDP' s served as a control. Clot lysis was monitored as the release of 
1251-labelled fibrin products into the supernatant at 60 min. 
No modulation of plasmic lysis of fibrin was detected when the platelets were preincubated with 
the low molecular weight fibrin peptides (Table 2). The inhibition of plasmic lysis observed in the 
presence of platelets was partially overcome when the platelets were preincubated with the 
FDP's. This inhibition was due to the high molecular weight fibrin products as a similar result to 
that illustrated in Table 2 was obtained when the products were used after removal of the low 
molecular weight fibrin peptides by dialysis. 
Table 2. Plasmic degradation of 1251-labelled fibrin clot (250 µg) at 60 min and modification by incorporated 
platelets, alone or preincubated with FDP, FDP control, a peptide control or peptides derived from neutrophil 
conditioned medium solubilization of fibrin clot (1.5 mg FDP or peptides/2x108 platelets/250 µg 1251-labelled fibrin 
clot in a final volume of I ml). Each value is the mean of duplicates which did not differ by more than 10% and 
four experiments gave results within 10% of these. 
Constituents of 1251-labelled fibrin clot 1251-labelled fibrin % inhibition of 
released (µg) plasmin-mediated 
fibrinolysis 
urokinase/plasminogen 185 0 
urokinase/plasminogen + platelets 60 68 
urokinase/plasminogen + platelets + FDP 107 42 
urokinase/plasminogen + platelets + FDP control 65 65 
urokinase/plasminogen + platelets + peptides 55 70 
urokinase/plasminogen + platelets + peptide control 55 70 
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Discussion 
From the results presented in this chapter it appears that platelet-mediated inhibition of plasmic 
lysis can be overcome, in part, by the presence of neutrophils in the clot. In vivo, neutrophils 
become incorporated into the forming clot via a dynamic process involving neutrophil membrane 
integrin receptors and platelet expressed P-selectin (Palabrica et al, 1992). Other factors, for 
example the use of thrombolytic therapy, may also influence the number of neutrophils at the site 
of tissue damage and thus associated with the clot. The infusion of streptokinase has been shown 
to result in a significant increase in the number of circulating neutrophils (Adams et al, 1995; 
Ranjadayalan et al, 1991). Thus in vivo, thrombolytic therapy with plasminogen activators may 
proceed via both the generation of plasmin and a secondary process involving an increase in the 
neutrophil content of the thrombus. This would be in line with the proposal by Langleben et al 
(1 990) that success of thrombolytic therapy is not only due to plasmic lysis but also in part to 
intrinsic cellular activity. The cellular component of the fibrinolytic process may well become 
important in clot lysis when inhibition of plasmic lysis occurs through the release of P AI-1 from 
platelets . The mechanism of the neutrophil-mediated reversal of plasrnic clot lysis in the presence 
of platelets observed is not clear. It could be due to the intrinsic fibrinolytic activity of the 
neutrophil and/or inactivation of P AI-1 directly by the proteolytic activity of the neutrophil 
membrane. Studies have shown that the neutrophil serine protease, elastase, can inactivate P AI-1 
(Wu et al, 1995). The protease within the neutrophil membrane responsible for fibrin lysis, under 
conditions of non-release of lysosomal enzymes, is a serine protease. A small but consistent 
increase in plasmic lysis in the presence of neutrophil conditioned medium (ie FDP control) and 
platelets is observed indicating possible inactivation of P AI-1 by the membrane enzyme content of 
the neutrophil conditioned medium. Results presented in the previous chapter indicate that 
considerable amounts of this protease are released from the membrane in the presence of fibrin . 
Thus this proteolytic activity may well inactivate P AI-1 ( although this study did not address this 
point) and reverse platelet induced inhibition of plasmic clot lysis when intact neutrophils are 
present in the clot together with platelets. 
FDP ' s have been demonstrated to possess biological activity, particularly with regard to platelet 
function (Peerschke and Galanakis, 1996; Kloczewiak et al, 1982; Plow et al, 1987; Du et al, 
1991). The interaction of platelets with one another after initial adhesion to a thrombogenic 
substrate is fundamental to the formation of thrombus. It is possible therefore that the fibrin 
products generated during neutrophil membrane-mediated clot lysis will alter plasmic lysis in the 
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presence of platelets, through modulation of the interaction of fibrinogen with the platelet. In 
particular degradation products containing the RGD or KQAGDV sequences have been shown to 
inhibit platelet aggregation and clot retraction. Uncoupling of the interaction of fibrin binding to 
the platelet GPIIb-IIIa receptor by a potent antiadhesive peptide D-RGDW sequence, has also 
been demonstrated to enhance plasmic solubilization of fibrin at the platelet surface (Braaten et al, 
1994). In addition to the well described platelet recognition sequences Peerschke and Galanakis 
( 1996) have shown evidence for divalent cation dependent and independent platelet interactions 
with novel, non-RGD, non-dodecapeptide containing platelet recognition sequences in plasmin-
derived FDP' s D and E and it has been suggested that RGD sites may not figure prominently in 
fibrinogen binding (Farrell et al, 1992). 
The low molecular weight fibrin peptides generated during clot lysis by the activity of the 
neutrophil membrane were able to inhibit platelet aggregation but did not affect clot retraction. It 
has been demonstrated that sequences within fibrin that inhibit platelet aggregation may not affect 
clot retraction (Cohen et al, 1989). Recently evidence was presented by Rooney et al (1996) that 
the y chain C-terminus of fibrin( ogen) is essential for platelet aggregation but not for clot 
retraction. This distinct action for regions within fibrinogen might well explain why the low 
molecular weight fibrin peptides inhibit platelet aggregation but do not influence clot lysis. The 
inhibition of platelet aggregation by the fibrin peptides indicates interference by the peptides with 
the interaction of fibrinogen with the platelet surface. This appears to be insufficient to effect 
alteration of plasrnic fibrin solubilization in the presence of platelets. The lack of ability of these 
fibrin peptides to enhance plasmic lysis of platelet containing clots might be related to their 
inability to modulate clot retraction. This is a process that compacts the fibrin bound to the 
surface of the platelet and prevents the diffusion of plasminogen activators and plasrninogen into 
the clot matrix (Kunitada et al, 1992). It is characterized by the alignment of fibrin fibres 
following binding of polymerizing fibrinogen to the platelet receptor and in doing so determines 
clot tension and creates areas of high density at the surface of the platelet (Chao et al, 1976; 
Braaten et al, 1994). Inhibition of clot retraction is associated with reduction in the resistance of 
platelet rich clots to plasmic lysis (Kunitada et al, 1992). 
In contrast to the effect of the low molecular weight FDP's on plasmic clot lysis, the high 
molecular weight fibrin products were able to partially overcome the resistance of plasmic clot 
lysis in the presence of platelets. The mechanism for this is not clear as these products did not 
inhibit clot retraction. Even though the effect of these products on platelet aggregation could not 
92 
be determined in this study it is possible that they do inhibit platelet aggregation, which in turn 
could alter plasmic clot lysis in the presence of platelets. Their effect on platelet aggregation could 
not be determined as they caused "spontaneous" platelet aggregation, which is most probably the 
result of active thrombin contaminating these products. This arises through the irreversible 
binding of thrombin to fibrinogen during the initial clot formation process, which would remain in 
an active form bound to the resulting FDP's (Weitz et al, 1990; Francis et al, 1983) and would 
have the capacity to stimulate platelets preincubated with an FDP mix. The preparative process of 
peptide formation in the experiments involved the addition of TCA, ether extraction and washes 
with TF A ( see Appendix 1 : Methods), all of which may have served to inactivate any bound 
thrombin bound to fibrin peptides. Thus spontaneous platelet aggregation before the addition of 
exogenous thrombin did not present a problem in the platelet aggregation studies involving 
peptides. 
From the results presented in this study it may be concluded that the products generated by lysis 
of fibrin by a neutrophil membrane serine protease have several beneficial effects during 
inflammation. The significant inhibition of platelet aggregation by peptides formed as a result of 
neutrophil-mediated fibrinolysis may represent an important negative feedback system operative 
in vivo. Following effective thrombus formation and arrest of haemorrhage subsequent cellular 
fibrinolytic activity releases products which prevent further platelet aggregation and clot 
formation. However, recanalization, localization of the clot to the site of tissue injury and 
approximation of the edges of the wound is still allowed to proceed as these products do not 
modulate the retraction process. In addition the reversal of the resistance to plasmic degradation, 
usually seen in the presence of platelets, by release of neutrophil-derived fibrin products would 
also contribute to an increased rate of fibrinolysis and recanalization. 
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Digestion of 1251-labelled plasmin-derived fibrin degradation 
products by neutrophil lysosomal enzymes 
Introduction 
Plasmin-mediated fibrinolysis, which yields major core products D-dimer (184 kDa), E (41 kDa), 
D (83-100 kDa) as well as other lower molecular weight degradation products (Pizzo et al, 
1973), is considered a major pathway for solubilization of fibrin. However, nonplasmin-mediated 
pathways of fibrinolysis and in particular those mediated by neutrophils are recognized as being 
important for clot solubilization. The accumulation of neutrophils at sites of inflammation and 
vascular injury where fibrin deposition occurs is a dynamic process involving specific neutrophil 
receptors (Palabrica et al, 1992; Wright et al, 1988; Altieri et al, 1993). This interaction with and 
adherence of neutrophils to extracellular matrix proteins can result in cellular activation and 
release of lysosomal enzymes (Nathan et al, 1989, Liles et al, 1995) which contribute to 
fibrinolysis. Thus the products of plasmin-mediated fibrinolysis and neutrophil lysosomal enzymes 
are in close proximity in vivo. This may be particularly relevant clinically in situations where 
patients are receiving infusions of thrombolytic agents. Infusion of one such agent, streptokinase, 
results in a significant increase in the number of circulating neutrophils (Adams et al, 1995; 
Ranjadayalan et al, 1991) together with a rise in circulating levels of HNE and neutrophil-
elastase-derived fibrinopeptide BP30•43 (Ranjadayalan et al, 1991), implying the presence of 
activated neutrophils. 
Neutrophil lysosomal enzyme lysis of fibrin has been ascribed to elastase and cathepsin G (Moroz, 
1984) and yields distinctly different products from neutrophil membrane-associated and plasmic 
lysis of fibrin (Chapter 5; Plow and Edgington, 1975; Plow et al, 1983; Francis and Marder, 
1986). Neutrophil lysosomal enzymes could possibly provide a valuable direct alternative to 
plasmic fibrin solubilization if released in high concentration or indirectly through elastase 
conversion of plasminogen to miniplasminogen (Kolev et al, 1996). The further importance of 
elastase to the process of clot lysis is recognised through its ability to inactivate plasmin inhibitor 
which becomes incorporated into fibrin clots during in vivo clot formation (Wu et al, 1995). Two 
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recent studies have shown that elastase is able to degrade D-dimer (Bach-Gansmo et al, 1996) 
and other plasmin-derived FDP's (Leavell et al, 1996). This secondary digestion of plasmin-
derived FDP's produced molecules which were more potent chemoattractants than native plasmin 
FDP's (Leavell et al, 1996). 
The aim of this study was to investigate the ability of neutrophil lysosomal enzymes to further 
degrade the end products of plasmic fibrin degradation and to characterize the enzymatic and 
biochemical processes involved in this pathway. 
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Results 
Degradation of plasmic 1251-labelled fibrin products with neutrophil lysosomal enzymes 
Degradation of 125I-labelled fibrin with plasmin generated major degradation products that 
migrated on SDS-P AGE, in the absence of reducing conditions, to apparent molecular weights of 
182 kDa (probable D dimer), 130 kDa, 98 kDa (probable D fragment), 52 kDa, 42 kDa (probable 
fragment E), 36 kDa and a number of fragments <30 kDa (Fig 1). The products with apparent 
molecular weights of 182 kDa, 130 kDa, 98 kDa, 52 kDa and 42 kDa were degraded within 30 
min by neutrophil lysosomal enzymes (5x106 cell equivalents) (Fig 1). Further incubation of the 
reaction mixture, once these degradation products had formed, lead to the generation of high 
molecular weight products of 182 kDa and 120 kDa which were not sensitive to the further 
addition of plasmin (Fig 1). The addition of a fresh preparation of lysosomal enzymes led to 
repeated degradation and reformation of these high molecular weight products (Fig 1 ). A 
decrease in the time of the initial degradation of the plasmin-derived degradation products and an 
increase in the time required for the formation of the high molecular weight products was 
observed as the concentration of lysosomal enzyme was increased ( data not shown). Removal of 
plasminogen from the plasmin-derived 125I-labelled fibrin degradation products by lysine 
sepharose affinity chromatography did not prevent the production of high molecular weight 
products during degradation with lysosomal enzymes (data not shown). 
Incubation of the plasmin-derived 125I-labelled fibrin degradation products with pure human 
neutrophil elastase resulted in rapid (within 30 min) degradation of the products with apparent 
molecular weights of 182 kDa, 130 kDa, 52 kDa and 42 kDa, while the product with an apparent 
molecular weight of 98 kDa was more resistant to elastase activity (Fig 1 ). In contrast, although 
pure human neutrophil cathepsin G was able to effect degradation of 125I-labelled fibrin products 
with apparent molecular weights of 98 kDa, 52 kDa, 42 kDa and <30 kDa, D-dimer was 
completely resistant and the 130 kDa product relatively resistant to cathepsin G activity (Fig 1). 
No high molecular weight products were formed during a 24 h incubation period of these 125I-
labelled fibrin degradation products with elastase or cathepsin G ( data not shown). 
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Effect of inhibitors on the degradation of plasmin-derived 1251-labelled fibrin degradation 
products by neutrophil lysosomal enzymes 
The inhibitors TPCK, TLCK, E64 and a specific cathepsin G inhibitor did not inhibit either 
lysosomal enzyme degradation of the plasmic fibrin degradation products or the production of the 
lysosomal enzyme-derived high molecular weight 125I-labelled fibrin degradation products (data 
not shown). However, the serine protease inhibitors AEBSF and PMSF completely inhibited this 
degradation (Fig 2) while inhibition of degradation of the 182 kDa product was observed in the 
presence of the specific elastase inhibitor MeO-Suc-(Ala)rPro-ValCH2Cl (Fig 2). 
Although no inhibition of degradation of the plasmin-derived 125I-labelled fibrin degradation 
products by neutrophil lysosomal enzymes occurred in the presence of EDT A or either spermine 
(100 rnM) or spermidine (100 rnM), primary amines that inhibit factor XIII transglutaminase 
activity, the subsequent formation of high molecular weight degradation products did not occur 
(Fig 2). Spermine or spermidine at a concentration of 10 rnM delayed the production of the 
lysosomal-enzyme derived high molecular weight degradation products, with initiation of 
reformation in the absence of inhibitor occurring at 90 min but in the presence of 10 rnM inhibitor 
reformation began at 5 hr ( data not shown). 
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Figure 1 SDS-PAGE analysis (10% non-reduced) of the 1251-labelled protein in solution: fibrinogen standard (track 
l); products resulting from full solubilization of fibrin clot (250 µg) by the addition of urokinase (40 IU/ml) and 
human plasminogen (40 µg/ml) (track 2); products generated on addition of neutrophil lysosomal enzyme (5xl06 
cell equivalents) to plasmin-derived fibrin products shown in track 2 for 30 min, 60 min, 90 min, 3 h, 24 h (tracks 
3-8); nature of products generated on further addition of neutrophil lysosomal enzyme (5xl06 cell equivalents) to 
the products in track 8 (24 h neutrophil lysosomal enzyme digest of plasmic fibrin digest) at 30 min and 24 h 
(tracks 9 and 10); addition of human plasminogen (40 µg/ml) and urokinase (40 IU/ml) to the products in track 8 
(24 h neutrophil lysosomal enzyme digest of plasmic fibrin digest) (track 11), products generated by addition of 
pure human neutrophil elastase (25 µg/mg of protein) to plasmin-derfved fibrin products shown in track 2 at 3 h 
and 24 h (tracks 12 and 13), products generated by addition of pure human leukocyte cathepsin G (25 µg/mg of 
protein) to plasmin-derived fibrin products shown in track 2 at 3 hand 24 h (tracks 14 and 15). Molecular weight 
markers as indicated. 
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Figure 2 SDS-PAGE analysis (10% non-reduced) of the 125I-labelled protein in solution: on full solubilization of 
fibrin clot (250 µg) by the addition of urokinase ( 40 IV/ml) and human plasminogen ( 40 µg/ml) (track l ); addition 
of neutrophil lysosomal enzyme (5xl06 cell equivalents) to plasmin-derived products shown in track 1 at 90 min 
with no inhibitor (track 2), in the presence of spermine (100 mM) at 90 min (track 3), in the presence of PMSF (1 
mM) at 90 min (track 4), in the presence of AEBSF (1 mM) at 90 min (track 5), in the presence of Me0-Suc-
(Alah-Pro-ValCH2Cl (IO µM) at 90 min and 3 h (tracks 6 and 7), in the presence of EDTA (10 mM) at 90 min 
(track 8). Molecular weight markers as indicated. 
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Inhibition of disulfide bonding 
Incubation of the 125I-labelled FDP's with neutrophil lysosomal enzymes in the presence of a 
reducing agent did not prevent the formation of high molecular weight 125I-labelled fibrin-derived 
products (Fig 3) . 
Figure 3 SDS-PAGE analysis (10%) of 125I-labelled protein in solution: fibrinogen standard (trackl); products 
resulting from full solubilization of fibrin clot (250 µg) by the addition of urokinase (40 IU/ml) and human 
plasminogen (40 µg/ml) in the presence of dithiothreitol (1 mM) (track 2) followed by addition of neutrophil 
lysosomal enzyme (5xl06 cell equivalents) to plasmin-derived fibrin products shown in track 2 at 30 min, 60 min, 
90 min, 8 hand 24 h (tracks 3-6); nature of products generated on addition of neutrophil lysosomal enzyme (5x106 
cell equivalents) to plasmin-derived fibrin products at 24 h run under non-reducing (track 7) and reducing 
conditions (track 8). Molecular weight markers as indicated. 
--- --
Mr x 10-3 
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!so-electric point of the lysosomal enzyme-derived high molecular weight 1251-labelled fibrin 
degradation products 
Two dimensional iso-electrophoresis determined the pl of the 182 kDa lysosomal enzyme-derived 
high molecular weight 1251-labelled FDP to be 5.6 while the pl of the plasmin-derived product 
with this molecular weight was 6.1 (Fig 4) . 
Figure 4 !so-electric focusing of 1251-labelled fibrin degradation products produced after full solubilization of 
fibrin clot by plasmin and by the addition of neutrophil lysosomal enzyme to these products, followed by 
SDS-PAGE. A. 1251-labelled fibrin degradation products produced by plasrnic digestion of fibrin clot and by the 
addition of neutrophil lysosomal enzyme to these products were analysed on an isoelectric PAG plate with a broad 
pH range as indicated. B. The products separated on the isoelectric PAG plates (A) were then subjected to SDS-
PAGE (10% non-reduced) followed by autoradiography. The product of apparent molecular weight 182 kDa 
generated by plasmin and neutrophil lysosomal enzyme and the position to which they migrated in the first 
dimension, corresponding to isoelectric points 5.6 and 6.1, are indicated with arrows. Track 1 - plasmic digestion 
products; track 2 - products following addition of neutrophil lysosomal enzyme. 
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\Vestern blotting using monoclonal antibody directed against D-dimer 
Plasmin-derived FDP's were incubated with a neutrophil lysosomal enzyme preparation (37°C) 
and sampling was performed over a period of 24 hr. These samples were then subjected to SD S-
PAGE (10% non-reduced) . The separated proteins were transferred to an Immobilon-P 
membrane via a western blotting technique (Towbin et al, 1979) and probed with a monoclonal 
antibody directed against D-dimer, which shows no reactivity with fibrin monomer. The results 
are shown in Fig 5. The anti-D-dimer antibody did not recognize fibrinogen. However, it showed 
strong reactivity with material running at appparent molecular weight >90 k.Da in the plasmic 
fibrin digest as well as the products >80 k.Da that are reformed when the plasrnic products are 
incubated with lysosomal enzymes. A control experiment, where no primary antibody was used, 
showed no non-specific binding of the second antibody-peroxidase conjugate (data not shown). 
Figure 5 SDS-PAGE analysis (10% non-reduced) of a plasmic digest of fibrin and lysosomal enzyme digestion of 
the plasmin products (A) and probing of the products with monoclonal antibody directed against D-dimer (B). 
Fibrinogen standard (track l); full solubilization of fibrin clot (250 µg) by the addition of urokinase ( 40 IU/rnl) and 
human plasminogen (-+0 ug/ml) (track 2); addition of neutrophil lysosomal enzyme (5xl06 cell equilavents) to 
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Discussion 
From the results presented it is evident that lysosomal enzymes are able to rapidly degrade 
plasmin-derived fibrin products, in particular those products with molecular weights consisitent 
with D-dimer and fragment E, resulting in a corresponding increase in the concentration of 
products of lower molecular weight. With time, however, there is reformation of high molecular 
weight 1251-labelled fibrin products. The rate at which these products are reform~d depended on 
the concentration of lysosomal enzyme used, with more rapid degradation occurring at high 
concentrations but subsequent slower reformation. The high molecular weight products formed 
during lysosomal enzyme degradation are insensitive to cleavage by plasmin but the further 
addition of lysosomal enzyme allowed repeated breakdown and subsequent reformation. 
Characterisation of the lysosomal enzymes involved in the initial degradation of the plasmic 
products revealed them to be sensitive to serine protease inhibitors, AEBSF and PMSF and the 
elastase inhibitor MeO-Suc-(Ala)2-Pro-ValCH2Cl. The formation of the high molecular weight 
products could not be assessed in the presence of elastase inhibitors, as they prevented breakdown 
of plasmin products, but when using pure human neutrophil elastase as the enzyme for plasmic 
product degradation no subsequent reformation occurred. In the presence of 10 mM EDT A 
lysosomal enzyme-mediated degradation of plasrnic products occurred but no subsequent 
reformation was observed, implying a calcium dependent process. Disulfide bonding is present 
within the reformed material as performing the experiment or running the SDS-PAGE under 
reducing conditions lowers the apparent molecular weight of the reformed products. 
The pl of the reformed product, with an apparent molecular weight of 182 kDa which is identical 
to the apparent molecular weight of a plasmic product (probable D-dimer) was different. 
However, a monoclonal antibody directed against D-dimer and therefore specific for crosslinked 
material, recognizes the high molecular weight products produced over time, following addition 
of neutrophil lysosomal enzyme to plasmin-derived FDP ' s. 
Plasminogen binds selectively to fibrin allowing for generation of plasrnin activity at the clot 
surface (Fears, 1989; Kaczmarek et al, 1993) and remains bound to products following digestion. 
Cross-linked complexes from dissolved clot that have been observed by electron microscopy 
reveal plasminogen bound to the end of fibrin or bridging the ends of two fibrin molecules with 
the formation of larger complexes (Weisel et al, 1994). However, plasminogen association with 
FDP's does not appear to be playing a role in the reformation process described in this study as its 
removal from the degradation products by lysine sepharose affinity chromatography did not affect 
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the production of high molecular weight material following addition of neutrophil lysosomal 
enzymes. 
Factor XIII is a calcium dependent enzyme, which on activation by thrombin is able to catalyse a 
reaction that links the glutamyl portion of a glutamine residue with a lysine side chain. This 
enzyme is bound as an a 2P2 tetramer to the D domain of fibrinogen (Greenberg et al, 1982; Mary 
et al, 1987) and would therefore be expected to be bound to plasmic FDP's in an active form as 
thrombin was used to form the initial clot. Fibrin clot is able to act as a reservoir for enzymatically 
active thrombin which is resistant to inactivation by circulating thrombin inhibitors (Weitz et al, 
1990). During plasmin-mediated fibrinolysis soluble FDP's are released into the circulation, with 
active thrombin complexed to these products (Francis et al, 1983). Plasmin is neither able to 
activate or degrade factor XIII (Rider and McDonagh, 1981) but several other enzymes besides 
thrombin are also able to activate factor XIII. These include trypsin and papain (Schwartz et al, 
1973; Conery and Berliner, 1983) and other plasma serine proteases, factor Xa and kallikrein 
(Folk and Finlayson, 1977; McDonagh and McDonagh, 1975; Laudano et al, 1983). It is tenable, 
therefore, that constituents of a neutrophil lysosomal enzyme preparation may be able to convert 
factor XIII to its active form by cleavage of the a-subunit Arg3rGly38 bond (Hornyak et al, 
1989). Thereafter, the presence of calcium ions allows p subunits to dissociate from the cleaved 
zymogen to yield catalytically active factor XIIIa (Chung et al, 1974). The presence of factor XIII 
inhibitors, . spermine and spermidine, was able to significantly retard the reformation of high 
molecular weight fibrin products and at a concentration of 100 mM completely inhibit it. In the 
presence of EDT A, which would render this calcium dependent enzyme inactive, this process was 
completely abolished. 
The various products produced by plasmic activity on fibrin have been shown to have 
immunomodulatory effects. These include downregulation of neutrophil oxidative metabolism 
(Kazura et al, 1989), modulation of neutrophil/endothelial cell interactions (Fischer et al, 1991) 
and neutrophil chemotaxis (Kazura et al, 1989). In particular, fragment E has been shown to be a 
potent source of angiogenic activity (Thompson et al, 1992) and may be important in producing 
focal smooth-muscle cell proliferation (Strirk et al, 1993), a key event in the formation of 
stenosing atherosclerotic lesions. This study shows that neutrophils are able to rapidly degrade 
these plasmin-derived FDP' s which may have important biological consequences in vivo. It has 
been suggested that circulating levels of D-dimer may be suitable as a laboratory marker of deep 
venous thrombosis (Declerck et al, 1987), pulmonary embolism (Bounameaux et al, 1990) and 
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for monitoring thrombolysis in patients with acute myocardial infarction (Lew et al, 1986), 
although this remains controversial (Francis et al, 1986; Jude et al, 1992). In addition, Lassila et 
al ( 1993) found a significant association between the severity of peripheral arterial occlusive 
disease and the levels of circulating D-dimer. 
Bangalore and Travis (1994) and Owens et al (1995a) showed that the neutrophil lysosomal 
enzymes elastase and cathepsin G rebind to the cell membrane following release into the 
extracellular medium and in this form are relatively resistant to proteinase inhibitors. This might 
be important when the close association of neutrophils with fibrin( ogen) substrate via integrin 
receptor interaction is considered, which leads to the formation of a "protected pocket" excluding 
circulating proteinase inhibitors (Weitz et al, 1987). The association of activated neutrophils with 
fibrin, with the potential for degrading these plasmin derived products, may well compromise the 
predictive value of circulating D-dimer laboratory markers. In addition neutrophil lysosomal 
enzyme proteolysis of plasmic fibrin products might account for the sometimes discrepent results 
in fibrinogen/FDP's and D-dimer values seen in clinical practice, where relatively lower D-dimer 
values than those expected from FDP levels were measured (Sato et al, 1995). This scenario is 
further complicated by the results obtained in this study by western blotting of the products 
produced during lysosomal enzyme digestion of the plasmic fibrin products. The reformed 
material is recognized by a monoclonal antibody directed against D-dimer. Wylie and Walsh 
(1996) reported on variable immunoreactivity of D-dimer preparations for a monoclonal antibody 
DD-3B6/22 and it was suggested that this may be due to extra proteolytic cleavages during 
fibrinolysis . A subsequent report (Rylatt and Bundesen, 1996) challenged this hypothesis as being 
irrelevant in the in vivo situation due to high systemic levels of proteinase inhibitors. 
In this study we have shown that neutrophils are able to further process the end products of 
plasmic fibrin degradation and in doing so may have the potential for modulating the immune 
response and influencing the predictive value of tests measuring the levels of circulating D-dimer 
in certain pathological conditions. It appears that these neutrophil-derived products also have the 
capacity to produce high molecular weight material probably as a factor XIII and calcium 
dependent process. Investigation into the potential biological importance of the reformed material 
was beyond the scope of this study. 
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CHAPTERS 
Summary and conclusions 
It has long been recognized that neutrophils are found within thrombi (Rulot, 1904; Opie, 1907) 
and their presence, due to specific cellular adhesive processes (Palabrica et al, 1992; Sako et al, 
1993; Dore et al, 1996) significantly increases the rate of fibrin degradation. The ability of 
elastase and cathepsin G, proteases present within the azurophilic granules of the neutrophil, to 
degrade fibrin in a manner distinct from that of plasrnin has previously been shown (Moroz, 
1984). This study shows that proteases of the neutrophil membrane also possess fibrinolytic 
potential and are operative at relatively low activation states of the cell. Although non-stimulated 
neutrophils were able to effect clot lysis, stimulation with PMA at a dose that does not release 
lysosomal enzymes increased the rate of clot solubilization. Clot lysis, which was detectable 
within two min of incubating cells with fibrin clot, was effected by a membrane-associated serine 
protease that dissociates into bands with apparent molecular weights of 501 kDa, 398 kDa, 316 
kDa, 245 kDa and 209 kDa on SDS-P AGE. This appears to be the same as a previously reported 
membrane-associated protease which is partially resistant to MeO-Suc-(Ala)i-Pro-ValCH2Cl. 
inhibition and degrades both CRP and fibrinogen (Shephard et al, 1989; Kelly et al, 1994). The 
resulting fibrin degradation was distinct from that of plasrnin, · neutrophil lysosomal enzymes and 
pure HNE, was greater when neutrophils were incorporated within the fibrin matrix and could act 
together with plasmin to enhance fibrinolysis . Initial plasmin attack of the fibrin clot appears to 
expose neutrophil sensitive sites which allows for more efficient neutrophil-mediated 
solubilization to occur. This may be important in the in vivo situation where clot stabilization has 
occurred due to the release of plasminogen activator inhibitors from incorporated platelets. 
Members of the integrin family of adhesion receptors have been found to be of great importance 
for the interaction ofneutrophils with fibrinogen (Wright et al, 1988; Altieri et al, 1990 and 1993; 
Diamond and Springer, 1993 b ). In the case of neutrophil membrane fibrinolytic activity, 
occupation of the CD 11 c/CD 18 receptor by the relevant monoclonal antibody, significantly 
inhibits this process. This suggests that the protease under investigation is situated at or in close 
proximity to this receptor. It was shown that association of the fibrin substrate with the cell 
allowed for release of the enzyme into the extracellular medium. Conditioned medium from 
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neutrophils pre-exposed to fibrin resulted in greater subsequent fibrinolysis than the use of 
conditioned medium from naive cells. Members of the integrin family have been shown to play a 
role both in adhesion as well as signal transduction, into and out of the cell (Pavalko and 
LaRoche, 1993; Petty and Todd, 1996). The results obtained indicate that crosslinked fibrin may 
occupy the CD 11 c/CD 18 receptor and in doing so initiate signal transduction pathways which 
upregulate the enzyme. This upregulation of activity appears to be due to the activation of cellular 
kinases, in particular PKC with the calcium/calmodulin dependent kinases and the myosin light 
chain kinase being of much lesser significance. 
The products generated by lysis of fibrin by neutrophil membrane serine proteases show biological 
activity in assays of platelet function . The low molecular weight peptides were shown to 
significantly inhibit platelet aggregation in a concentration dependent manner. The higher 
molecular weight fibrin products were able to partially overcome the resistance to plasrnic lysis, 
which occurs in the presence of platelets (Falk, 1992). In both cases activity is presumably related 
to interaction of these FDP's with the platelet fibrinogen receptor, GPIIb-Illa, although specific 
binding studies were not performed. Neither the peptides nor the higher molecular weight material 
showed any significant modulation of clot retraction, a process essential for efficient localisation 
of clot at the site of tissue injury, wound healing and recanalization of occluded vessels. Thus, 
products released following neutrophil membrane fibrinolytic activity on established thrombus 
may act to inhibit further platelet aggregation and improve efficiency of plasmin-mediated clot 
lysis, without impairing the ability of platelets to bring about clot retraction. 
The classically described fibrinolytic pathway mediated by plasrnin results in the formation of a 
number of predictable end products (Pizzo et al, 1973) which possess a range of biological 
properties (Kazura et al, 1989; Fischer et al, 1991, Robson et al, 1993; Lorenzet et al, 1992). 
This process may be the result of endogenous enzyme activity or the infusion of exogenous 
plaminogen activators for therapeutic use in a variety of thromboembolic disorders. In the latter 
case this results in extremely high levels of circulating FDP's (Adams et al, 1995). This study 
demonstrates that serine proteases within a lysosomal enzyme preparation released from the 
neutrophil are able to further process these products, initially into low molecular weight material. 
However with time, high molecular weight material is formed . This reformation is prevented by 
both calcium and factor XIII inhibitors and the products are recognized by a monoclonal antibody 
raised against the plasmin derived FDP D-dimer. This processing by neutrophils of the end 
products of plasmic fibrin degradation may have the potential for modulating the immune 
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response. In addition it may influence the predictive value of tests measuring circulating D-dimer, 
currently used as a laboratory marker for disorders such as deep vein thrombosis (Declerk et al, 
1987), pulmonary embolism (Bounameaux et al, 1990) and severity of peripheral arterial 
occlusive disease (Lassila et al, 1993) as well as monitoring thrombolysis in myocardial infarction 
(Lew et al, 1986). 
It is hoped that these investigations are able to provide a greater understanding of the role 
neutrophils play in fibrinolysis and how they may modulate the inflammatory process by the 
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Appendix 1: Methods 
Reagents 
All chemicals and reagents were obtained from Sigma Chemical Co. (St Louis, MO) except for 
those listed below. 
Iodination 
[
125I]-Na was from Amersham International, UK. Iodogen was purchased from Pierce and 
Warriner, Cheshire, UK. 
Polyac,ylamide gel electrophoresis and isoelectric focussing 
A kit containing prestained molecular weight markers for use in SDS-P AGE was obtained from 
Amersham International, Amersham, UK. The kit includes myosin (200 kDa), phosphorylase b 
(97 kDa), bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa), 
trypsin inhibitor (21 kDa) and lysozyme (14 kDa). Autoradiography was performed using Kodak 
XAR-5 film (Eastman Kodak, Rochester, NY). Two dimensional isoelectric focussing was 
performed using ampholine polyacrylamide gel plates (pH range 3.5-9.3) with an isoelectric 
calibration kit from Pharmacia, Uppsala, Sweden. 
Monoclonal antibodies, enzymes and inhibitors 
Monoclonal antibodies ( all mouse IgG 1) to CD 16 (F cRIII, low avidity F c receptor), CD 11 a 
(LFA-1 a chain), CD1 lb (Macl a chain), CDl lc (p150,95 a chain), CD18 (B chain of B2 
integrin) and CD4 la (intact GPIIb-Illa, B3 integrin) were obtained from Sanbio, Uden, 
Netherlands. The monoclonal antibody to fibrin degradation product, D-dimer (mouse IgG1) was 
obtained from Biogenesis Ltd., Poole, UK. 4-(2-aminoethyl)-benzenesulphonyl fluoride (AEBSF, 
Pefabloc® -SC) (serine protease inhibitor) and bisindolylmaleimide (protein kinase C inhibitor) 
were obtained from Boehringer Mannheim, Germany. 1-[N,O-bis-(5-isoquinolinesulfonyl)-N-
methyl-L-tyrosyl]-4-phenylpiperazine (KN-62, Ca2+/calmodulin kinase inhibitor) and 1-(5-
chloronaphthalene-1 sulphonyl)-lH-hexahydro-1,4-diazepine (ML-9, myosin light chain kinase 
inhibitor) were obtained from Calbiochem-Novabiochem, San Diego CA, USA as was pure 
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human neutrophil elastase. Urokinase was from Ukidan, Rome, Italy. Plasminogen was purified 
from human plasma according to the method of Deutsch and Mertz (1970). 
Peptide purification 
Sep-Pak C18 cartridges were obtained from Waters Chromatography division, Millipore 
Corporation, Milford MA, USA. HPLC (high performance liquid chromatography) grade 
methanol and acetonitrile was from Baxter Healthcare Corporation, Muskegon MI, USA 
Electro11111icroscopy 
Spurrs resin was obtained from from Agar Scientific Ltd, Stanstead, UK. 
ECL Westem blotting 
Imrnobilon-P transfer membrane was obtained from Millipore Corporation, Milford MA, USA 
and the ECL ( enhanced chemiluminescence) detection kit from Arnersham International, UK. 
Preparation and iodination of fibrinogen 
Fibrinogen was isolated by ammonium sulphate precipitation from plasma obtained from 
heparinized blood donated by healthy laboratory workers (Atencio et al, 1965). Contaminating 
plasminogen was removed using lysine immobilized on Sepharose 4B (Deutsch and Mertz, 1970). 
The fibrinogen preparation contained a trace amount of factor XIII which was used to catalyze 
crosslinking during fibrin formation. The clottability of the purified fibrinogen was 97%. 
Fibrinogen was iodinated using iodogen as an oxidizing agent and 0.5 µCi[ 125I]-Na/µg fibrinogen 
(Fracker and Speck, 1978). The specific activity of the 125I-labelled fibrinogen was 0.5 µCi/µg 
protein. SDS-PAGE (non-reduced) and autoradiograph analysis (Kodak XAR-5) of this 125I-
labelled fibrinogen ( 400 000 cpm/track) revealed no evidence of degradation and it maintained its 
97% clottability. 
Preparation of neutrophils, conditioned medium, lysosomal enzymes and membranes 
Neutrophils were separated from heparinized venous blood (5 U preservative-free heparin/ml 
blood) by dextran sedimentation and Hypaque/Ficoll gradient centrifugation (Boyum, 1968) and 
resuspended in indicator free Hanks balanced salt solution (HBSS). Neutrophil viability was 97-
99% as determined by exclusion of trypan blue and found to be 98-100% pure using differential 
counts made on Wright-Giemsa stained smears. Neutrophil conditioned medium was prepared by 
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incubating neutrophils in the presence or absence of PMA (10 ng/ml) at 37°C for 20 mm 
(Shephard et al, 1989). With this preparation insignificant amounts of P-glucuronidase and a 
maximum of 12% of the total vitamin B12-binding protein of the intact cells is released (Shephard 
et al, 1989; Pontremoli et al, 1986). Centrifugation at 400 g for 5 min at 4°C was used to remove 
the cells for the preparation of the cell free conditioned medium which was used within 5 min of 
collection (Shephard et al, 1989). Lysosomal enzymes were obtained by degranulation of 
neutrophils in response to FMLP (1 µM) in the presence of cytochalasin B (5µg/ml) (Bentwood 
and Henson, 1980; Shephard et al, 1988). Membranes were prepared by hypotonic lysis of 
neutrophils and sucrose density gradient ultracentrifugation (Shephard et al, 1989). 
Preparation and degradation of 1251-labelled fibrin clot 
Fibrin clots were prepared by the addition of 125I-labelled fibrinogen at a final concentration of 2 
mg/ml HBSS and clotted by the addition of bovine thrombin (0.4 units/ml final concentration). 
The clots were incubated for 2 hr (3 7°C), to effect crosslinking, and thereafter squeezed and 
added to either non-stimulated or PMA ( 10 ng/ml)-stimulated neutrophils, conditioned medium 
from non-stimulated or PMA ( 10 ng/ml)-stimulated neutrophils or neutrophil lysosomal enzymes 
in a final volume of 500 µl. Neutrophils were stimulated with PMA by addition of PMA to give a 
final concentration of 10 ng/ml and immediately afterwards the preformed clot was added. 
Conditioned medium was prepared as described above. The number of neutrophils or neutrophil 
equivalents/500 µl used per experiment is given in the figure legends of the relevant results 
section. Plasmin solubilization of 125I-labelled fibrin (125 µg) was executed by the addition of a 
preformed clot to human plasminogen (5 or 15 µg/ml final concentration) and urokinase (final 
concentration 50 IU/ml) in a final volume of 500 µl HBSS. Solubilization of the preformed clot by 
pure human neutrophil elastase was monitored by the addition of elastase (250 ng) to the 
preformed clot (250 µg) in a final volume of 500 µl. Incorporation of the source of neutrophil 
enzyme into the fibrin matrix occurred by mixing either neutrophils, neutrophil conditioned 
medium or lysosomal enzymes with bovine thrombin (0.4 units/ml final concentration) followed 
by the addition of 1.0 mg 125I-labelled fibrinogen in a final volume of 500 µl. The number of 
neutrophils or neutrophil equivalents/500 µl incorporated into such clots is stated in the figure 
legends. When the effect of enzyme inhibitors and monoclonal antibodies to leukocyte adhesion 
molecules (see Chapter 6) on clot degradation was investigated these were preincubated (15 min, 
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37°C) with the neutrophil enzyme source either pnor to addition of the squeezed clot or 
incorporation of the enzyme source into the clot. 
Degradation of the resulting fibrin clots was monitored by the release of radioactivity into the 
supernatant using a Packard Auto-gamma counter. 
The nature of the 1251-labelled protein in solution on full solubilization of the fibrin clot by PMA-
stimulated neutrophils, conditioned medium from PMA-stimulated neutrophils, - lysosomal 
enzymes, pure human neutrophil elastase or plasmin, was determined by SDS-PAGE (10% non-
reducing conditions) (Laemmli, 1970). For this an aliquot of the soluble protein was mixed with 
an equal volume of 4% SDS sample buffer and boiled. Gels were immediately dried and the 
products visualized by autoradiography. 
The molecular size of the neutrophil fibrin-degrading protease 
A neutrophil membrane preparation (Shephard et al, 1989) from 230x106 cells was separated by 
SDS-PAGE (3-13%) under non-reducing conditions. A kit containing pre-stained molecular 
weight markers for molecular weights 14-200 kD, ferritin (subunit size 220 kD), purified human 
fibrinogen (340 kD) and fibronectin ( 440 kD) were used as calibration standards. After removal 
of SDS (Granelli-Piperno and Reich, 1978) the gel was cut into 2 mm slices. The slices were 
assayed for enzyme activity by incubating each slice (37°C, 24 hr) with 1251-labelled fibrin clots 
(250 µg) in a final volume of 250 µl. Solubilization was monitored by the release of radioactivity 
into the supernatant. 
Degradation by neutrophil lysosomal enzymes of the end products of plasmin digestion 
1251-labelled fibrinogen at a final concentration of 1 mg/ml HBSS was clotted by the addition of 
bovine thrombin at 0.4 units/ml final concentration. The clots were incubated for 2 hr (37°C), to 
effect crosslinking, and thereafter squeezed and solubilized (24 hr, 37°C) by plasmin (Deutsch and 
Mertz, 1970) by the addition of urokinase (50 IU/ml) and human plasminogen (40 µg/ml) in a 
final volume of 250 µl. Neutrophil lysosomal enzyme preparation from 5xl06 cells, pure human 
leukocyte cathepsin G (25 µg/mg protein) or pure human neutrophil elastase (25 µg/mg protein) 
was then added to the end products (250 µg) of plasmic 1251-labelled fibrin degradation (final 
volume 1 ml). When required the reactions were done in the presence of the thiol protease 
inhibitors leupeptin (20 µM) and trans-epoxysuccinyl-L-leucylamido-(4-guanido) butane (E64, 
400 µM), the chymotrypsin inhibitor L-1-tosylamido-2-phenyl-ethyl-chloromethylketone (TPCK, 
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500 µM), the trypsin inhibitor a 1-p-tosyl-L-lysine-chloromethyl-ketone (TLCK, 500 µM), the 
metalloprotease inhibitor ethylene diamine tetra acetic acid (EDT A, 10 mM), the serine protease 
inhibitors 4-(2-aminoethyl)-benzene sulfonyl fluoride (AEBSF, 1 mM) and phenylmethylsulphonyl 
fluoride (PMSF, 1 mM), the cathepsin G inhibitor Suc-(Ala)2-Pro-PheCH2Cl (1 mM), the 
neutrophil elastase inhibitors a 1-antitrypsin (1.5 mg/ml) and MeO-Suc-(Ala)2-ProValCH2Cl (10 
µM) and DL-dithiothreitol (1 mM), a reagent used for maintaining sulfhydryl groups in their 
reduced state. These inhibitors were preincubated (15 min, 37°C) with the neutrophil lysosomal 
enzyme preparation before the addition of the plasmic 1251-labelled-fibrin digest. The effect of 
spermine and spermidine ( 10 mM and 100 mM), primary amines that inhibit factor XIII, on the 
nature of the lysosomal enzyme degraded 1251-labelled fibrin degradation products was also 
investigated by incubating spermine and spermidine with 1251-labelled fibrin clots during plasmin 
digestion. The nature of the 1251-labelled fibrin degradation products was analysed by SDS-PAGE 
(10%) (Laemmli, 1970) in the absence of reducing conditions, except where indicated in the 
results, by boiling an aliquot of the degradation products with an equal volume of 4% SDS sample 
buffer. Gels were immediately dried and the products visualized by autoradiography. 
Two-dimensional iso-electric focusing of plasmin-derived fibrin degradation products 
1251-labelled fibrin degradation products generated by plasmin at 24 hr and products generated by 
neutrophil lysosomal enzyme action on these plasmin-derived products were dialysed against 
water overnight at 4°C, freeze dried and resuspended at 4 mg/ml in 20 mM Tris (pH 8.3), 1 % 
(w/v) sodium dodecyl sulphate and 7 M urea (Strachan et al, 1988). Samples were loaded onto a 
prefocused Ampholine polyacrylamide gel (PAG) plate (5% polyacrylamide with 3% crosslinkage 
and 2.2% [w/v] ampholine) with a broad pH range between 3.5 and 9.3. An isoelectric calibration 
kit containing standards with a pH range between 3.5 and 9.3 was included. The proteins were 
focused on the PAG plate with a constant power of 15 W, 1 500 V and 25 mA at 10°C then 
stained with Coomassie (0.12%), dried between two sheets of polyester film and 
autoradiographed. For second dimension SDS-PAGE (10%, non-reduced) (Laemmli, 1970) 
followed by autoradiography the P AG plate was sealed above the polyacrylamide gel with 1 % 
low melting agarose in SDS-sample buffer (0 .004 M Tris [pH 6.8] with 4% [w/v] SDS and 24% 
[ v/v] glycerol). 
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Electrophoresis and immunoblotting of plasmin-derived fibrin degradation products 
Fibrin degradation products generated by plasmin at 24 hr and products generated by neutrophil 
lysosomal enzyme action on these plasmin-derived products over a time period of 24 hours were 
subjected to SDS-PAGE (non-reduced, 10%) (Laemmli, 1970). The separated proteins were 
transferred to an Immobilon-P transfer membrane (Towbin et al, 1979), thereafter non-specific 
binding sites were blocked by overnight incubation (room temperature) in 5% blocking solution 
(50 mM tris, 80 mM NaCl, 2% BSA, 0.2% NP-40 and 5% fat-free milk powder; pH 8). All 
subsequent steps were performed using a 2% blocking solution. The Immobilon-P membrane was 
then probed using a monoclonal antibody directed against human D-dimer (a control track using 
no primary antibody was also set up) at 5 µg/ml final concentration. Antigen/antibody binding was 
made visible with appropriate antibody-peroxidase conjugates. An ECL detection kit was used in 
the final development (Andrews, 1986). 
Preparation of fibrin degradation products (FDP's) and fibrin peptides by neutrophil 
conditioned medium degradation of fibrin 
Both the entire FDP mix formed by neutrophil conditioned medium degradation of fibrin and the 
peptide component alone were used in experiments to investigate aspects of platelet function. For 
this neutrophil conditioned medium was incorporated within fibrin clot then incubated for 24 hr 
(3 7°C) to effect full clot solubilization. The low molecular weight fibrin peptides were prepared 
by the addition of 50% TCA (w/v) to the degradation mix (0°C) to a final concentration of 10%. 
Insoluble protein was removed by centrifugation (400g for 10 min at 4°C) and TCA was 
extracted from the soluble peptide mix four times with four volumes of diethyl ether (Shephard et 
al, 1988). The peptides were freeze dried and then resolubilized in a tenth of the original volume 
with distilled water. The peptides were desalted using a Sep-Pak C18 cartridge after treatment 
with methanol and equilibration with O .1 % trifluoroacetic acid (TF A) ( 4 column volumes) 
according to manufacturers instructions. Peptides were then loaded onto the column and after 
washing with 0.1 % TFA, the adsorbed peptides were eluted with 100% acetonitrile. After 
evaporation of the solvent, peptides were redissolved in HBSS. An FDP mix control and peptide 
control were produced by processing neutrophil conditioned medium in the same manner as 
described above, but without the presence of fibrinogen. 
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Electron microscopy 
Fibrin samples with and without neutrophils (± PMA) incorporated within the matrix were 
processed for viewing by electron microscopy. At selected time points the clot was fixed in 2.5% 
gluteraldehyde in phosphate buffer. 
Scanning electron microscopy 
Following washing, the clot preparations were dehydrated through a graded series of ethanol 
concentrations and dried from CO2 by the critical point method. The samples were sputter coated 
with gold palladium and examined in a LEICA S440 scanning electron microscope (Cambridge, 
UK). 
Transmission electron microscopy 
Following washing the clot preparations were post fixed in osmium tetroxide for 2 hr, rinsed in 
distilled water and dehydrated through a graded series of ethanol concentrations. Thereafter the 
samples were placed in 100% acetone and embedded in Spurr' s resin. The embedded samples 
were sectioned using a Leica Ultracut S microtome (Vienna, Austria) and viewed using the JEOL 
200CX transmission electron microscope (Tokyo, Japan). 
117 
Platelet purification 
The method of platelet purification was a modification of that described by Mustard et al (1989). 
Blood was collected via venipuncture with a 19-gauge needle from healthy adult volunteers. 
These donors were on no medication known to interfere with coagulation or platelet function for 
at least 10 days prior to donation. Blood samples were collected in one-sixth volume CCD (93 
mM trisodium citrate, 7 mM citric acid, 140 mM dextrose; pH 6.5) with 0.35% BSA at 37°C. 
Platetlets do not aggregate readily at this pH, while BSA is a protective protein which prevents 
activation during the purification process (Mustard et al, 1989). This blood was centrifuged at 
200 g (20 min, 26°C) to obtain platelet rich plasma and thereafter made up with an equal volume 
of CCD with 0.35% BSA and the platelets pelleted (990 g, 10 min). The pelleted platelets were 
then washed in PBS (pH 7.4) with 0.35% BSA Aprrase and PGii were not included in the 
isolation buffers. Final resuspension was then performed with HBSS with 3.35% BSA Platelets in 
this medium have been shown to be responsive to all aggregating and release-inducing agents 
such as thrombin, P AF and sodium arachidonate (Mustard et al, 1989). The purified platelets 
were used in a series of experiments to investigate platelet aggregation (platelet aggregometer 
from Chronolog Corporation, Havertown, Pa, USA), clot retraction and plasmic degradation of 
platelet-rich fibrin clots. Experimental details of platelet aggregation and clot retraction are 
described in Chapter 6. 
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Appendix 3: Experimental data 
Chapter 5 
Figure 2: page 66 
Solubilization of preformed 1251-labelled fibrin clot by various enzyme sources. The results shown are 
the range of values obtained from 10 different experiments. 
A. With respect to enzyme levels at 60 min. Reactions contained the indicated number of neutrophils 
or neutrophil equivalents and 250 µg preformed 1251-labelled fibrin clot. 
1251-labelled fibrin solubilized (µg) at 60 min 
Cell number 
1.25 X 106 2.5 X 106 5 X 106 10 X 106 
Conditioned medium 5-7 7-8 7-8 8-9 
Conditioned medium (PMA) 9 - 10 12 - 14 14 - 16 20-22 
Neutrophils 14 - 18 26 -29 30 - 34 29 - 32 
Neutrophils (PMA) 19 - 21 31 - 38 34 - 38 40-44 
Lysosomal enzyme 35 - 39 39 - 43 55 - 61 81 - 87 
B. With respect to clot size at 60 min. Reactions contained 2.5x106 neutrophils or neutrophil 
equivalents and the indicated weight of preformed 1251-labelled fibrin clot. 
1251-labelled fibrin solubilized (µg) by 2.5 x 106 neutrophils 
or neutrophil equivalents at 60 min 
125 µg clot 250 µg clot 1000 µg clot 
Conditioned medium (PMA) 5 - 6 12 - 14 64- 72 
Neutrophils (PMA) 15 - 17 33 - 37 106 - 114 
Lysosomal enzyme 24- 27 40-44 176-193 
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C. With respect to time. Reactions contained 125 µg preformed 1251-labelled fibrin and either 2.5x 
106 neutrophils or neutrophil equivalents or plasmin generated by activation of 5 µg or 15 µg 
plasminogen/ml with 0.4 IU urokinase/ml. 
1251-labelled fibrin solubilized (µg) by2.5 x 106 neutrophils or 
neutrophil equivalents or 5/15 µg plasminogen 
30 min 60 min 90 min 
Conditioned medium 2-3 7-8 11 - 12 
Neutrophils 7-8 16 - 18 21 - 23 
Lysosomal enzyme 11 - 13 24 -27 27 - 30 
Plasminogen ( 5 µg) 1 - 3 3-6 31 - 37 
Plasminogen ( 15 µg) 4-6 16 - 18 65 - 73 
Figure 3: page 68 
Comparison of clot solubilization by neutrophils added to a preformed 1 mg 1251-labelled fibrin clot 
and neutrophils incorporated into a 1 mg 1251-labelled fibrin matrix. Reactions contained either 
2.5xl06 neutrophils or neutrophil equivalents. The results shown are the range of values obtained in 
10 different experiments. 
1251-labelled fibrin solubilized (µg) from 1000 µg clot 
Addition of enzyme source Incorporation of enzyme 
to preformed clot source into clot 
Conditioned medium 30 - 34 143 - 154 
Conditioned medium (PMA) 48 - 51 269 - 311 
Neutrophils 111 - 120 361 - 373 
Neutrophils (PMA) 128 - 139 422 - 450 
Lysosomal enzyme 213 - 222 687 - 731 
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Figure 4: page 69 
Influence of PMA-stimulated neutrophils (2.5xl06) or PMA-stimulated neutrophil conditioned 
medium (from 2.5x106 neutrophils) on plasmin solubilization of a 125 µg preformed 1251-labelled 
fibrin clot. Each data point is the mean value of triplicates (which did not differ by more than 2%). 
The results from 3 replicate experiments is given. *Result illustrated in figure 4. 
1251-labelled fibrin solubilized (µg) 
*Experiment 1 Experiment 2 Experiment 3 
30 60 90 30 60 90 30 60 90 
min min min 
Conditioned medium (PMA) 8 16 24 6 15 22 7 16 25 
Neutrophils (PMA) 4 7 12 4 6 11 3 7 13 
Conditioned medium (PMA) + 34 66 100 31 68 106 29 69 103 
plasrnin at "O" 
Neutrophils (PMA) + plasrnin 22 31 77 20 30 75 23 32 77 
at "O" 
Neutrophils (PMA) + plasrnin 5 40 91 6 38 87 7 39 92 
at 30 min 
Neutrophils (PMA) + plasmin 2 30 60 2 28 57 1 32 59 
solubilization for 30 min then 
addition ofEACA + aprotinin 
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Insert Table 1: page 72 
Solubilization (60 min) of preformed 1251-labelled fibrin (250µg) clot by 2.5 x 106 PMA-stimulated 
neutrophils or lysosomal enzymes from 2.5 x 106 neutrophils or 250 ng pure human neutrophil 
elastase in the presence of enzyme inhibitors as indicated. The results shown are the range of values 





Aprotinin (20 units/ml) 
EDTA(5 mM) 
E64 (20 mM) 
Suc-(Ala)z-Pro-PheCh2Cl (lmM) 
Z-Gly-Leu-PheCh2Cl (0.1 mM) 
Sue (Ala)z-Val-Ch2Cl (1 mM) 
Suc-(Ala) 3CH2Cl (1 mM) 
AEBSF (1 mM) 
MeO-Suc-(Ala)z-Pro-ValCH2Cl (0.1 mM) 
Neutrophil lysosomal enzymes 
None 
Z-Gly-Leu-PheCH2Cl (0.1 mM) 
AEBSF (1 mM) 
MeO-Suc-(Ala)z-Pro-ValCH2Cl (0.1 mM) 
Pure human neutrophil elastase 
None 
AEBSF (1 mM) 
MeO-Suc-(Ala)2-Pro-ValCH2Cl (0.1 mM) 
125 
125I-labelled fibrin solubilized (µg) 
34 - 38 
37 - 40 
36 - 38 
37 -40 
36 - 38 
38 
35 - 37 
37 
37 
1 - 4 
22- 24 
48 - 50 
26 -29 
2-6 
7 - 11 
67 - 71 
1 - 4 
1 - 4 
Table 3: page 77 
Influence of monoclonal antibodies directed against various neutrophil receptors on 1251-labelled 
fibrin degradation (60 min) by PMA-stimulated neutrophils (2.5xl06 neutrophils/1 mg fibrin clot) 
incorporated into fibrin matrix. The results shown are the mean values obtained of triplicates (that 
did not vary by more than 5%) in 2 separate experiments. The cost of antibodies did not permit the 
performance of more experiments. 
*Results illustrated in Table 3. 
% Inhibition of degradation 
Monoclonal antibody Experiment 1 * Experiment 2 
None 0 0 
anti-CD I la 15 14 
anti-CD I lb 13 12 
anti-CD I le 58 60 
anti-CD 18 58 59 
anti-CD 16 0 1 
anti-CD 41 0 0 
Table 4: page 78 
Influence of various kinase inhibitors on fibrin degradation by non-stimulated and PMA-stimulated 
neutrophils at 60 min (2.5xl06 neutrophils/1 mg fibrin clot). The results shown are the range of 
values obtained in 3 experiments. 
Inhibitor % Inhibition (-PMA) % Inhibition (+PMA) 
None 0 0 
ML-9 0-2 12 - 14 
Bisindolylmaleimide 10 - 12 32 - 36 
KN-62 2-4 13 - 21 
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Chapter 6 
Table 1: page 86 
Plasmic degradation of ml-labelled fibrin clot at 60 min with modification by incorporated platelets 
and incorporated platelets together with PMA-stimulated neutrophils (2.5xl06 neutrophils/2xl08 
platelets/125 µg ml-labelled fibrin clot) . Illustrated are the range of results obtained from 3 separate 
experiments. 
Constituents of clot 1251-labelled fibrin % Inhibition of 
released (µg) plasmin degradation 
UK/ pig 97 - 99 -
UK/ pig+ pit 48 - 50 49 - 51 
UK / pig + pit + neutrophils 71 - 73 26-28 
Table 2: page 90 
Plasmic degradation of ml-labelled fibrin clot (250 µg) at 60 min and modification by incorporated 
platelets, alone or preincubated with FOP, FOP control, a peptide control or peptides derived from 
neutrophil conditioned medium solubilization of fibrin clot ( 1. 5 mg FOP or peptides/2x 108 
platelets/250 µg ml-labelled fibrin clot) . Illustrated are the range ofresults obtained from four 
replicate experiments. 
Constituents of clot 1251-labelled fibrin % Inhibition of 
released (µg) plasmin degradation 
UK/ pig 181 - 185 0 
UK/ pig+ pit 56 - 64 65 - 70 
UK / pig + plt + FOP 98 - 116 37 - 47 
UK / pig + pit + FOP control 61 - 69 63 - 67 
UK / pig + pit + peptides 53 - 59 68 - 71 
UK / pig + pit + peptide controls 51 - 59 68 - 72 
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